Judge 
Party 
Law Firm Amgen Inc. et al v. Sanofi et al
1:14-cv-01317 | Delaware District Court
Interested in this case?
Request a Demo Track this case, and find millions of cases like it, let us show you how.
Division
Wilmington
Judge
Judge Richard G. Andrews
Filed
Oct. 17, 2014
Terminated
Oct. 3, 2019
Case Flags
CLOSED,
LEAD,
MEDIATION-SRF,
PATENT,
and
SPECIALMASTER
Nature of Suit
830 Patent
Cause
35:0145
Jury Demand
Plaintiff
The docket is incomplete. Sign up for verified information.
| Filing Date | # | Docket Text |
|---|---|---|
| 3/11/2025 | 1102 | Order |
| 3/10/2025 | 1101 | Status Report |
| 2/28/2025 | 1100 | MEMORANDUM ORDER: I will award the following: Fees of the Clerk and Marshal $715.00; Witness fees, etc. $22,749.49; Trial Transcripts $21,994.31; Non-trial hearing transcripts $2,720.21; Deposition costs TBD; Document production c osts TBD; Copies $74,493.35. The parties are to submit a joint report with numbers that they agree would implement my rulings for the "deposition costs" and "document production costs" categories. The report is due in ten days (see Memorandum Order for further details). Signed by Judge Richard G. Andrews on 2/28/2025. (aas) |
| 6/17/2024 | 1099 | SO ORDERED Granting 1098 Joint Stipulation to Substitute Party and Amend Case Caption. Signed by Judge Richard G. Andrews on 6/17/2024. (nms) (Entered: 06/17/2024) |
| 6/10/2024 | CORRECTING ENTRY: The stipulation filed at D.I. 1097 has been removed from the docket per the corrected filing at D.I. 1098 . (nms) (Entered: 06/10/2024) | |
| 6/10/2024 | 1098 | Joint Stipulation to Substitute Party and Amend Case Caption, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 6/10/2024 (nms). Modified on 6/10/2024 (nms). (Entered: 06/10/2024) |
| 5/24/2024 | 1096 | REPLY BRIEF re 1092 MOTION for Review of Taxation of Costs filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) (Entered: 05/24/2024) |
| 5/14/2024 | 1095 | ANSWERING BRIEF in Opposition re 1092 MOTION for Review of Taxation of Costs, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. Reply Brief due date per Order re D.I. 1094 5/24/2024. (Higgins, James) Modified on 5/21/2024 (nms). (Entered: 05/14/2024) |
| 4/26/2024 | SO ORDERED, re 1094 STIPULATION to Extend Briefing Deadlines (*Reset Briefing Schedule: re 1092 MOTION for Review of Taxation of Costs. Answering Brief due 5/14/2024, Reply Brief due 5/24/2024). Signed by Judge Richard G. Andrews on 4/26/2024. (nms) (Entered: 04/26/2024) | |
| 4/26/2024 | 1094 | STIPULATION to Extend Briefing Deadlines - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 4/26/2024 (nms). (Entered: 04/26/2024) |
| 4/19/2024 | 1093 | OPENING BRIEF in Support re 1092 MOTION for Review of Taxation of Costs filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Answering Brief/Response due date per Local Rules is 5/3/2024. (Czerwonka, Scott) (Entered: 04/19/2024) |
| 4/19/2024 | 1092 | MOTION for Review of Taxation of Costs - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) (Entered: 04/19/2024) |
| 4/12/2024 | 1091 | [SEALED] Clerk's Taxation of Costs in amount of $ 23,254.49 against Plaintiffs. Request for Costs 1083 is GRANTED IN PART/DENIED IN PART in favor of Sanofi, Sanofi-Aventis U.S. LLC, f/d/b/a Aventis Pharmaceuticals Inc., and Regeneron Pharmaceuticals Inc. (emailed to the parties). (dmp, ) (Entered: 04/12/2024) |
| 2/16/2024 | 1090 | ACKNOWLEDGMENT OF RECEIPT of all trial exhibits from the trial held March 8, 2016 through March 16, 2016 before the Honorable Sue L. Robinson. (nmf) (Entered: 02/16/2024) |
| 11/27/2023 | 1089 | NOTICE of Withdrawal of Pro Hac Vice Counsel Victoria L. Reines by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC (Czerwonka, Scott) (Entered: 11/27/2023) |
| 10/20/2023 | 1088 | OBJECTIONS to 1083 Bill of Costs, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 10/20/2023 (nms). (Entered: 10/20/2023) |
| 9/19/2023 | SO ORDERED, re 1087 STIPULATION and Proposed Order Extending Deadline to file an objection to the Bill of Costs to October 20, 2023. Signed by Judge Richard G. Andrews on 9/19/2023. (nms) (Entered: 09/19/2023) | |
| 9/19/2023 | 1087 | STIPULATION and Proposed Order Extending Deadline to file an objection to the Bill of Costs to October 20, 2023 - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 9/19/2023 (nms). (Entered: 09/19/2023) |
| 8/28/2023 | 1086 | REDACTED VERSION of 1083 Bill of Costs by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) (Entered: 08/28/2023) |
| 8/21/2023 | 1085 | DECLARATION of Victoria Reines re 1083 Bill of Costs, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 1-3, # 2 Exhibit 4A, # 3 Exhibit 4B, # 4 Exhibits 5-9)(Czerwonka, Scott) Modified on 8/21/2023 (nms). (Entered: 08/21/2023) |
| 8/21/2023 | 1084 | EXHIBITS A-C to 1083 Bill of Costs, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 8/21/2023 (nms). (Entered: 08/21/2023) |
| 8/21/2023 | 1083 | [SEALED] Bill of Costs, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 8/21/2023 (nms). (Entered: 08/21/2023) |
| 7/21/2023 | 1082 | SO ORDERED granting 1081 Stipulation and Proposed Order Regarding Deadline for Bill of Costs. Signed by Judge Richard G. Andrews on 7/21/2023. (nms) (Entered: 07/21/2023) |
| 7/20/2023 | 1081 | STIPULATION and [Proposed] Order Regarding Deadline for Bill of Costs by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) (Entered: 07/20/2023) |
| 6/16/2023 | SO ORDERED, re 1080 Stipulation and [Proposed] Order Regarding Deadline for Bill of Costs. Signed by Judge Richard G. Andrews on 6/16/2023. (nms) (Entered: 06/16/2023) | |
| 6/16/2023 | 1080 | STIPULATION and [Proposed] Order Regarding Deadline for Bill of Costs by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) (Entered: 06/16/2023) |
| 2/27/2023 | 1079 | Letter to Laurie Gray, Office of the Clerk for the Supreme Court of the United States, dated 2/27/2023, from the Clerk of Court, responding to request for record transmittal (D.I. 1078 ). (nms) (Entered: 02/27/2023) |
| 2/27/2023 | 1078 | Letter to the Clerk of Court, from the Clerk of Court for the Federal Circuit, dated February 14, 2023, regarding transmittal of court record. (nms) (Entered: 02/27/2023) |
| 7/7/2021 | 1077 | ACKNOWLEDGMENT OF RECEIPT of defendants' trial exhibits (see D.I. 815 Exhibit List). (nms) (Entered: 07/07/2021) |
| 7/7/2021 | 1076 | SO ORDERED Granting 1075 STIPULATION and Proposed Order Extending Deadline. Signed by Judge Richard G. Andrews on 7/7/2021. (nms) (Entered: 07/07/2021) |
| 7/2/2021 | 1075 | STIPULATION and Proposed Order Extending Deadline - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 7/6/2021 (nms). (Entered: 07/02/2021) |
| 6/30/2021 | 1074 | ACKNOWLEDGMENT OF RECEIPT of Plaintiffs exhibits and the joint exhibits for the jury trial held on February 19, 2019, and continued on February 21, 2019, through February 25, 2019 (see D.I. 815 Exhibit List). (nms) (Entered: 06/30/2021) |
| 6/28/2021 | 1073 | Lette to Counsel, dated June 28, 2021, from the Clerk of Court, regarding the return or disposal of trial exhibits (see Exhibit List at D.I. 815 ). (nms) (Entered: 06/28/2021) |
| 6/28/2021 | 1072 | MANDATE of USCA as to 1063 Notice of Appeal (Federal Circuit), filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. USCA Decision: Affirmed. (Attachments: # 1 Opinion, # 2 Judgment)(nms) (Entered: 06/28/2021) |
| 6/21/2021 | 1071 | ORDER of USCA as to 1063 Notice of Appeal (Federal Circuit), filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. Decision of USCA: The petition for panel rehearing is denied. The petition for rehearing en banc is denied. The mandate of the court will issue on June 28, 2021. (nms) (Entered: 06/21/2021) |
| 12/17/2020 | 1070 | NOTICE of Withdrawal of Pro Hac Vice Counsel, David N. Greenwald by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. (Higgins, James) (Entered: 12/17/2020) |
| 5/19/2020 | 1069 | NOTICE of Withdrawal of Counsel, Katherine Nicole Clouse by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. (Higgins, James) (Entered: 05/19/2020) |
| 3/25/2020 | 1068 | NOTICE of Withdrawal of Counsel, Rebecca Harker Duttry by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. (Higgins, James) (Entered: 03/25/2020) |
| 3/25/2020 | 1067 | NOTICE of Change of Firm Affiliation for Christopher B. Mead, Esq. by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. (Higgins, James) (Entered: 03/25/2020) |
| 11/13/2019 | 1066 | NOTICE of Withdrawal of Pro Hac Vice Counsel, Megan Y. Yung by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. (Higgins, James) (Entered: 11/13/2019) |
| 11/6/2019 | 1065 | TRANSCRIPT REQUEST by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. (a transcript is already on file) (Sharp, Melanie) (Entered: 11/06/2019) |
| 10/24/2019 | 1064 | NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re 1063 Notice of Appeal (Federal Circuit), filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. USCA Case Number 2020-1074. (nms) (Entered: 10/24/2019) |
| 10/23/2019 | Notice of Appeal and Docket Sheet to US Court of Appeals for the Federal Circuit re 1063 Notice of Appeal (Federal Circuit). (kmd) (Entered: 10/23/2019) | |
| 10/23/2019 | Notification regarding 1063 Notice of Appeal (Federal Circuit) sent to Reporter Hawkins. (kmd) (Entered: 10/23/2019) | |
| 10/23/2019 | Notification regarding 1063 Notice of Appeal (Federal Circuit) sent to Reporter Triozzi. (kmd) (Entered: 10/23/2019) | |
| 10/23/2019 | Notification regarding 1063 Notice of Appeal (Federal Circuit) sent to Reporter Gunning. (kmd) (Entered: 10/23/2019) | |
| 10/23/2019 | APPEAL - Credit Card Payment of $505.00 received re 1063 Notice of Appeal (Federal Circuit) filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. ( Filing fee $505, receipt number 0311-2762036.) (Sharp, Melanie) (Entered: 10/23/2019) | |
| 10/23/2019 | 1063 | NOTICE OF APPEAL to the Federal Circuit of 1061 Judgment . Appeal filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Sharp, Melanie) (Entered: 10/23/2019) |
| 10/11/2019 | 1062 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,563,698; 8,829,165; 8,859,741. (Attachments: # 1 Final Judgment)(nms) (Entered: 10/11/2019) |
| 10/3/2019 | 1061 | FINAL JUDGMENT (CASE CLOSED). Signed by Judge Richard G. Andrews on 10/3/2019. (nms) (Entered: 10/03/2019) |
| 10/2/2019 | 1060 | NOTICE of Lodging Demonstratives from the Jury Trial by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Attachments: # 1 Tab 1, # 2 Tab 2, # 3 Tab 3, # 4 Tab 4, # 5 Tab 5, # 6 Tab 6)(Czerwonka, Scott) Modified on 10/2/2019 (nms). (Entered: 10/02/2019) |
| 10/1/2019 | 1059 | NOTICE of Lodging of Demonstratives from the Jury Trial, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Tabs 1-10, # 2 Tabs 11-21)(Sharp, Melanie) Modified on 10/1/2019 (nms). (Entered: 10/01/2019) |
| 10/1/2019 | CORRECTING ENTRY: The Notice of Docketing filed at D.I. 1059 has been removed. Trial exhibits are not to be filed on the docket, but lodged physically with the Court after trial (which was done). Should the parties wish to lodge the demonstrative exhibits they should do so under the cover of a notice of lodging. (nms) (Entered: 10/01/2019) | |
| 9/30/2019 | 1058 | Joint Status Report, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits A-C)(Higgins, James) Modified on 10/1/2019 (nms). (Entered: 09/30/2019) |
| 9/26/2019 | 1057 | SO ORDERED Granting 1056 Stipulation and Order for Protective Extension of the Deadline for Filing of a Notice of Appeal. Signed by Judge Richard G. Andrews on 9/26/2019. (nms) (Entered: 09/26/2019) |
| 9/25/2019 | 1056 | STIPULATION and Proposed Order for Protective Extension of the Deadline for Filing a Notice of Appeal, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 9/25/2019 (nms). (Entered: 09/25/2019) |
| 9/23/2019 | 1055 | ORAL ORDER: A joint status report is due no later than five days from the date of this Order. Included with the report should be an agreed upon form of final judgment. Ordered by Judge Richard G. Andrews on 9/23/2019. (nms) (Entered: 09/23/2019) |
| 9/16/2019 | 1054 | Official Transcript of Oral Argument held on 08/08/19 before Judge Richard G. Andrews. Court Reporter/Transcriber Stacy Ingram,Telephone number 1-856-297-9332. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 10/7/2019. Redacted Transcript Deadline set for 10/17/2019. Release of Transcript Restriction set for 12/16/2019. (Triozzi, Heather) (Entered: 09/16/2019) |
| 9/11/2019 | 1053 | MEMORANDUM ORDER: Defendants' Motion to Unredact Defendants' Opening Brief in Support of Motion Under Fed. R. Civ. P. 59 for New Trial (D.I. 989 ) is GRANTED as to page 2 of DTX 3221 and the corresponding portions of D.I. 885 , and the last sentence of the first paragraph of page eight of D.I. 885 . The Motion is DENIED as to all else. Signed by Judge Richard G. Andrews on 9/11/2019. (nms) (Entered: 09/11/2019) |
| 9/4/2019 | Remark: The In Camera submission submitted under the cover of D.I. 617 has been destroyed per the consent of counsel. (nms) (Entered: 09/04/2019) | |
| 8/28/2019 | 1052 | ORAL ORDER: The Motions for Judgment as a Matter of Law (D.I. 793 , 802 ) are DISMISSED per the Court's rulings at D.I. 1050 and D.I. 1051 . Ordered by Judge Richard G. Andrews on 8/28/2019. (nms) (Entered: 08/28/2019) |
| 8/28/2019 | 1051 | ORDER: Defendants' Motion for Judgment as a Matter of Law (D.I. 886 ) is GRANTED for lack of enablement and DENIED as to written description. Defendants' Motion for a New Trial (D.I. 883 ) is conditionally DENIED. Plaintiffs' Motion fro Permanent Injunction (D.I. 871 ) is DISMISSED as moot. Signed by Judge Richard G. Andrews on 8/28/2019. (nms) (Entered: 08/28/2019) |
| 8/28/2019 | 1050 | MEMORANDUM OPINION. Signed by Judge Richard G. Andrews on 8/28/2019. (nms) (Entered: 08/28/2019) |
| 8/15/2019 | 1049 | ORAL ORDER: Amgen's Letter (D.I. 1047) is STRUCK. Any further filings that are not submitted in compliance with either a Court order or the Local Rules will be, at a minimum, struck. Signed by Judge Richard G. Andrews on 8/15/2019. (crb) Modified on 8/20/2019 (nms). (Entered: 08/15/2019) |
| 8/15/2019 | 1048 | Letter to The Honorable Richard G. Andrews, from David E. Wilks, regarding Amgen's August 14, 2019 letter (D.I. 1047). (Wilks, David) Modified on 8/20/2019 (nms). (Entered: 08/15/2019) |
| 8/12/2019 | 1046 | Letter to The Honorable Richard G. Andrews from Melanie K. Sharp, Esq. regarding August 8, 2019 Hearing. (Sharp, Melanie) (Entered: 08/12/2019) |
| 8/12/2019 | 1045 | Letter to The Honorable Richard G. Andrews from David Wilks regarding August 8, 2019 hearing. (Wilks, David) (Entered: 08/12/2019) |
| 8/8/2019 | Minute Entry for proceedings held before Judge Richard G. Andrews - Motion Hearing held on 8/8/2019 re 886 MOTION for Judgment as a Matter of Law Under Fed. R. Civ. P. 50(b). Local counsel present for plaintiffs: M. Sharp, J. Higgins. Local counsel present for defendants: D. Wilks, S. Czerwonka. (Court Reporter Stacy Ingram (Hawkins Reporting)). (crb) (Entered: 08/08/2019) | |
| 8/8/2019 | 1044 | Official Transcript of Hearing held on 6/13/2019 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather M. Triozzi,Telephone number 573-6195. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 8/29/2019. Redacted Transcript Deadline set for 9/9/2019. Release of Transcript Restriction set for 11/6/2019. (dh) (Entered: 08/08/2019) |
| 8/8/2019 | 1043 | Official Transcript of Hearing held on 6/21/2019 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather M. Triozzi,Telephone number 573-6195. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 8/29/2019. Redacted Transcript Deadline set for 9/9/2019. Release of Transcript Restriction set for 11/6/2019. (dh) (Entered: 08/08/2019) |
| 8/5/2019 | 1042 | Official Transcript of Preliminary Injunction Hearing held on 06/06/19 before Judge Richard G. Andrews. Court Reporter/Transcriber Jennifer Guy,Telephone number 484-467-4359. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 8/26/2019. Redacted Transcript Deadline set for 9/5/2019. Release of Transcript Restriction set for 11/4/2019. (Triozzi, Heather) (Entered: 08/05/2019) |
| 8/5/2019 | 1041 | ORAL ORDER: The hearing scheduled for 8/8/2019, at 2:00 PM will now be held in Courtroom 4A. Ordered by Judge Richard G. Andrews on 8/5/2019. (nms) (Entered: 08/05/2019) |
| 7/15/2019 | 1040 | ORAL ORDER: A hearing on the Motion for Judgment as a Matter of Law Under Fed. R. Civ. P. 50(b) (D.I. 886 ) is now set for 8/8/2019, at 2:00 PM in Courtroom 6A. The parties are limited to 30 minutes per side. Ordered by Judge Richard G. Andrews on 7/15/2019. (nms) (Entered: 07/15/2019) |
| 7/15/2019 | 1039 | REDACTED VERSION of 1038 Letter, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 7/15/2019 (nms). (Entered: 07/15/2019) |
| 7/15/2019 | 1038 | [SEALED] Letter to The Honorable Richard G. Andrews, from Melanie K. Sharp, Esq., regarding response to Defendants' July 12 Letter (D.I. 1037 ). (Sharp, Melanie) Modified on 7/16/2019 (nms). (Entered: 07/15/2019) |
| 7/12/2019 | 1037 | Letter to The Honorable Richard G. Andrews, from David E. Wilks, regarding Neurology article. (Attachments: # 1 Exhibit 1)(Wilks, David) Modified on 7/12/2019 (nms). (Entered: 07/12/2019) |
| 7/8/2019 | 1036 | REDACTED VERSION of 1034 Reply in Support of Objections, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 7/9/2019 (nms). (Entered: 07/08/2019) |
| 7/2/2019 | REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # 1034 . (nms) (Entered: 07/02/2019) | |
| 7/1/2019 | 1035 | NOTICE of Withdrawal of Counsel, Michelle M. Ovanesian by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. (Higgins, James) (Entered: 07/01/2019) |
| 6/26/2019 | CORRECTING ENTRY: The Notice filed at D.I. 1033 has been removed from the docket per the parties request. (nms) (Entered: 06/26/2019) | |
| 6/21/2019 | Minute Entry for proceedings held before Judge Richard G. Andrews - Oral Argument held on 6/21/2019. Local counsel present for plaintiffs: M. Sharp, L. Moskowitz. Local counsel present for defendants: D. Wilks. (Court Reporter Heather Triozzi, Dale Hawkins.) (crb) (Entered: 07/26/2019) | |
| 6/21/2019 | 1034 | [SEALED] Reply in Support of Objections to Adverse Event Report Materials, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Higgins, James) Modified on 6/21/2019 (nms). (Entered: 06/21/2019) |
| 6/20/2019 | 1032 | ORAL ORDER: The hearing set for 6/21/2019, will now commence at 11:45 AM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 6/20/2019. (nms) (Entered: 06/20/2019) |
| 6/18/2019 | 1031 | REDACTED VERSION of 1025 Response to Objections, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A-D, # 2 Exhibit E, # 3 Exhibit F)(Czerwonka, Scott) (Entered: 06/18/2019) |
| 6/18/2019 | 1030 | Witness List for Oral Argument held on 6/13/2019. (crb) (Entered: 06/18/2019) |
| 6/17/2019 | 1029 | REDACTED VERSION of 1022 Objections, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 6/17/2019 (nms). (Entered: 06/17/2019) |
| 6/17/2019 | REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # 1022 . (nms) (Entered: 06/17/2019) | |
| 6/13/2019 | Minute Entry for proceedings held before Judge Richard G. Andrews - Oral Argument held on 6/13/2019. Local counsel present for plaintiffs: M. Sharp. Local counsel present for defendants: D. Wilks. (Witnesses: Steven Pieri, Hank Kessler, Ernst Berndt, Sharon Oster, Michelle Carnahan, Charles McCulloch, Michael Szarek, Stephen Doyle). (Court Reporters Heather Triozzi, Dale Hawkins.) (crb) (Entered: 06/14/2019) | |
| 6/13/2019 | 1028 | Letter to The Honorable Richard G. Andrews from James L. Higgins, Esq. regarding Motion to Seal the Courtroom for Limited Portions of Witness Testimony on June 13, 2019. (Sharp, Melanie) (Entered: 06/13/2019) |
| 6/13/2019 | SO ORDERED, re 1027 MOTION for Pro Hac Vice Appearance of Attorney Krista M. Carter, filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC, and 1026 MOTION for Pro Hac Vice Appearance of Attorney Michael H. Sapiro, filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Richard G. Andrews on 6/13/2019. (nms) (Entered: 06/13/2019) | |
| 6/13/2019 | 1027 | MOTION for Pro Hac Vice Appearance of Attorney Krista M. Carter - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Text of Proposed Order, # 2 Certification)(Czerwonka, Scott) (Entered: 06/13/2019) |
| 6/13/2019 | 1026 | MOTION for Pro Hac Vice Appearance of Attorney Michael H. Sapiro - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Text of Proposed Order, # 2 Certification)(Czerwonka, Scott) (Entered: 06/13/2019) |
| 6/11/2019 | 1025 | [SEALED] RESPONSE to 1022 Objections, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Certificate of Service)(Czerwonka, Scott) Modified on 6/12/2019 (nms). (Entered: 06/11/2019) |
| 6/7/2019 | 1024 | Witness List for Permanent Injunction hearing held on 6/6/2019. (crb) (Entered: 06/10/2019) |
| 6/7/2019 | 1023 | Letter to The Honorable Richard G. Andrews from James L. Higgins, Esq. regarding Declarations of Witnesses Testifying During the Permanent Injunction Hearing. (Higgins, James) (Entered: 06/07/2019) |
| 6/6/2019 | Minute Entry for proceedings held before Judge Richard G. Andrews - Permanent Injunction hearing held on 6/6/2019. Local counsel present for plaintiffs: M. Sharp. Local counsel present for defendants: D Wilks. (Witnesses: E. Stein, R. Eckel) (Court Reporter Jennifer Guy.) (crb) (Entered: 06/10/2019) | |
| 6/6/2019 | 1022 | [SEALED] OBJECTIONS to Adverse Event Report Materials, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Sharp, Melanie) Modified on 6/6/2019 (nms). (Entered: 06/06/2019) |
| 6/4/2019 | 1021 | SO ORDERED re STIPULATION on Conduct of Injunction Hearing (see Stipulation for further details). Signed by Judge Richard G. Andrews on 6/3/2019. (nms) (Entered: 06/04/2019) |
| 6/4/2019 | 1020 | Letter to The Honorable Richard G. Andrews, from James L. Higgins, Esq., regarding enclosing the Declarations of Drs. Stein and Eckel, scheduled to testify on June 6, 2019. (Higgins, James) Modified on 6/4/2019 (nms). (Entered: 06/04/2019) |
| 6/3/2019 | 1019 | ORAL ORDER: In connection with the permanent injunction hearing, the parties are requested to jointly provide two paper copies of the declarations (without any attached exhibits) at least 48 hours before the day and time at which the witness is scheduled to testify (i.e., Stein and Eckel by June 4 at 2 p.m.). The Court anticipates reading the declarations before the witnesses are cross-examined on them. Ordered by Judge Richard G. Andrews on 6/3/2019. (nms) (Entered: 06/03/2019) |
| 5/30/2019 | 1018 | Amended NOTICE to Take Deposition of Robert Eckel on June 4, 2019, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) Modified on 5/31/2019 (nms). (Entered: 05/30/2019) |
| 5/29/2019 | 1017 | PROPOSED Stipulation on Conduct of Injunction Hearing, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 5/30/2019 (nms). (Entered: 05/29/2019) |
| 5/24/2019 | 1016 | NOTICE to Take Deposition of Robert Eckel on June 3, 2019 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 05/24/2019) |
| 5/24/2019 | 1015 | REDACTED VERSION of 1008 Reply, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 5/28/2019 (nms). (Entered: 05/24/2019) |
| 5/23/2019 | 1014 | Amended NOTICE to Take Deposition of Michael Szarek on May 24, 2019, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) Modified on 5/23/2019 (nms). (Entered: 05/23/2019) |
| 5/23/2019 | 1013 | STIPULATION Regarding Lipoprotein A by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Entered: 05/23/2019) |
| 5/22/2019 | 1012 | NOTICE to Take Deposition of Robert Eckel on May 30, 2019 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 05/22/2019) |
| 5/22/2019 | 1011 | NOTICE to Take Deposition of Michael Szarek on May 31, 2019 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 05/22/2019) |
| 5/22/2019 | 1010 | NOTICE to Take Deposition of Hank Kessler on May 23, 2019 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 05/22/2019) |
| 5/17/2019 | 1009 | REDACTED VERSION of 1006 Answering Brief in Opposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 5/17/2019 (nms). (Entered: 05/17/2019) |
| 5/17/2019 | 1008 | [SEALED] REPLY re 989 MOTION to Unredact Defendants' Opening Brief in Support of Motion Under Fed. R. Civ. P. 59 for New Trial, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 5/17/2019 (nms). (Entered: 05/17/2019) |
| 5/15/2019 | 1007 | NOTICE to Take Deposition of Steven Pieri on May 16, 2019 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 05/15/2019) |
| 5/10/2019 | 1006 | [SEALED] ANSWERING BRIEF in Opposition re 989 MOTION to Unredact Defendants' Opening Brief in Support of Motion Under Fed. R. Civ. P. 59 for New Trial filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..Reply Brief due date per Local Rules is 5/17/2019. (Attachments: # 1 Exhibits 1-2, # 2 Certificate of Service)(Higgins, James) (Entered: 05/10/2019) |
| 5/6/2019 | 1005 | REDACTED VERSION of 993 Letter, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 5/6/2019 (nms). (Entered: 05/06/2019) |
| 5/3/2019 | 1004 | REDACTED VERSION of 989 MOTION to Unredact Defendants' Opening Brief in Support of Motion Under Fed. R. Civ. P. 59 for New Trial by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A-I)(Czerwonka, Scott) (Entered: 05/03/2019) |
| 5/3/2019 | 1003 | Official Transcript of Hearing held on 4/29/2019, before Special Master Yvonne Takvorian Saville, providing rulings on disputes. Court Reporter/Transcriber Basye Santiago Reporting, Telephone number 302-573-2300. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 5/24/2019. Redacted Transcript Deadline set for 6/3/2019. Release of Transcript Restriction set for 8/1/2019. (nms) (Entered: 05/03/2019) |
| 4/30/2019 | 1002 | Letter to The Honorable Richard G. Andrews, from James L. Higgins, Esq., regarding electronic versions of Amgen's Letter to the Court Regarding Praluent's Label (D.I. 993). (Higgins, James) Modified on 5/1/2019 (nms). (Entered: 04/30/2019) |
| 4/29/2019 | 1001 | REDACTED VERSION of 981 Declaration of Amal El Bakhar, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8)(Ovanesian, Michelle) Modified on 4/30/2019 (nms). (Entered: 04/29/2019) |
| 4/29/2019 | 1000 | REDACTED VERSION of 977 Declaration of Henry Kessler, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 4/30/2019 (nms). (Entered: 04/29/2019) |
| 4/29/2019 | 999 | REDACTED VERSION of 979 Declaration of Steven T. Pieri, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 4/30/2019 (nms). (Entered: 04/29/2019) |
| 4/29/2019 | 998 | REDACTED VERSION of 978 Declaration of Charles E. McCulloch, Ph.D., by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 4/30/2019 (nms). (Entered: 04/29/2019) |
| 4/29/2019 | 997 | REDACTED VERSION of 980 Declaration of Evan A. Stein, M.D., Ph.D., by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 4/30/2019 (nms). (Entered: 04/29/2019) |
| 4/29/2019 | 996 | REDACTED VERSION of 975 Declaration of Ernst R. Berndt, Ph.D., by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 4/30/2019 (nms). (Entered: 04/29/2019) |
| 4/29/2019 | 995 | REDACTED VERSION of 976 Declaration of Somnath Chattopadhyay, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 4/30/2019 (nms). (Entered: 04/29/2019) |
| 4/29/2019 | 994 | REDACTED VERSION of 974 Reply Brief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 4/30/2019 (nms). (Entered: 04/29/2019) |
| 4/29/2019 | 993 | [SEALED] Letter to The Honorable Richard G. Andrews, from Melanie K. Sharp, Esq., regarding response to Defendants' April 27, 2019 Letter (D.I. 991 ). (Sharp, Melanie) Modified on 4/30/2019 (nms). (Entered: 04/29/2019) |
| 4/29/2019 | 992 | REDACTED VERSION of 982 Reply Brief, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) (Entered: 04/29/2019) |
| 4/27/2019 | 991 | Letter to The Honorable Richard G. Andrews from Scott B. Czerwonka regarding a recent development relevant to Amgens motion for a Permanent Injunction against Praluent. (Attachments: # 1 Exhibit A)(Czerwonka, Scott) (Entered: 04/27/2019) |
| 4/26/2019 | Set Answering Brief Deadline re 989 MOTION to Unredact Defendants' Opening Brief in Support of Motion Under Fed. R. Civ. P. 59 for New Trial. Answering Brief/Response due date per Local Rules is 5/10/2019. (nms) (Entered: 04/29/2019) | |
| 4/26/2019 | 990 | Letter to The Honorable Richard G. Andrews, from Scott B. Czerwonka, regarding corrected Table 3 to the Declaration of Mark G. Duggan, PhD (D.I. 929 ). (Attachments: # 1 Exhibit A)(Czerwonka, Scott) Modified on 4/29/2019 (nms). (Entered: 04/26/2019) |
| 4/26/2019 | 989 | [SEALED] MOTION to Unredact Defendants' Opening Brief in Support of Motion Under Fed. R. Civ. P. 59 for New Trial - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits A-I, # 2 Certificate of Service)(Czerwonka, Scott) Modified on 4/29/2019 (nms). (Entered: 04/26/2019) |
| 4/26/2019 | 988 | REDACTED VERSION of 987 Letter, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 4/26/2019 (nms). (Entered: 04/26/2019) |
| 4/25/2019 | 987 | [SEALED] Letter to The Honorable Richard G. Andrews, from James L. Higgins, enclosing electronic versions of Amgen's Reply Briefs and declarations. (Higgins, James) Modified on 4/25/2019 (nms). (Entered: 04/25/2019) |
| 4/25/2019 | 986 | Letter to The Honorable Richard G. Andrews from Scott B. Czerwonka regarding enclosing electronic versions of defendants' reply briefs. (Czerwonka, Scott) Modified on 4/25/2019 (nms). (Entered: 04/25/2019) |
| 4/25/2019 | 985 | REDACTED VERSION of 944 Letter, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 4/25/2019 (nms). (Entered: 04/25/2019) |
| 4/25/2019 | REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # 944 . (nms) (Entered: 04/25/2019) | |
| 4/23/2019 | CORRECTING ENTRY: Per counsel's request the pdf of the certificate of service for D.I. 982 has been added to that filing as it was inadvertently omitted. (nms) (Entered: 04/23/2019) | |
| 4/23/2019 | 984 | REQUEST for Oral Argument by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC re 883 MOTION for New Trial Under Fed. R. Civ. P. 59, 886 MOTION for Judgment as a Matter of Law Under Fed. R. Civ. P. 50(b). (Wilks, David) (Entered: 04/23/2019) |
| 4/22/2019 | 983 | REPLY BRIEF re 886 MOTION for Judgment as a Matter of Law Under Fed. R. Civ. P. 50(b) filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) (Entered: 04/22/2019) |
| 4/22/2019 | 982 | [SEALED] REPLY BRIEF re 883 MOTION for New Trial Under Fed. R. Civ. P. 59 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) (Additional attachment(s) added on 4/23/2019: # 1 Certificate of Service) (nms). (Entered: 04/22/2019) |
| 4/22/2019 | 981 | [SEALED] DECLARATION of Amal El Bakhar re 974 Reply Brief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits 245-261, # 2 Exhibits 262 part 1, # 3 Exhibit 262 part 2, # 4 Exhibits 263-279, # 5 Exhibits 280-295, # 6 Exhibits 296-303, # 7 Exhibits 304-327, # 8 Exhibits 328-335, # 9 Certificate of Service)(Sharp, Melanie) Modified on 4/23/2019 (nms). (Entered: 04/22/2019) |
| 4/22/2019 | 980 | [SEALED] DECLARATION of Evan A. Stein, M.D., Ph.D. re 974 Reply Brief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) Modified on 4/23/2019 (nms). (Entered: 04/22/2019) |
| 4/22/2019 | 979 | [SEALED] DECLARATION of Steven T. Pieri re 974 Reply Brief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) Modified on 4/23/2019 (nms). (Entered: 04/22/2019) |
| 4/22/2019 | 978 | [SEALED] DECLARATION Charles E. McCulloch, Ph.D. re 974 Reply Brief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) Modified on 4/23/2019 (nms). (Entered: 04/22/2019) |
| 4/22/2019 | 977 | [SEALED] DECLARATION of Henry Kessler re 974 Reply Brief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) Modified on 4/23/2019 (nms). (Entered: 04/22/2019) |
| 4/22/2019 | 976 | [SEALED] DECLARATION of Somnath Chattopadhyay re 974 Reply Brief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) Modified on 4/23/2019 (nms). (Entered: 04/22/2019) |
| 4/22/2019 | 975 | [SEALED] DECLARATION of Ernst R. Berndt, Ph.D. re 974 Reply Brief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) Modified on 4/23/2019 (nms). (Entered: 04/22/2019) |
| 4/22/2019 | 974 | [SEALED] REPLY BRIEF re 870 MOTION for Permanent Injunction filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) (Entered: 04/22/2019) |
| 4/15/2019 | 973 | REDACTED VERSION of 953 Declaration of Anne W. Pearlman, Volume 9, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 4/16/2019 (nms). (Entered: 04/15/2019) |
| 4/15/2019 | 972 | REDACTED VERSION of 952 Declaration of Anne W. Pearlman, Volume 8, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 4/16/2019 (nms). (Entered: 04/15/2019) |
| 4/15/2019 | 971 | REDACTED VERSION of 951 Declaration of Anne W. Pearlman, Volume 7, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 229-231, # 2 Exhibits 232-254, # 3 Exhibits 255-271)(Czerwonka, Scott) Modified on 4/16/2019 (nms). (Entered: 04/15/2019) |
| 4/15/2019 | 970 | REDACTED VERSION of 950 Declaration of Anne W. Pearlman, Volume 6, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 197-202, # 2 Exhibits 203-207, # 3 Exhibits 208-222)(Czerwonka, Scott) Modified on 4/16/2019 (nms). (Entered: 04/15/2019) |
| 4/15/2019 | 969 | REDACTED VERSION of 949 Declaration of Anne W. Pearlman, Volume 5, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 138-145, # 2 Exhibits 146-154, # 3 Exhibits 155-162, # 4 Exhibits 163-169, # 5 Exhibits 170-184, # 6 Exhibits 185-186)(Czerwonka, Scott) Modified on 4/16/2019 (nms). (Entered: 04/15/2019) |
| 4/15/2019 | 968 | REDACTED VERSION of 948 Declaration of Anne W. Pearlman, Volume 4, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 90-93, # 2 Exhibits 94-99, # 3 Exhibits 100-107, # 4 Exhibits 108-1103, # 5 Exhibits 114-120, # 6 Exhibits 121-123, # 7 Exhibits 124-131)(Czerwonka, Scott) Modified on 4/16/2019 (nms). (Entered: 04/15/2019) |
| 4/15/2019 | 967 | REDACTED VERSION of 947 Declaration of Anne W. Pearlman, Volume 3, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 4/16/2019 (nms). (Entered: 04/15/2019) |
| 4/15/2019 | 966 | REDACTED VERSION of 946 Declaration of Anne W. Pearlman, Volume 2, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 39-48, # 2 Exhibits 49-53)(Czerwonka, Scott) Modified on 4/16/2019 (nms). (Entered: 04/15/2019) |
| 4/15/2019 | 965 | REDACTED VERSION of 945 Declaration of Anne W. Pearlman, Volume 1, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 1-28)(Czerwonka, Scott) Modified on 4/16/2019 (nms). (Entered: 04/15/2019) |
| 4/15/2019 | 964 | REDACTED VERSION of 934 Declaration of Sharon Oster, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Czerwonka, Scott) Modified on 4/15/2019 (nms). (Entered: 04/15/2019) |
| 4/15/2019 | 963 | REDACTED VERSION of 933 Declaration of Michael Szarek, PH.D, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A)(Czerwonka, Scott) Modified on 4/15/2019 (nms). (Entered: 04/15/2019) |
| 4/15/2019 | 962 | REDACTED VERSION of 932 Declaration of Leonard Schleifer, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 4/15/2019 (nms). (Entered: 04/15/2019) |
| 4/15/2019 | 961 | REDACTED VERSION of 931 Declaration of Shannon Faught, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 4/15/2019 (nms). (Entered: 04/15/2019) |
| 4/15/2019 | 960 | REDACTED VERSION of 930 Declaration of Robert Eckel, M.D., by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A)(Czerwonka, Scott) Modified on 4/15/2019 (nms). (Entered: 04/15/2019) |
| 4/15/2019 | 959 | REDACTED VERSION of 929 Declaration of Mark Duggan, PhD, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A)(Czerwonka, Scott) Modified on 4/15/2019 (nms). (Entered: 04/15/2019) |
| 4/15/2019 | 958 | REDACTED VERSION of 928 Declaration of Eugenia Dubuk, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 4/15/2019 (nms). (Entered: 04/15/2019) |
| 4/15/2019 | 957 | REDACTED VERSION of 927 Declaration of Michael Doyle, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Czerwonka, Scott) Modified on 4/15/2019 (nms). (Entered: 04/15/2019) |
| 4/15/2019 | 956 | REDACTED VERSION of 926 Declaration of Michelle Carnahan, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 4/15/2019 (nms). (Entered: 04/15/2019) |
| 4/15/2019 | 955 | REDACTED VERSION of 925 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) (Entered: 04/15/2019) |
| 4/12/2019 | 954 | Letter to The Honorable Richard G. Andrews, from Scott B. Czerwonka, enclosing electronic versions of Defendants' Answering Brief and supporting documents. (Czerwonka, Scott) Modified on 4/12/2019 (nms). (Entered: 04/12/2019) |
| 4/12/2019 | 953 | [SEALED] Declaration of Anne W. Pearlman, Volume 9 re 925 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 321-333, # 2 Certificate of Service)(Czerwonka, Scott) Modified on 4/12/2019 (nms). (Entered: 04/12/2019) |
| 4/12/2019 | 952 | [SEALED] Declaration of Anne W. Pearlman, Volume 8 re 925 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 4/12/2019 (nms). (Entered: 04/12/2019) |
| 4/12/2019 | 951 | [SEALED] Declaration of Anne W. Pearlman, Volume 7 re 925 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 229-231, # 2 Exhibits 232-243, # 3 Exhibits 244-255, # 4 Exhibits 256-267, # 5 Exhibits 268-271, # 6 Certificate of Service)(Czerwonka, Scott) Modified on 4/12/2019 (nms). (Entered: 04/12/2019) |
| 4/12/2019 | 950 | [SEALED] Declaration of Anne W. Pearlman, Volume 6 re 925 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 190-198, # 2 Exhibits 199-202, # 3 Exhibits 203-222, # 4 Certificate of Service)(Czerwonka, Scott) Modified on 4/12/2019 (nms). (Entered: 04/12/2019) |
| 4/12/2019 | 949 | [SEALED] Declaration of Anne W. Pearlman, Volume 5 re 925 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 138-144, # 2 Exhibits 145-152, # 3 Exhibits 153-161, # 4 Exhibits 162-163, # 5 Exhibits 164-174, # 6 Exhibits 175-181, # 7 Exhibits 182-184, # 8 Exhibits 185-186, # 9 Certificate of Service)(Czerwonka, Scott) Modified on 4/12/2019 (nms). (Entered: 04/12/2019) |
| 4/12/2019 | 948 | [SEALED] Declaration of Anne W. Pearlman, Volume 4 re 925 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 80-93, # 2 Exhibits 94-96, # 3 Exhibits 97-104, # 4 Exhibits 105-108, # 5 Exhibits 109-118, # 6 Exhibits 119-120, # 7 Exhibits 121-122, # 8 Exhibits 123-129, # 9 Exhibits 130-131, # 10 Certificate of Service)(Czerwonka, Scott) Modified on 4/12/2019 (nms). (Entered: 04/12/2019) |
| 4/12/2019 | CORRECTING ENTRY: The main pdfs for D.I. 925 , 930 , 933 , and 934 have been replaced per counsel's request. Citation and exhibit errors have been corrected. (nms) (Entered: 04/12/2019) | |
| 4/12/2019 | 947 | [SEALED] Declaration of Anne W. Pearlman, Volume 3 re 925 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 59 - part 1, # 2 Exhibit 59 - part 2, # 3 Exhibit 59 - part 3, # 4 Exhibits 60-65, # 5 Exhibits 66-72, # 6 Certificate of Service)(Czerwonka, Scott) Modified on 4/12/2019 (nms). (Entered: 04/12/2019) |
| 4/12/2019 | 946 | [SEALED] Declaration of Anne W. Pearlman, Volume 2 re 925 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 37-39, # 2 Exhibits 40-42, # 3 Exhibit 43 - part 1, # 4 Exhibit 43 - part 2, # 5 Exhibit 43 - part 3, # 6 Exhibits 44-49, # 7 Exhibits 50-52, # 8 Exhibits 53, # 9 Certificate of Service)(Czerwonka, Scott) Modified on 4/12/2019 (nms). (Entered: 04/12/2019) |
| 4/12/2019 | 945 | [SEALED] DECLARATION of Anne W. Pearlman, Volume 1 re 925 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 1-10, # 2 Exhibits 11-13, # 3 Exhibits 14-22, # 4 Exhibit 23, # 5 Exhibits 24-28, # 6 Certificate of Service)(Czerwonka, Scott) Modified on 4/12/2019 (nms). (Entered: 04/12/2019) |
| 4/12/2019 | CORRECTING ENTRY: The nine volume declaration filed at D.I. 935 through D.I. 943 has been removed from the docket. Counsel advised there were multiple errors that needed to be corrected (citations, missing exhibits, etc.). Counsel will refile a corrected declaration. (nms) (Entered: 04/12/2019) | |
| 4/11/2019 | 944 | [SEALED] Letter to The Honorable Richard G. Andrews, from James L. Higgins, Esq., regarding enclosing electronic versions of Amgen's briefs and supporting documents. (Higgins, James) Modified on 4/11/2019 (nms). (Entered: 04/11/2019) |
| 4/9/2019 | CORRECTING ENTRY: The main pdf for D.I. 943 has been replaced with an amended version per counsel's request. Exhibit 310 has been added as it was inadvertently omitted in the first instance. (nms) (Entered: 04/09/2019) | |
| 4/8/2019 | 934 | [SEALED] DECLARATION of Sharon M. Oster re 925 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits A-B, # 2 Certificate of Service)(Czerwonka, Scott) Modified on 4/9/2019 (nms). (Main Document 934 replaced on 4/12/2019) (nms). (Entered: 04/08/2019) |
| 4/8/2019 | 933 | [SEALED] DECLARATION of Michael Szarek, PH.D. re 925 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Czerwonka, Scott) Modified on 4/9/2019 (nms). (Main Document 933 replaced on 4/12/2019) (nms). (Entered: 04/08/2019) |
| 4/8/2019 | 932 | [SEALED] DECLARATION of Leonard S. Schleifer re 925 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 4/9/2019 (nms). (Entered: 04/08/2019) |
| 4/8/2019 | 931 | [SEALED] DECLARATION of Shannon Faught re 925 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 4/9/2019 (nms). (Entered: 04/08/2019) |
| 4/8/2019 | 930 | [SEALED] DECLARATION of Robert H. Eckel, M.D. re 925 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Czerwonka, Scott) Modified on 4/9/2019 (nms). (Main Document 930 replaced on 4/12/2019) (nms). (Entered: 04/08/2019) |
| 4/8/2019 | 929 | [SEALED] DECLARATION of Mark G. Duggan, PhD re 925 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Czerwonka, Scott) Modified on 4/9/2019 (nms). (Entered: 04/08/2019) |
| 4/8/2019 | 928 | [SEALED] DECLARATION of Eugenia Dubuk re 925 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 4/9/2019 (nms). (Entered: 04/08/2019) |
| 4/8/2019 | 927 | [SEALED] DECLARATION of Michael Doyle, M.D. re 925 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 1-2, # 2 Certificate of Service)(Czerwonka, Scott) Modified on 4/9/2019 (nms). (Entered: 04/08/2019) |
| 4/8/2019 | 926 | [SEALED] DECLARATION of Michelle Carnahan re 925 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 4/9/2019 (nms). (Entered: 04/08/2019) |
| 4/8/2019 | 925 | [SEALED] ANSWERING BRIEF in Opposition re 870 MOTION for Permanent Injunction filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Reply Brief due date per Local Rules is 4/15/2019. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) (Main Document 925 replaced on 4/12/2019) (nms). (Entered: 04/08/2019) |
| 4/8/2019 | 924 | DECLARATION of Michelle M. Ovanesian re 923 Answering Brief in Opposition, and 922 Answering Brief in Opposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits 1-5)(Sharp, Melanie) Modified on 4/9/2019 (nms). (Entered: 04/08/2019) |
| 4/8/2019 | 923 | ANSWERING BRIEF in Opposition re 886 MOTION for Judgment as a Matter of Law Under Fed. R. Civ. P. 50(b) filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..Reply Brief due date per Local Rules is 4/15/2019. (Sharp, Melanie) (Entered: 04/08/2019) |
| 4/8/2019 | 922 | ANSWERING BRIEF in Opposition re 883 MOTION for New Trial Under Fed. R. Civ. P. 59 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..Reply Brief due date per Local Rules is 4/15/2019. (Sharp, Melanie) (Entered: 04/08/2019) |
| 4/2/2019 | 921 | NOTICE of Withdrawal of Plaintiffs' Notice of Intent to Redact by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. re 894 Notice of Intent to Request Transcript Redaction (Higgins, James) (Entered: 04/02/2019) |
| 3/25/2019 | 920 | REDACTED VERSION of 901 Declaration of Amal El Bakhar, Volume 7, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/26/2019 (nms). (Entered: 03/25/2019) |
| 3/25/2019 | 919 | REDACTED VERSION of 900 Declaration of Amal El Bakhar, Volume 6, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/26/2019 (nms). (Entered: 03/25/2019) |
| 3/25/2019 | 918 | REDACTED VERSION of 899 Declaration of Amal El Bakhar, Volume 5, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4)(Ovanesian, Michelle) Modified on 3/26/2019 (nms). (Entered: 03/25/2019) |
| 3/25/2019 | 917 | REDACTED VERSION of 898 Declaration of Amal El Bakhar, Volume 4, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Part 2, # 2 Part 3)(Ovanesian, Michelle) Modified on 3/26/2019 (nms). (Entered: 03/25/2019) |
| 3/25/2019 | 916 | REDACTED VERSION of 897 Declaration of Amal El Bakhar, Volume 3, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/26/2019 (nms). (Entered: 03/25/2019) |
| 3/25/2019 | 915 | REDACTED VERSION of 896 Declaration of Amal El Bakhar, Volume 2, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4)(Ovanesian, Michelle) Modified on 3/26/2019 (nms). (Entered: 03/25/2019) |
| 3/25/2019 | 914 | REDACTED VERSION of 895 Declaration of Amal El Bakhar, Volume 1, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/26/2019 (nms). (Entered: 03/25/2019) |
| 3/25/2019 | 913 | REDACTED VERSION of 874 Declaration of Somnath Chattopadhyay, P.E., by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/26/2019 (nms). (Entered: 03/25/2019) |
| 3/25/2019 | 912 | REDACTED VERSION of 875 Declaration of Robert Bradway, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/26/2019 (nms). (Entered: 03/25/2019) |
| 3/25/2019 | 911 | REDACTED VERSION of 872 Declaration of Henry Kessler, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/26/2019 (nms). (Entered: 03/25/2019) |
| 3/25/2019 | 910 | REDACTED VERSION of 873 Declaration of Steven T. Pieri, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/26/2019 (nms). (Entered: 03/25/2019) |
| 3/25/2019 | 909 | REDACTED VERSION of 879 Declaration of Charles E. McCulloch, Ph.D., by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/26/2019 (nms). (Entered: 03/25/2019) |
| 3/25/2019 | 908 | REDACTED VERSION of 877 Declaration Evan A. Stein, M.D., Ph.D., by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/26/2019 (nms). (Entered: 03/25/2019) |
| 3/25/2019 | 907 | REDACTED VERSION of 878 Declaration of Ernst R. Berndt, Ph.D., by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/26/2019 (nms). (Entered: 03/25/2019) |
| 3/25/2019 | 906 | REDACTED VERSION of 871 Opening Brief in Support, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/26/2019 (nms). (Entered: 03/25/2019) |
| 3/25/2019 | 905 | REDACTED VERSION of 888 Opening Brief in Support, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 1-4)(Czerwonka, Scott) (Entered: 03/25/2019) |
| 3/25/2019 | 904 | REDACTED VERSION of 885 Opening Brief in Support, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1Exhibits 1-24)(Czerwonka, Scott) Modified on 3/26/2019 (nms). (Entered: 03/25/2019) |
| 3/21/2019 | 903 | Letter to The Honorable Richard G. Andrews, from Scott B. Czerwonka, regarding electronic versions of Defendants' Motion for New Trial and Motion for Judgment as a Matter of Law. (Czerwonka, Scott) Modified on 3/22/2019 (nms). (Entered: 03/21/2019) |
| 3/21/2019 | 902 | [SEALED] Letter to The Honorable Richard G. Andrews, from James L. Higgins, Esq., regarding electronic versions of Amgen's Opening Brief. (Higgins, James) Modified on 3/22/2019 (nms). (Entered: 03/21/2019) |
| 3/21/2019 | 901 | [SEALED] Declaration of Amal El Bakhar, Volume 7 re 870 MOTION for Permanent Injunction, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits 205-227, # 2 Exhibits 228-244, # 3 Certificate of Service)(Sharp, Melanie) Modified on 3/21/2019 (nms). (Entered: 03/21/2019) |
| 3/21/2019 | 900 | [SEALED] Declaration of Amal El Bakhar, Volume 6 re 870 Motion for Permanent Injunctive Relief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits 139-161, # 2 Exhibits 162-181, # 3 Certificate of Service)(Sharp, Melanie) Modified on 3/21/2019 (nms). (Entered: 03/21/2019) |
| 3/21/2019 | 899 | [SEALED] Declaration of Amal El Bakhar, Volume 5 re 870 Motion for Permanent Injunctive Relief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits 82-92, # 2 Exhibit 93, Part 1, # 3 Exhibit 93, Part 2, # 4 Exhibits 94-101, # 5 Exhibits 102-122, # 6 Certificate of Service)(Sharp, Melanie) Modified on 3/21/2019 (nms). (Entered: 03/21/2019) |
| 3/21/2019 | 898 | [SEALED] Declaration of Amal El Bakhar, Volume 4 re 870 Motion for Permanent Injunctive Relief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits 72-75, # 2 Exhibits 76-77, # 3 Certificate of Service)(Sharp, Melanie) Modified on 3/21/2019 (nms). (Entered: 03/21/2019) |
| 3/21/2019 | 897 | [SEALED] Declaration of Amal El Bakhar, Volume 3 re Motion for Permanent Injunctive Relief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits 52-65, # 2 Certificate of Service)(Sharp, Melanie) Modified on 3/21/2019 (nms). (Entered: 03/21/2019) |
| 3/21/2019 | 896 | [SEALED] Declaration of Amal El Bakhar, Volume 2 re 870 Motion for Permanent Injunctive Relief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits 25-31, # 2 Exhibits 32-39, # 3 Certificate of Service)(Sharp, Melanie) Modified on 3/21/2019 (nms). (Entered: 03/21/2019) |
| 3/21/2019 | 895 | [SEALED] DECLARATION of Amal E. Bakhar, Volume 1 re 870 MOTION for Permanent Injunction, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits 1-10, # 2 Exhibits 11-20, # 3 Certificate of Service)(Sharp, Melanie) Modified on 3/21/2019 (nms). (Entered: 03/21/2019) |
| 3/21/2019 | CORRECTING ENTRY: The main pdfs for D.I. 877 , 878 , and 879 have been replaced per counsel's request. Citation corrections have been made. D.I. 880, 882, 889, 890, 891, 892, and 893 have been removed from the docket. Counsel has identified inadvertent omission of pages for some of the exhibits as well as other non-substantive changes. Counsel will refile the corrected version of this declaration and its exhibits. (nms) (Entered: 03/21/2019) | |
| 3/20/2019 | CORRECTING ENTRY: The main pdfs for D.I. 880, 882, 889, 890, 891, 892, and 893 have been replaced with amended versions. The cover pages for the filings have been updated. (nms) (Entered: 03/20/2019) | |
| 3/19/2019 | 894 | NOTICE of Intent to Request Redaction re 865 Transcript, 863 Transcript, 864 Transcript, and 866 Transcript, by Amgen, Inc., Amgen Manufacturing, Limited, and Amgen USA, Inc.. (Ovanesian, Michelle) Modified on 3/20/2019 (nms). (Entered: 03/19/2019) |
| 3/19/2019 | CORRECTING ENTRY: The main pdf for D.I. 885 has been replaced with an amended version. The title on the filing has been corrected. (nms) (Entered: 03/19/2019) | |
| 3/19/2019 | CORRECTING ENTRY: The filings transacted on 3/18/2019, at D.I. 881, 884, 887, 890, 892, 893, 895, 896, 897, 899, 900, 902, 903, and 904 have been removed from the docket. The volumes of exhibits relating to the declaration of Amal E. Bakhar have been reworked in a more efficient way. Initially filed in 21 volumes the exhibits are now in 7 volumes. D.I. 880 now reflects exhibits 1-20. D.I. 882, reflects exhibits 21-39. D.I. 889 reflects exhibits 40-65. D.I. 890 reflects exhibits 66-77. D.I. 891 reflects exhibits 78-122. D.I. 892 reflects exhibits 123-181. And D.I. 893 reflects exhibits 182-244. The sequential re-numbering of the D.I. numbers on the docket has been corrected as much as possible. (nms) (Entered: 03/19/2019) | |
| 3/18/2019 | 888 | [SEALED] OPENING BRIEF in Support re 886 MOTION for Judgment as a Matter of Law Under Fed. R. Civ. P. 50(b), filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Answering Brief/Response due date per Local Rules is 4/1/2019. (Attachments: # 1 Exhibits 1-4, # 2 Certificate of Service)(Czerwonka, Scott) Modified on 3/19/2019 (nms). (Entered: 03/18/2019) |
| 3/18/2019 | 886 | MOTION for Judgment as a Matter of Law Under Fed. R. Civ. P. 50(b) - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Proposed Order)(Czerwonka, Scott) Modified on 3/19/2019 (nms). (Entered: 03/18/2019) |
| 3/18/2019 | 885 | [SEALED] OPENING BRIEF in Support re 883 MOTION for New Trial Under Fed. R. Civ. P. 59, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Answering Brief/Response due date per Local Rules is 4/1/2019. (Attachments: # 1 Exhibits 1-24, # 2 Certificate of Service)(Czerwonka, Scott) Modified on 3/19/2019 (nms). (Main Document 885 replaced on 3/19/2019) (nms). (Entered: 03/18/2019) |
| 3/18/2019 | 883 | MOTION for New Trial Under Fed. R. Civ. P. 59 - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Proposed Order)(Czerwonka, Scott) Modified on 3/19/2019 (nms). (Entered: 03/18/2019) |
| 3/18/2019 | 879 | [SEALED] DECLARATION of Charles E. McCulloch, Ph.D. re 871 Opening Brief in Support, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Sharp, Melanie) Modified on 3/18/2019 (nms). (Main Document 879 replaced on 3/21/2019) (nms). (Entered: 03/18/2019) |
| 3/18/2019 | 878 | [SEALED] DECLARATION of Ernst R. Berndt, PhD re 871 Opening Brief in Support, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) Modified on 3/18/2019 (nms). (Main Document 878 replaced on 3/21/2019) (nms). (Entered: 03/18/2019) |
| 3/18/2019 | 877 | [SEALED] DECLARATION of Evan A. Stein, M.D., Ph.D. re 871 Opening Brief in Support, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Sharp, Melanie) Modified on 3/18/2019 (nms). (Main Document 877 replaced on 3/21/2019) (nms). (Entered: 03/18/2019) |
| 3/18/2019 | 876 | DECLARATION of Jeremy Grunstein, Ph.D. re 871 Opening Brief in Support, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Sharp, Melanie) Modified on 3/18/2019 (nms). (Entered: 03/18/2019) |
| 3/18/2019 | 875 | [SEALED] DECLARATION of Robert Bradway re 871 Opening Brief in Support, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) Modified on 3/18/2019 (nms). (Entered: 03/18/2019) |
| 3/18/2019 | 874 | [SEALED] DECLARATION of Somnath Chattopadhyay, P.E. re 871 Opening Brief in Support, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) Modified on 3/18/2019 (nms). (Entered: 03/18/2019) |
| 3/18/2019 | 873 | [SEALED] DECLARATION of Steven T. Pieri re 871 Opening Brief in Support, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) Modified on 3/18/2019 (nms). (Entered: 03/18/2019) |
| 3/18/2019 | 872 | [SEALED] DECLARATION of Henry Kessler re 871 Opening Brief in Support, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) Modified on 3/18/2019 (nms). (Entered: 03/18/2019) |
| 3/18/2019 | 871 | [SEALED] OPENING BRIEF in Support re 870 MOTION for Permanent Injunction filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..Answering Brief/Response due date per Local Rules is 4/1/2019. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) (Entered: 03/18/2019) |
| 3/18/2019 | 870 | MOTION for Permanent Injunction - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Text of Proposed Order)(Higgins, James) (Entered: 03/18/2019) |
| 3/14/2019 | 869 | ORAL ORDER: Amgen's Corrected Objections (D.I. 765 ) are DISMISSED as moot. Ordered by Judge Richard G. Andrews on 3/14/2019. (nms) (Entered: 03/14/2019) |
| 3/13/2019 | 868 | REDACTED VERSION of 858 Letter, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit C, # 2 Exhibit D)(Czerwonka, Scott) (Entered: 03/13/2019) |
| 3/12/2019 | 867 | ORDER Regarding Injunction Hearing and Briefing. Signed by Judge Richard G. Andrews on 3/12/2019. (nms) (Entered: 03/12/2019) |
| 3/12/2019 | 866 | Official Transcript of Jury Trial held on 2/25/19 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather Triozzi/Dale Hawkins,Telephone number 302-573-6195. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 4/2/2019. Redacted Transcript Deadline set for 4/12/2019. Release of Transcript Restriction set for 6/10/2019. (Triozzi, Heather) (Entered: 03/12/2019) |
| 3/12/2019 | 865 | Official Transcript of Jury Trial held on 2/22/19 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather Triozzi/Dale Hawkins,Telephone number 302-573-6195. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 4/2/2019. Redacted Transcript Deadline set for 4/12/2019. Release of Transcript Restriction set for 6/10/2019. (Triozzi, Heather) (Entered: 03/12/2019) |
| 3/12/2019 | 864 | Official Transcript of held on 2/21/19 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather Triozzi/Dale Hawkins,Telephone number 302-573-6195. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 4/2/2019. Redacted Transcript Deadline set for 4/12/2019. Release of Transcript Restriction set for 6/10/2019. (Triozzi, Heather) (Entered: 03/12/2019) |
| 3/12/2019 | 863 | Official Transcript of Jury Trial held on 2/19/19 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather Triozzi/Dale Hawkins,Telephone number 302-573-6195. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 4/2/2019. Redacted Transcript Deadline set for 4/12/2019. Release of Transcript Restriction set for 6/10/2019. (Triozzi, Heather) (Entered: 03/12/2019) |
| 3/7/2019 | 862 | Letter to The Honorable Richard G. Andrews from Melanie K. Sharp, Esq. regarding enclosed Joint Proposed Order on permanent injunction hearing and briefing schedule. (Attachments: # 1 Text of Proposed Order)(Sharp, Melanie) (Entered: 03/07/2019) |
| 3/7/2019 | CORRECTING ENTRY: The Exhibit List at D.I. 815 was replaced with an amended version. (crb) (Entered: 03/07/2019) | |
| 3/6/2019 | 861 | REDACTED VERSION of 810 Cross Proffer, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 1-16)(Czerwonka, Scott) Modified on 3/6/2019 (nms). (Entered: 03/06/2019) |
| 3/6/2019 | 860 | REDACTED VERSION of 809 Cross Proffer, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 1-16)(Czerwonka, Scott) Modified on 3/6/2019 (nms). (Entered: 03/06/2019) |
| 3/6/2019 | 859 | REDACTED VERSION of 798 Response to Objections by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 1)(Czerwonka, Scott) (Entered: 03/06/2019) |
| 3/5/2019 | 858 | [SEALED] Letter to The Honorable Richard G. Andrews from Scott B. Czerwonka regarding Exhibits Inadvertently Omitted to Proffer of Leonard Schleifer (D.I. 770 ). (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Certificate of Service)(Czerwonka, Scott) Modified on 3/5/2019 (nms). (Entered: 03/05/2019) |
| 3/4/2019 | 857 | REDACTED VERSION of 808 Exhibits, Volume 7 re Objections and Counter-Proffer, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/5/2019 (nms). (Entered: 03/04/2019) |
| 3/4/2019 | 856 | REDACTED VERSION of 807 Exhibits, Volume 6 re Objections and Counter-Proffer, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/5/2019 (nms). (Entered: 03/04/2019) |
| 3/4/2019 | 855 | REDACTED VERSION of 806 Exhibits, Volume 5 re Objections and Counter-Proffer, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/5/2019 (nms). (Entered: 03/04/2019) |
| 3/4/2019 | 854 | REDACTED VERSION of 805 Exhibits, Volume 4 re Objections and Counter-Proffer, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/5/2019 (nms). (Entered: 03/04/2019) |
| 3/4/2019 | 853 | REDACTED VERSION of 804 Exhibits, Volume 3 re Objections and Counter-Proffer, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/5/2019 (nms). (Entered: 03/04/2019) |
| 3/4/2019 | 852 | REDACTED VERSION of 803 Exhibits, Volume 2 re Objections and Counter-Proffer, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/5/2019 (nms). (Entered: 03/04/2019) |
| 3/4/2019 | 851 | REDACTED VERSION of 801 Exhibits, Volume 1 re Objections and Counter-Proffer, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/5/2019 (nms). (Entered: 03/04/2019) |
| 3/4/2019 | 850 | REDACTED VERSION of 800 Objections and Counter-Proffer to Proffers of Scott Boyd, M.D., Ph.D and Michael J. Eck, M.D., Ph.D., by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/5/2019 (nms). (Entered: 03/04/2019) |
| 3/4/2019 | 849 | REDACTED VERSION of 799 Objections and Counter-Proffer to Second Remand Proffer of Dr. Leonard Schleifer, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/5/2019 (nms). (Entered: 03/04/2019) |
| 3/4/2019 | 848 | REDACTED VERSION of 789 MEMORANDUM in Support, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Czerwonka, Scott) (Entered: 03/04/2019) |
| 3/4/2019 | 847 | REDACTED VERSION of 788 MEMORANDUM in Support, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) (Entered: 03/04/2019) |
| 3/1/2019 | 846 | REDACTED VERSION of 797 Proffer of Excerpted Expert Opinions of Gregory A. Petsko, D. Phil., by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/1/2019 (nms). (Entered: 03/01/2019) |
| 3/1/2019 | 845 | REDACTED VERSION of 796 Objections, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/1/2019 (nms). (Entered: 03/01/2019) |
| 3/1/2019 | 844 | REDACTED VERSION of 795 Objections, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/1/2019 (nms). (Entered: 03/01/2019) |
| 3/1/2019 | 843 | REDACTED VERSION of 794 Objections, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/1/2019 (nms). (Entered: 03/01/2019) |
| 3/1/2019 | 842 | REDACTED VERSION of 793 MOTION for Judgment as a Matter of Law by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) (Entered: 03/01/2019) |
| 3/1/2019 | 841 | REDACTED VERSION of 772 MOTION for Limited Admission by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)(Czerwonka, Scott) (Entered: 03/01/2019) |
| 3/1/2019 | 840 | Letter to The Honorable Richard G. Andrews from David E. Wilks regarding Response to the Permanent Injunction Schedule submitted by Melanie K. Sharp on March 1, 2019. (Wilks, David) (Entered: 03/01/2019) |
| 3/1/2019 | 839 | Letter to The Honorable Richard G. Andrews from Melanie K. Sharp, Esq. regarding Permanent Injunction Hearing and Briefing. (Attachments: # 1 Text of Proposed Order)(Sharp, Melanie) (Entered: 03/01/2019) |
| 2/28/2019 | 838 | REDACTED VERSION of 802 MOTION for Judgment as a Matter of Law Under Fed. R. Civ. P. 50(A) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) (Entered: 02/28/2019) |
| 2/28/2019 | 837 | REDACTED VERSION of 787 Proffer, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 1-31)(Czerwonka, Scott) Modified on 3/1/2019 (nms). (Entered: 02/28/2019) |
| 2/28/2019 | 836 | REDACTED VERSION of 786 Exhibits, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 3/1/2019 (nms). (Entered: 02/28/2019) |
| 2/28/2019 | 835 | REDACTED VERSION of 785 Exhibits, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 3/1/2019 (nms). (Entered: 02/28/2019) |
| 2/28/2019 | 834 | REDACTED VERSION of 784 Exhibits, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 3/1/2019 (nms). (Entered: 02/28/2019) |
| 2/28/2019 | 833 | REDACTED VERSION of 783 Exhibits, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 3/1/2019 (nms). (Entered: 02/28/2019) |
| 2/28/2019 | 832 | REDACTED VERSION of 782 Exhibits, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 3/1/2019 (nms). (Entered: 02/28/2019) |
| 2/28/2019 | 831 | REDACTED VERSION of 781 Exhibits, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 3/1/2019 (nms). (Entered: 02/28/2019) |
| 2/28/2019 | 830 | REDACTED VERSION of 780 Exhibits, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 3/1/2019 (nms). (Entered: 02/28/2019) |
| 2/28/2019 | 829 | REDACTED VERSION of 779 Exhibits, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 3/1/2019 (nms). (Entered: 02/28/2019) |
| 2/28/2019 | 828 | REDACTED VERSION of 778 Exhibits, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 3/1/2019 (nms). (Entered: 02/28/2019) |
| 2/28/2019 | 827 | REDACTED VERSION of 777 Exhibits, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 3/1/2019 (nms). (Entered: 02/28/2019) |
| 2/28/2019 | 826 | REDACTED VERSION of 776 Exhibits, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 3/1/2019 (nms). (Entered: 02/28/2019) |
| 2/28/2019 | 825 | REDACTED VERSION of 775 Exhibits, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 3/1/2019 (nms). (Entered: 02/28/2019) |
| 2/28/2019 | 824 | REDACTED VERSION of 774 Proffer, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 3/1/2019 (nms). (Entered: 02/28/2019) |
| 2/28/2019 | 823 | REDACTED VERSION of 773 Memorandum in Opposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 3/1/2019 (nms). (Entered: 02/28/2019) |
| 2/26/2019 | 822 | REDACTED VERSION of 771 Memorandum in Opposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 2/27/2019 (nms). (Entered: 02/26/2019) |
| 2/26/2019 | 821 | REDACTED VERSION of 767 Exhibit 1 to Proposed Final Pretrial Order, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 2/27/2019 (nms). (Entered: 02/26/2019) |
| 2/26/2019 | 820 | REDACTED VERSION of 770 Statement, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit E, # 4 Exhibit F)(Czerwonka, Scott) Modified on 2/27/2019 (nms). (Entered: 02/26/2019) |
| 2/26/2019 | 819 | REDACTED VERSION of 769 MEMORANDUM in Support, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) (Entered: 02/26/2019) |
| 2/26/2019 | 818 | REDACTED VERSION of 817 Jury Verdict. (crb) (Entered: 02/26/2019) |
| 2/26/2019 | 817 | [SEALED] JURY VERDICT. (crb) (Entered: 02/26/2019) |
| 2/26/2019 | 816 | [SEALED] Jury Notes. (crb) (Entered: 02/26/2019) |
| 2/25/2019 | 815 | Exhibit and Witness List for Jury Trial held 2/19/19, 2/21/19-2/25/19. (crb) (Main Document 815 replaced on 3/7/2019) (crb). (Entered: 02/25/2019) |
| 2/25/2019 | 814 | ORDER directing that jurors be provided lunch (cc: Finance). Signed by Judge Richard G. Andrews on 2/25/2019. (nms) (Entered: 02/25/2019) |
| 2/25/2019 | 813 | REDACTED VERSION of 765 Objections, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 2/25/2019 (nms). (Entered: 02/25/2019) |
| 2/25/2019 | Minute Entry for proceedings held before Judge Richard G. Andrews - Jury Trial (Day 3) completed on 2/25/2019. Counsel present for Plaintiffs: M. Sharp. Counsel present for Defendants: D. Wilks. (Closings, Final Jury Instructions, Deliberations, Verdict) (Court Reporter Heather Triozzi, Dale Hawkins.) (crb) (Entered: 02/25/2019) | |
| 2/25/2019 | 812 | Final Jury Instructions (to be read in open court). (nms) (Entered: 02/25/2019) |
| 2/25/2019 | 811 | FINAL VERDICT Form. (nms) (Entered: 02/25/2019) |
| 2/25/2019 | Minute Entry for proceedings held before Judge Richard G. Andrews - Jury Trial (Day 3) held on 2/22/2019. Local counsel present for Plaintiffs: M. Sharp. Local counsel present for Defendants: D. Wilks. (Court Reporter Heather Triozzi, Dale Hawkins.) (crb) (Entered: 02/25/2019) | |
| 2/25/2019 | 810 | [SEALED] Cross-Proffer of Simon Jackson, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Certificate of Service)(Czerwonka, Scott) Modified on 2/25/2019 (nms). (Entered: 02/25/2019) |
| 2/25/2019 | 809 | [SEALED] Cross-Proffer of Anthony Rees and Gregory Petsko, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Certificate of Service)(Czerwonka, Scott) Modified on 2/25/2019 (nms). (Entered: 02/25/2019) |
| 2/25/2019 | 808 | [SEALED] EXHIBITS, Volume 7 re 800 Objections and Counter-Proffer to Proffers of Scott Boyd, M.D., Ph.D and Michael J. Eck, M.D., Ph.D., by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 64, # 2 Exhibit 65, # 3 Exhibit 66, # 4 Exhibit 67, # 5 Exhibit 68, # 6 Exhibit 69, # 7 Certificate of Service)(Sharp, Melanie) Modified on 2/25/2019 (nms). (Entered: 02/25/2019) |
| 2/25/2019 | 807 | [SEALED] EXHIBITS, Volume 6 re 800 Objections and Counter-Proffer to Proffers of Scott Boyd, M.D., Ph.D and Michael J. Eck, M.D., Ph.D., by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 47, # 2 Exhibit 48, # 3 Exhibit 49, # 4 Exhibit 50, # 5 Exhibit 51, Part 1, # 6 Exhibit 51, Part 2, # 7 Exhibit 52, Part 1, # 8 Exhibit 52, Part 2, # 9 Exhibit 53, # 10 Exhibit 54, # 11 Exhibit 55, # 12 Exhibit 56, # 13 Exhibit 57, # 14 Exhibit 58, # 15 Exhibit 59, # 16 Exhibit 60, # 17 Exhibit 61, # 18 Exhibit 62, # 19 Certificate of Service)(Sharp, Melanie) Modified on 2/25/2019 (nms). (Entered: 02/25/2019) |
| 2/25/2019 | 806 | [SEALED] EXHIBIT, Volume 5 re 800 Objections and Counter-Proffer to Proffers of Scott Boyd, M.D., Ph.D and Michael J. Eck, M.D., Ph.D.], by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 35, Part 2, # 2 Exhibit 35, Part 3, # 3 Exhibit 36, # 4 Exhibit 37, # 5 Exhibit 38, # 6 Exhibit 39, # 7 Exhibit 40, # 8 Exhibit 41, Part 1, # 9 Exhibit 41, Part 2, # 10 Exhibit 42, # 11 Exhibit 43, # 12 Exhibit 44, # 13 Exhibit 45, # 14 Certificate of Service)(Sharp, Melanie) Modified on 2/25/2019 (nms). (Entered: 02/25/2019) |
| 2/25/2019 | 805 | [SEALED] EXHIBITS, Volume 4 re 800 Objections and Counter-Proffer to Proffers of Scott Boyd, M.D., Ph.D and Michael J. Eck, M.D., Ph.D., by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 27, # 2 Exhibit 28, # 3 Exhibit 29, Part 1, # 4 Exhibit 29, Part 2, # 5 Exhibit 30, # 6 Exhibit 31, # 7 Exhibit 32, # 8 Exhibit 33, # 9 Exhibit 34, # 10 Certificate of Service)(Sharp, Melanie) Modified on 2/25/2019 (nms). (Entered: 02/25/2019) |
| 2/25/2019 | 804 | [SEALED] EXHIBITS, Volume 3 re 800 Objections and Counter-Proffer to Proffers of Scott Boyd, M.D., Ph.D and Michael J. Eck, M.D., Ph.D., by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 15, # 2 Exhibit 16, # 3 Exhibit 17, # 4 Exhibit 18, # 5 Exhibit 19, # 6 Exhibit 20, # 7 Exhibit 21, # 8 Exhibit 22, # 9 Exhibit 23, # 10 Exhibit 24, # 11 Exhibit 25, # 12 Certificate of Service)(Sharp, Melanie) Modified on 2/25/2019 (nms). (Entered: 02/25/2019) |
| 2/25/2019 | 803 | [SEALED] EXHIBITS, Volume 2 re 800 Objections and Counter-Proffer to Proffers of Scott Boyd, M.D., Ph.D and Michael J. Eck, M.D., Ph.D.], by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 6, # 2 Exhibit 7, # 3 Exhibit 8, # 4 Exhibit 9, # 5 Exhibit 10, # 6 Exhibit 11, # 7 Exhibit 12, # 8 Exhibit 13, # 9 Certificate of Service)(Sharp, Melanie) Modified on 2/25/2019 (nms). (Entered: 02/25/2019) |
| 2/25/2019 | 802 | [SEALED] MOTION for Judgment as a Matter of Law Under Fed. R. Civ. P. 50(A) - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 2/25/2019 (nms). (Entered: 02/25/2019) |
| 2/25/2019 | 801 | [SEALED] EXHIBITS, Volume 1 re 800 Objections and Counter-Proffer to Proffers of Scott Boyd, M.D., Ph.D and Michael J. Eck, M.D., Ph.D., by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 2, # 2 Exhibit 3, # 3 Exhibit 4, # 4 Certificate of Service)(Sharp, Melanie) Modified on 2/25/2019 (nms). (Entered: 02/25/2019) |
| 2/25/2019 | 800 | [SEALED] Objections and Counter-Proffer to Proffers of Scott Boyd, M.D., Ph.D and Michael J. Eck, M.D., Ph.D., by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Appendix A, # 2 Certificate of Service)(Sharp, Melanie) Modified on 2/25/2019 (nms). (Entered: 02/25/2019) |
| 2/25/2019 | 799 | [SEALED] Objections to 796 Objections, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits 1-22, # 2 Certificate of Service)(Higgins, James) Modified on 2/25/2019 (nms). (Entered: 02/25/2019) |
| 2/24/2019 | 798 | [SEALED] RESPONSE to 765 Objections, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 1, # 2 Certificate of Service)(Czerwonka, Scott) Modified on 2/25/2019 (nms). (Entered: 02/24/2019) |
| 2/22/2019 | 797 | [SEALED] Proffer of Excerpted Expert Opinions of Gregory A. Petsko, D. Phil. Regarding Defendants' Inconsistent Patent Filings, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Sharp, Melanie) Modified on 2/22/2019 (nms). (Entered: 02/22/2019) |
| 2/22/2019 | 796 | [SEALED] Objections to Second Proffer of Leonard Schleifer, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. . (Attachments: # 1 Exhibits 1-7, # 2 Certificate of Service)(Higgins, James) Modified on 2/22/2019 (nms). (Entered: 02/22/2019) |
| 2/22/2019 | 795 | [SEALED] Objections to Proffer of Scott Boyd, M.D., Ph.D., by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits 1-8, # 2 Certificate of Service)(Higgins, James) Modified on 2/22/2019 (nms). Modified on 2/25/2019 (nms). (Entered: 02/22/2019) |
| 2/22/2019 | 794 | [SEALED] Objections to Proffer of Michael J. Eck, M.D., Ph.D.,by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits 1-8, # 2 Certificate of Service)(Higgins, James) Modified on 2/22/2019 (nms). Modified on 2/25/2019 (nms). (Entered: 02/22/2019) |
| 2/22/2019 | 793 | [SEALED] MOTION for Judgment as a Matter of Law - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) (Entered: 02/22/2019) |
| 2/22/2019 | 792 | Bench Memorandum Regarding the Court's Proposed Final Jury Instructions and Anticipated Defendants' Proposed Revisions, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. (Sharp, Melanie) Modified on 2/22/2019 (nms). (Entered: 02/22/2019) |
| 2/22/2019 | 791 | Bench Memorandum in Support of Revisions to the Court's Proposed Final Jury Instructions, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Czerwonka, Scott) Modified on 2/22/2019 (nms). (Entered: 02/22/2019) |
| 2/22/2019 | 790 | Proffer of Prior Testimony by Michael Eck Regarding Defendants' Inconsistent Patent Filings, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Sharp, Melanie) Modified on 2/22/2019 (nms). (Entered: 02/22/2019) |
| 2/22/2019 | Minute Entry for proceedings held before Judge Richard G. Andrews - Jury Trial (Day 2) held on 2/21/2019. Local counsel present for Plaintiffs: M. Sharp. Local counsel present for Defendants: D. Wilks. (Court Reporter Heather Triozzi, Dale Hawkins.) (crb) (Entered: 02/22/2019) | |
| 2/22/2019 | 789 | [SEALED] Bench Memorandum Regarding Amgen's Attempts to Use Catabolic Program Evidence for Enablement Purposes, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Certificate of Service)(Czerwonka, Scott) Modified on 2/22/2019 (nms). (Entered: 02/22/2019) |
| 2/22/2019 | 788 | [SEALED] Bench Memorandum Regarding Amgen's Improper Reliance on Antibodies That Were Not Disclosed in the '630 Provisional, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 2/22/2019 (nms). (Entered: 02/22/2019) |
| 2/21/2019 | 787 | [SEALED] Proffer of Michael J. Eck, M.D., Ph.D., by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 1-31, # 2 Certificate of Service)(Czerwonka, Scott) Modified on 2/21/2019 (nms). (Entered: 02/21/2019) |
| 2/21/2019 | 786 | [SEALED] EXHIBITS, Volume 12 of 12 re 774 Proffer, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 2/21/2019 (nms). (Entered: 02/21/2019) |
| 2/21/2019 | 785 | [SEALED] EXHIBITS, Volume 11 of 12 re 774 Proffer, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 2/21/2019 (nms). (Entered: 02/21/2019) |
| 2/21/2019 | 784 | [SEALED] EXHIBITS, Volume 10 of 12 re 774 Proffer, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 2/21/2019 (nms). (Entered: 02/21/2019) |
| 2/21/2019 | 783 | [SEALED] EXHIBITS, Volume 9 of 12 re 774 Proffer, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 2/21/2019 (nms). (Entered: 02/21/2019) |
| 2/21/2019 | 782 | [SEALED] EXHIBITS, Volume 8 of 12 re 774 Proffer, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 2/21/2019 (nms). (Entered: 02/21/2019) |
| 2/21/2019 | 781 | [SEALED] EXHIBITS, Volume 7 of 12 re 774 Proffer, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 2/21/2019 (nms). (Entered: 02/21/2019) |
| 2/21/2019 | 780 | [SEALED] EXHIBITS, Volume 6 of 12 re 774 Proffer, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 2/21/2019 (nms). (Entered: 02/21/2019) |
| 2/21/2019 | 779 | [SEALED] EXHIBITS, Volume 5 of 12 re 774 Proffer, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 2/21/2019 (nms). (Entered: 02/21/2019) |
| 2/21/2019 | 778 | [SEALED] EXHIBITS, Volume 4 of 12 re 774 Proffer, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 2/21/2019 (nms). (Entered: 02/21/2019) |
| 2/21/2019 | 777 | [SEALED] EXHIBITS, Volume 3 of 12 re 774 Proffer, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 2/21/2019 (nms). (Entered: 02/21/2019) |
| 2/21/2019 | 776 | [SEALED] EXHIBITS, Volume 2 of 12 re 774 Proffer, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 2/21/2019 (nms). (Entered: 02/21/2019) |
| 2/21/2019 | 775 | [SEALED] EXHIBITS, Volume 1 of 12 re 774 Proffer, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 2/21/2019 (nms). (Entered: 02/21/2019) |
| 2/21/2019 | 774 | [SEALED] Proffer of Scott Boyd, M.D., Ph.D., by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 2/21/2019 (nms). (Entered: 02/21/2019) |
| 2/21/2019 | 773 | [SEALED] MEMORANDUM in Opposition re 772 MOTION for Limited Admission filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..Reply Brief due date per Local Rules is 2/28/2019. (Attachments: # 1 Exhibit 3)(Sharp, Melanie) (Entered: 02/21/2019) |
| 2/20/2019 | 772 | [SEALED] MOTION for Limited Admission - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Text of Proposed Order, # 9 Certificate of Service)(Czerwonka, Scott) (Entered: 02/20/2019) |
| 2/19/2019 | 771 | [SEALED] MEMORANDUM in Opposition re 769 Bench Memorandum Regarding Exclusion of Post-Priority Date Evidence, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) Modified on 2/21/2019 (nms). (Entered: 02/19/2019) |
| 2/19/2019 | Minute Entry for proceedings held before Judge Richard G. Andrews - Jury Trial (Day 1) held on 2/19/2019. Local counsel present for Plaintiffs: M. Sharp. Local counsel present for Defendants: D. Wilks. (Jury Selection, Preliminary Jury Instructions, Openings) (Court Reporter Heather Triozzi, Dale Hawkins.) (crb) (Entered: 02/19/2019) | |
| 2/19/2019 | 770 | [SEALED] Proffer of Leonard Schleifer, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit E, # 4 Exhibit F, # 5 Certificate of Service)(Czerwonka, Scott) Modified on 2/19/2019 (nms). (Entered: 02/19/2019) |
| 2/19/2019 | CORRECTING ENTRY: A Certificate of Service has been added to D.I. 769 at counsel's request. The certificate was inadvertently omitted in the initial filing. (nms) (Entered: 02/19/2019) | |
| 2/19/2019 | 769 | [SEALED] Bench Memorandum Regarding Amgen's Attempted Exclusion of Documents in Violation of D.I, 763, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) (Additional attachment(s) added on 2/19/2019: # 1 Certificate of Service) (nms). Modified on 2/19/2019 (nms). (Entered: 02/19/2019) |
| 2/19/2019 | 768 | Letter to The Honorable Richard G. Andrews, from James L. Higgins, Esq., regarding Joint Revised Preliminary Jury Instructions. (Higgins, James) Modified on 2/19/2019 (nms). (Entered: 02/19/2019) |
| 2/19/2019 | 767 | [SEALED] EXHIBIT 1 to 708 Proposed Pretrial Order, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Higgins, James) Modified on 2/19/2019 (nms). (Entered: 02/19/2019) |
| 2/18/2019 | 766 | Proposed Joint Jury Instructions, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 2/19/2019 (nms). (Entered: 02/18/2019) |
| 2/15/2019 | 765 | [SEALED] OBJECTIONS to Special Master's Ruling Denying Discovery on Defendants' Willful Infringement, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. . (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Certificate of Service)(Sharp, Melanie) Modified on 2/19/2019 (nms). (Entered: 02/15/2019) |
| 2/15/2019 | 764 | REDACTED VERSION of 750 Letter, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 2/19/2019 (nms). (Entered: 02/15/2019) |
| 2/15/2019 | CORRECTING ENTRY: The Objections filed at D.I. 764 have been removed from the docket as they contained non-substantive errors (cover pages to exhibits were missing). Counsel is to refile a corrected version. (nms) (Entered: 02/15/2019) | |
| 2/14/2019 | 763 | ORDER Regarding Motions in Limine (see Order for further details). Signed by Judge Richard G. Andrews on 2/14/2019. (nms) (Entered: 02/14/2019) |
| 2/13/2019 | 762 | Preliminary Jury Instructions (*to be read in open court). (nms) (Entered: 02/13/2019) |
| 2/13/2019 | 761 | Voir Dire Questions (*to be read in open court). (nms) (Entered: 02/13/2019) |
| 2/13/2019 | 760 | ORAL ORDER: The parties are requested to resubmit the list of witnesses so that only those likely to testify live or by video at the invalidity trial are on the list. The parties are also requested to resubmit the list of lawyers so that it only includes lawyers and law firms who will have a speaking role at the trial and Delaware counsel who will be present during trial. Ordered by Judge Richard G. Andrews on 2/13/2019. (nms) (Entered: 02/13/2019) |
| 2/13/2019 | 759 | NOTICE OF SERVICE of Amgen's Amended Disclosure of Selected Claims filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Ovanesian, Michelle) (Entered: 02/13/2019) |
| 2/13/2019 | 758 | ORAL ORDER: Dr. Schleifers testimony is limited to five minutes on direct. His testimony is limited to proffer paragraphs 1, 2, 3, and the portion of 5 about Regenerons alliance with Sanofi in general (D.I. 742 -1), except that he cannot testify about the awards won by the company. While the aforementioned testimony is barely relevant, Dr. Schleifers testimony about Praluent in paragraph 4 is especially irrelevant and will confuse the issues without any justification. Testimony of Carnahan and Bradway (see D.I. 255 ) should be similarly limited in time and scope. Ordered by Judge Richard G. Andrews on 2/13/2019. (nms) (Entered: 02/13/2019) |
| 2/12/2019 | 757 | ORAL ORDER: D.I. 754 is STRICKEN from the record. Ordered by Judge Richard G. Andrews on 2/12/2019. (nms) (Entered: 02/12/2019) |
| 2/12/2019 | Pro Hac Vice Attorney Lauren L. Fornarotto for Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, and Sanofi-Aventis U.S. LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (ddp) (Entered: 02/12/2019) | |
| 2/12/2019 | CORRECTING ENTRY: The pdf for Exhibit A at D.I. 754 has been replaced with a corrected version per counsel's request. The NEF for the filing has been regenerated. (nms) Modified on 2/12/2019 (nms). (Entered: 02/12/2019) | |
| 2/12/2019 | SO ORDERED, re 756 MOTION for Pro Hac Vice Appearance of Attorney Lauren L. Fornarotto, filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Richard G. Andrews on 2/12/2019. (nms) (Entered: 02/12/2019) | |
| 2/11/2019 | 756 | MOTION for Pro Hac Vice Appearance of Attorney Lauren L. Fornarotto - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certification, # 2 Text of Proposed Order)(Czerwonka, Scott) Modified on 2/12/2019 (nms). (Entered: 02/11/2019) |
| 2/11/2019 | 755 | REDACTED VERSION of 748 Letter, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A)(Czerwonka, Scott) Modified on 2/12/2019 (nms). (Entered: 02/11/2019) |
| 2/11/2019 | CORRECTING ENTRY: The pdfs for D.I. 751 and 752 have been replaced with corrected versions. The NEFs for the filings will be regenerated. (nms) (Entered: 02/11/2019) | |
| 2/8/2019 | 753 | REDACTED VERSION of 745 Letter, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 2/11/2019 (nms). (Entered: 02/08/2019) |
| 2/8/2019 | 752 | ORDER: The Motion for Judgment on the Pleadings (D.I. 448 ) is GRANTED. Signed by Judge Richard G. Andrews on 2/8/2019. (nms) (Main Document 752 replaced on 2/11/2019) (nms). (Entered: 02/08/2019) |
| 2/8/2019 | 751 | MEMORANDUM OPINION. Signed by Judge Richard G. Andrews on 2/8/2019. (nms) (Main Document 751 replaced on 2/11/2019) (nms). (Entered: 02/08/2019) |
| 2/7/2019 | 750 | [SEALED] Letter to The Honorable Richard G. Andrews, from Melanie K. Sharp, Esq., regarding Amgen's Opposition to Defendants Renewed Motion to Exclude Certain Testimony from Steven Pieri. (Attachments: # 1 Exhibits A-C)(Sharp, Melanie) Modified on 2/8/2019 (nms). (Entered: 02/07/2019) |
| 2/6/2019 | 749 | ORDER ON MOTIONS IN LIMINE (see Order for further details). Signed by Judge Richard G. Andrews on 2/6/2019. (nms) (nms). (Entered: 02/06/2019) |
| 2/5/2019 | 748 | [SEALED] Letter to The Honorable Richard G. Andrews, from David E. Wilks, regarding Renewed Motion in Limine regarding Steven Pieri. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Wilks, David) Modified on 2/6/2019 (nms). (Entered: 02/05/2019) |
| 2/5/2019 | 747 | REDACTED VERSION of 718 Exhibits 13-48 to Proffer Concerning Defendants' Willful Infringement, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 2/5/2019 (nms). (Entered: 02/05/2019) |
| 2/4/2019 | REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # 718 . (nms) (Entered: 02/04/2019) | |
| 2/4/2019 | CORRECTING ENTRY: The pdf for the attachment at D.I. 744 has been replaced per counsel's request. (nms) (Entered: 02/04/2019) | |
| 2/4/2019 | Pro Hac Vice Attorney Katherine Nicole Clouse for Amgen Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (ceg) (Entered: 02/04/2019) | |
| 2/4/2019 | 746 | Letter to The Honorable Richard G. Andrews, from David E. Wilks, regarding motions in limine. (Wilks, David) Modified on 2/5/2019 (nms). (Entered: 02/04/2019) |
| 2/1/2019 | 745 | [SEALED] Letter to The Honorable Richard G. Andrews, from Melanie K. Sharp, Esq., regarding Amgen's request that the Court limit the liability phase testimony of certain Defendants' CEO-level testimony. (Attachments: # 1 Exhibits 1-11)(Sharp, Melanie) Modified on 2/4/2019 (nms). (Entered: 02/01/2019) |
| 2/1/2019 | 744 | Letter to The Honorable Richard G. Andrews, from James L. Higgins, Esq., regarding enclosing a proposed order with footnotes in support of Amgen's proposals. (Attachments: # 1 Proposed Order)(Higgins, James) Modified on 2/4/2019 (nms). (Attachment 1 replaced on 2/4/2019) (nms). (Entered: 02/01/2019) |
| 2/1/2019 | 743 | Joint Letter to The Honorable Richard G. Andrews from James L. Higgins, Esq. regarding the Court's Request for Joint Order Memorializing Rulings on Motions in Limine Discussed at Pretrial Conference. (Attachments: # 1 Text of Proposed Order)(Higgins, James) (Entered: 02/01/2019) |
| 2/1/2019 | 742 | Letter to The Honorable Richard G. Andrews from Scott B. Czerwonka regarding Proffer of Dr. Leonard Schleifer. (Attachments: # 1 Exhibit A)(Czerwonka, Scott) Modified on 2/4/2019 (nms). (Entered: 02/01/2019) |
| 2/1/2019 | 741 | REDACTED VERSION of 732 Reply Brief, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 2/1/2019 (nms). (Entered: 02/01/2019) |
| 2/1/2019 | 740 | REDACTED VERSION of 730 Memorandum in Opposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 2/1/2019 (nms). (Entered: 02/01/2019) |
| 1/31/2019 | 739 | REDACTED VERSION of 722 Response, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 2/1/2019 (nms). (Entered: 01/31/2019) |
| 1/31/2019 | 738 | Letter to The Honorable Richard G. Andrews, from Melanie K. Sharp, Esq., regarding response to Defendants' January 30, 2019 letter (D.I. 734 ). (Sharp, Melanie) Modified on 2/1/2019 (nms). (Entered: 01/31/2019) |
| 1/31/2019 | 737 | REDACTED VERSION of 723 Letter by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 14)(Czerwonka, Scott) (Entered: 01/31/2019) |
| 1/30/2019 | 736 | Official Transcript of Pretrial Conference held on 1/25/19 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather M. Triozzi,Telephone number 302-573-6195. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 2/20/2019. Redacted Transcript Deadline set for 3/4/2019. Release of Transcript Restriction set for 4/30/2019. (Triozzi, Heather) (Entered: 01/30/2019) |
| 1/30/2019 | 735 | NOTICE to Take Deposition of Steven Pieri on February 1, 2019 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 01/30/2019) |
| 1/30/2019 | 734 | Letter to The Honorable Richard G. Andrews from Scott B. Czerwonka regarding Local Rule 7.1.2(b) enclosing Opinion. (Attachments: # 1 Exhibit A)(Czerwonka, Scott) (Entered: 01/30/2019) |
| 1/29/2019 | 733 | REDACTED VERSION of 717 Proffer Concerning Defendants' Willful Infringement, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 1/30/2019 (nms). (Entered: 01/29/2019) |
| 1/28/2019 | 732 | [SEALED] REPLY BRIEF in Support of Motion in Limine to Preclude Amgen's Use of Post-Priority Date Evidence to Demonstrate That Its Patents Satisfy 35 U.S.C. § 112, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 1/29/2019 (nms). (Entered: 01/28/2019) |
| 1/28/2019 | 731 | Official Transcript of hearing before the Special Master held on 1/24/2019, before Judge Special Master Yvonne Takvorian Saville. Court Reporter/Transcriber Karen McCloskey, Basye Santiago Reporting. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER Redaction Request due 2/19/2019. Redacted Transcript Deadline set for 2/28/2019. Release of Transcript Restriction set for 4/29/2019. (nms) (Entered: 01/28/2019) |
| 1/25/2019 | 730 | [SEALED] MEMORANDUM in Opposition to Motion in Limine to Preclude Amgen's Use of Post-Priority-Date Evidence to Demonstrate that its Patents Satisfy 35 U.S.C. § 112, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..Reply Brief due date per Local Rules is 2/1/2019. (Attachments: # 1 Certificate of Service)(Higgins, James) Modified on 1/28/2019 (nms). (Entered: 01/25/2019) |
| 1/25/2019 | 729 | REDACTED VERSION of 711 Joint Proposed Pretrial Order, Exhibit 16, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 1/25/2019 (nms). (Entered: 01/25/2019) |
| 1/25/2019 | 728 | REDACTED VERSION of 710 Joint Proposed Pretrial Order, Exhibit 15 part 2, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 1/25/2019 (nms). (Entered: 01/25/2019) |
| 1/25/2019 | 727 | REDACTED VERSION of 709 Joint Proposed Pretrial Order, Exhibit 15 part 1, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 1/25/2019 (nms). (Entered: 01/25/2019) |
| 1/25/2019 | 726 | REDACTED VERSION of 708 Joint Proposed Pretrial Order, Exhibits 1-14, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 1/25/2019 (nms). (Entered: 01/25/2019) |
| 1/25/2019 | Minute Entry for proceedings held before Judge Richard G. Andrews - Final Pretrial Conference held on 1/25/2019. (Court Reporter Heather Triozzi, Dale Hawkins.) (crb) (Entered: 01/25/2019) | |
| 1/25/2019 | 725 | ORAL ORDER: Due to a scheduling conflict the Pretrial Conference set for 1/25/2019, will now commence at 10:00 AM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 1/25/2019. (nms) (Entered: 01/25/2019) |
| 1/24/2019 | 724 | ORDER re 707 Discovery Motion. Signed by Special Master Yvonne Takvorian Saville on 1/24/2019. (nms) (Entered: 01/24/2019) |
| 1/24/2019 | 723 | [SEALED] Letter to The Honorable Richard G. Andrews, from Scott B. Czerwonka, regarding supplement to Proposed Pretrial Order. (Attachments: # 1 Exhibit 14, # 2 Certificate of Service)(Czerwonka, Scott) Modified on 1/25/2019 (nms). (Entered: 01/24/2019) |
| 1/24/2019 | 722 | [SEALED] RESPONSE re 717 Proffer Concerning Willful Infringement, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 1/24/2019 (nms). (Entered: 01/24/2019) |
| 1/23/2019 | SO ORDERED, re 719 MOTION for Pro Hac Vice Appearance of Attorney Andrei Harasymiak, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. Signed by Judge Richard G. Andrews on 1/23/2019. (nms) (Entered: 01/23/2019) | |
| 1/23/2019 | CORRECTING ENTRY: The pdf for D.I. 712 has been replaced with a corrected version per counsel's request. A list of witnesses and attorney names has been added to the filing. (nms) (Entered: 01/23/2019) | |
| 1/23/2019 | 721 | ORAL ORDER: Plaintiffs are requested to file an opposition to Defendants' Motion in Limine to Preclude Amgen's Use of Post-Priority Date evidence by 5 PM January 25, 2019. Defendants are requested to file a response by 5 PM January 28, 2019. The Court will not consider Defendants' Motion in Limine to Preclude Testimony regarding the priority review voucher. Ordered by Judge Richard G. Andrews on 1/23/2019. (nms) (Entered: 01/23/2019) |
| 1/22/2019 | 720 | Letter to The Honorable Richard G. Andrews from James L. Higgins, Esq. regarding Proposed Juror Questionnaire. (Attachments: # 1 Enclosure)(Higgins, James) (Entered: 01/22/2019) |
| 1/22/2019 | 719 | MOTION for Pro Hac Vice Appearance of Attorney Andrei Harasymiak - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certification by Counsel)(Ovanesian, Michelle) (Entered: 01/22/2019) |
| 1/21/2019 | 718 | [SEALED] EXHIBITS 13-48 to 717 Proffer Concerning Defendants' Willful Infringement, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 31 - 37, # 2 Exhibit 38 - 48, # 3 Certificate of Service)(Higgins, James) Modified on 1/23/2019 (nms). (Entered: 01/21/2019) |
| 1/21/2019 | 717 | [SEALED] Proffer Concerning Defendants' Willful Infringement, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits 1-11, # 2 Exhibit 12, # 3 Certificate of Service)(Higgins, James) Modified on 1/23/2019 (nms). (Entered: 01/21/2019) |
| 1/18/2019 | 716 | Proposed Verdict Forms, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 1/23/2019 (nms). (Entered: 01/18/2019) |
| 1/18/2019 | 715 | Proposed Final Damages/Willfulness Phase Jury Instructions, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 1/23/2019 (nms). (Entered: 01/18/2019) |
| 1/18/2019 | 714 | Proposed Final Liability Trial Jury Instructions, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 1/23/2019 (nms). (Entered: 01/18/2019) |
| 1/18/2019 | 713 | Preliminary Proposed Jury Instructions, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 1/23/2019 (nms). (Entered: 01/18/2019) |
| 1/18/2019 | 712 | Proposed Voir Dire by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) (Main Document 712 replaced on 1/23/2019) (nms). (Entered: 01/18/2019) |
| 1/18/2019 | 711 | [SEALED] Joint Proposed Pretrial Order, Exhibit 16, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 1/23/2019 (nms). (Entered: 01/18/2019) |
| 1/18/2019 | 710 | [SEALED] Joint Proposed Pretrial Order, Exhibit 15 part 2, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 1/23/2019 (nms). (Entered: 01/18/2019) |
| 1/18/2019 | 709 | [SEALED] Joint Proposed Pretrial Order, Exhibit 15, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 15-B)(Higgins, James) Modified on 1/23/2019 (nms). (Entered: 01/18/2019) |
| 1/18/2019 | 708 | [SEALED] Joint Proposed Pretrial Order, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Appendix A, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14)(Higgins, James) Modified on 1/23/2019 (nms). (Entered: 01/18/2019) |
| 1/18/2019 | 707 | Discovery Motion - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 1/23/2019 (nms). (Entered: 01/18/2019) |
| 1/18/2019 | 706 | ORDER: Plaintiffs' Motion for Partial Summary Judgment (D.I. 634 ) is DENIED. Defendants' Cross Motion for Summary Judgment on Estoppel (D.I. 673 ) is GRANTED, and Defendants' Motion for Summary Judgment on Invalidity (D.I. 630 ) is DENIED. Signed by Judge Richard G. Andrews on 1/18/2019. (nms) (Entered: 01/18/2019) |
| 1/18/2019 | 705 | MEMORANDUM OPINION. Signed by Judge Richard G. Andrews on 1/18/2019. (nms) (Entered: 01/18/2019) |
| 1/16/2019 | SO ORDERED, re 704 MOTION for Pro Hac Vice Appearance of Attorney Megan Y. Yung, Esq., filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. Signed by Judge Richard G. Andrews on 1/16/2019. (nms) (Entered: 01/16/2019) | |
| 1/16/2019 | 704 | MOTION for Pro Hac Vice Appearance of Attorney Megan Y. Yung, Esq. - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certification by Counsel)(Ovanesian, Michelle) (Entered: 01/16/2019) |
| 1/11/2019 | 703 | Official Transcript of Oral Argument held on 01/03/19 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather M. Triozzi,Telephone number 302-573-6195. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 2/1/2019. Redacted Transcript Deadline set for 2/11/2019. Release of Transcript Restriction set for 4/11/2019. (Triozzi, Heather) (Entered: 01/11/2019) |
| 1/10/2019 | 702 | ORDER: Amgen's request for leave (D.I. 629 ) is DENIED. Sanofi's request for leave (D.I. 628 ) is DENIED (see Order for details). Signed by Judge Richard G. Andrews on 1/10/2019. (nms) (Entered: 01/10/2019) |
| 1/4/2019 | SO ORDERED, re 701 MOTION for Pro Hac Vice Appearance of Attorney Anne Pearlman, filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Richard G. Andrews on 1/4/2019. (nms) (Entered: 01/04/2019) | |
| 1/3/2019 | Minute Entry for proceedings held before Judge Richard G. Andrews - Motion Hearing held on 1/3/2019, re 448 MOTION for Judgment on the Pleadings Regarding Amgen's Willful Infringement Claim. (Court Reporter Heather Triozzi, Dale Hawkins.) (crb) Modified on 1/4/2019 (nms). (Entered: 01/03/2019) | |
| 1/3/2019 | Pro Hac Vice Attorney Sarah Chapin Columbia for Amgen Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (ceg) (Entered: 01/03/2019) | |
| 1/3/2019 | 701 | MOTION for Pro Hac Vice Appearance of Attorney Anne Pearlman - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certification, # 2 Text of Proposed Order)(Czerwonka, Scott) Modified on 1/4/2019 (nms). (Entered: 01/03/2019) |
| 1/2/2019 | 700 | ORAL ORDER: Due to a scheduling conflict the hearing set for 1/3/2019, will now commence at 3:00 PM. Further the hearing will be limited to argument regarding the motion filed at D.I. 448 only. Ordered by Judge Richard G. Andrews on 1/2/2019. (nms) (Entered: 01/02/2019) |
| 12/28/2018 | 699 | ORDER regarding exhibit and witness list for trial. Signed by Special Master Yvonne Takvorian Saville on 12/28/2018. (nms) (Entered: 12/28/2018) |
| 12/28/2018 | 698 | Official Transcript of hearing held on 11/26/2018 before Special Master Yvonne T. Saville, Esq.. Court Reporter/Transcriber Robert Wayne Wilcox, Jr., Basye Santiago Reporting. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER Redaction Request due 1/18/2019. Redacted Transcript Deadline set for 1/28/2019. Release of Transcript Restriction set for 3/28/2019. (nms) (Entered: 12/28/2018) |
| 12/18/2018 | 697 | REDACTED VERSION of 694 Supplemental Declaration of Michelle M. Ovanesian, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Part 2, # 2 Part 3)(Ovanesian, Michelle) Modified on 12/19/2018 (nms). (Entered: 12/18/2018) |
| 12/13/2018 | 696 | REDACTED VERSION of 692 Declaration of Victoria L. Reines, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 44-46)(Czerwonka, Scott) Modified on 12/13/2018 (nms). (Entered: 12/13/2018) |
| 12/13/2018 | 695 | REDACTED VERSION of 691 Reply Brief, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 12/13/2018 (nms). (Entered: 12/13/2018) |
| 12/11/2018 | 694 | [SEALED] DECLARATION of Michelle M. Ovanesian re 693 Reply Brief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 31, # 2 Exhibit 32, # 3 Exhibit 33, # 4 Exhibit 34, # 5 Exhibit 35, # 6 Exhibit 36, # 7 Certificate of Service)(Higgins, James) Modified on 12/12/2018 (nms). (Entered: 12/11/2018) |
| 12/11/2018 | 693 | REPLY BRIEF re 634 MOTION for Partial Summary Judgment to Estop Defendants from Asserting Written Description and Enablement Defenses that Contradict Defendants' Own PTO Filings and Objection to 673 Cross-Motion for Summary Judgment, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 12/12/2018 (nms). (Entered: 12/11/2018) |
| 12/11/2018 | 692 | [SEALED] DECLARATION re 691 Reply Brief, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 44-46)(Czerwonka, Scott) Modified on 12/11/2018 (nms). (Entered: 12/11/2018) |
| 12/11/2018 | 691 | [SEALED] REPLY BRIEF re 630 MOTION for Summary Judgment of Patent Invalidity filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) (Entered: 12/11/2018) |
| 12/11/2018 | 690 | REDACTED VERSION of 683 Declaration of Michelle M. Ovanesian, Volume 2, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 12/11/2018 (nms). (Entered: 12/11/2018) |
| 12/11/2018 | 689 | REDACTED VERSION of 682 Declaration of Michelle M. Ovanesian, Volume 1, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 12/11/2018 (nms). (Entered: 12/11/2018) |
| 12/11/2018 | 688 | REDACTED VERSION of 678 Answering Brief in Opposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 12/12/2018 (nms). (Entered: 12/11/2018) |
| 12/11/2018 | 687 | REDACTED VERSION of 680 Declaration of Anne W. Pearlman, Volume 4, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 12/11/2018 (nms). (Entered: 12/11/2018) |
| 12/11/2018 | 686 | REDACTED VERSION of 674 Memorandum in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 12/11/2018 (nms). (Entered: 12/11/2018) |
| 12/10/2018 | Remark: The In Camera document submitted under the cover of D.I. 617 has been destroyed with counsel's permission. (nms) (Entered: 12/10/2018) | |
| 12/7/2018 | 685 | ORDER: Plaintiffs' Objections (D.I. 616 ) are OVERRULED. Signed by Judge Richard G. Andrews on 12/7/2018. (nms) (Entered: 12/07/2018) |
| 12/7/2018 | 684 | ORDER: Defendants' Objections (D.I. 564 ) are OVERRULED. Signed by Judge Richard G. Andrews on 12/7/2018. (nms) (Entered: 12/07/2018) |
| 12/6/2018 | CORRECTING ENTRY: D.I. 676 has been removed from the docket. The exhibits filed at that entry have been added to the filing at D.I. 675 . (nms) (Entered: 12/06/2018) | |
| 12/4/2018 | 683 | [SEALED] Declaration of Michelle M. Ovanesian, Volume 2 re 678 Answering Brief in Opposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Ovanesian, Michelle) Modified on 12/5/2018 (nms). (Entered: 12/04/2018) |
| 12/4/2018 | 682 | [SEALED] DECLARATION of Michelle M. Ovanesian, Volume 1 re 678 Answering Brief in Opposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits A-E, # 2 Certificate of Service)(Ovanesian, Michelle) Modified on 12/5/2018 (nms). (Entered: 12/04/2018) |
| 12/4/2018 | 681 | Declaration of Anne W. Pearlman, Volume 5, re 674 Memorandum in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 12/5/2018 (nms). (Entered: 12/04/2018) |
| 12/4/2018 | 680 | [SEALED] Declaration of Anne W. Pearlman, Volume 4, re 674 Memorandum in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 12/5/2018 (nms). (Entered: 12/04/2018) |
| 12/4/2018 | 679 | Declaration of Anne W. Pearlman, Volume 3, re 674 Memorandum in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 12/5/2018 (nms). (Entered: 12/04/2018) |
| 12/4/2018 | 678 | [SEALED] ANSWERING BRIEF in Opposition re 630 MOTION for Summary Judgment of Patent Invalidity filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..Reply Brief due date per Local Rules is 12/11/2018. (Attachments: # 1 Appendix 1, # 2 Appendix 2, # 3 Certificate of Service)(Higgins, James) (Entered: 12/04/2018) |
| 12/4/2018 | 677 | Declaration of Anne W. Pearlman, Volume 2, re 674 Memorandum in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 12/5/2018 (nms). (Entered: 12/04/2018) |
| 12/4/2018 | 675 | DECLARATION of Anne W. Pearlman re 674 Memorandum in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 12/5/2018 (nms). (Additional attachment(s) added on 12/5/2018: # 1 Exhibit 1) (nms). (Entered: 12/04/2018) |
| 12/4/2018 | 674 | [SEALED] MEMORANDUM in Opposition re 634 MOTION for Partial Summary Judgment, and in Support of 673 Cross-Motion for Summary Judgment on Estoppel, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Reply Brief due date per Local Rules is 12/11/2018. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 12/5/2018 (nms). (Entered: 12/04/2018) |
| 12/4/2018 | 673 | Cross-Motion for Summary Judgment on Estoppel - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 12/5/2018 (nms). (Entered: 12/04/2018) |
| 12/4/2018 | 672 | REDACTED VERSION of 669 Letter, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 12/4/2018 (nms). (Entered: 12/04/2018) |
| 11/30/2018 | 671 | REDACTED VERSION of 670 Letter, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 11/30/2018 (nms). (Entered: 11/30/2018) |
| 11/27/2018 | 670 | [SEALED] Letter to The Honorable Richard G. Andrews, from Melanie K. Sharp, Esq., regarding Amgen's Opposition to request for leave to file daubert motions. (Attachments: # 1 Exhibits 1-3)(Sharp, Melanie) Modified on 11/28/2018 (nms). (Entered: 11/27/2018) |
| 11/27/2018 | 669 | [SEALED] Letter to The Honorable Richard G. Andrews, from David E. Wilks, regarding response to Amgen's Request for Leave to File Pre-Trial Daubert Motions. (Attachments: # 1 Certificate of Service, # 2 Exhibits A-F), # 3 Exhibits G-Q))(Wilks, David) Modified on 11/28/2018 (nms). (Entered: 11/27/2018) |
| 11/26/2018 | 668 | REDACTED VERSION of 641 Declaration of Michelle M. Ovanesian, Volume 6, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 11/27/2018 (nms). (Entered: 11/26/2018) |
| 11/26/2018 | 667 | REDACTED VERSION of 640 Declaration of Michelle M. Ovanesian, Volume 5, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 11/27/2018 (nms). (Entered: 11/26/2018) |
| 11/26/2018 | 666 | REDACTED VERSION of 639 Declaration of Michelle M. Ovanesian, Volume 4, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 11/27/2018 (nms). (Entered: 11/26/2018) |
| 11/26/2018 | 665 | REDACTED VERSION of 638 Declaration of Michelle M. Ovanesian, Volume 3, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 11/27/2018 (nms). (Entered: 11/26/2018) |
| 11/26/2018 | 664 | REDACTED VERSION of 637 Declaration of Michelle M. Ovanesian, Volume 2, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 11/27/2018 (nms). (Entered: 11/26/2018) |
| 11/26/2018 | 663 | REDACTED VERSION of 636 Declaration of Michelle M. Ovanesian, Volume 1, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 11/27/2018 (nms). (Entered: 11/26/2018) |
| 11/26/2018 | 662 | REDACTED VERSION of 635 Opening Brief in Support, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 11/27/2018 (nms). (Entered: 11/26/2018) |
| 11/26/2018 | 661 | REDACTED VERSION of 629 Letter, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 11/27/2018 (nms). (Entered: 11/26/2018) |
| 11/26/2018 | 660 | REDACTED VERSION of 649 Declaration of Victoria L. Reines, Volume 8, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 11/26/2018 (nms). (Entered: 11/26/2018) |
| 11/26/2018 | 659 | REDACTED VERSION of 648 Declaration of Victoria L. Reines, Volume 7, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 11/26/2018 (nms). (Entered: 11/26/2018) |
| 11/26/2018 | 658 | REDACTED VERSION of 647 Declaration of Victoria L. Reines, Volume 6, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 11/26/2018 (nms). (Entered: 11/26/2018) |
| 11/26/2018 | 657 | REDACTED VERSION of 646 Declaration of Victoria L. Reines, Volume 5, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 11/26/2018 (nms). (Entered: 11/26/2018) |
| 11/26/2018 | 656 | REDACTED VERSION of 645 Declaration of Victoria L. Reines, Volume 4, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 11/26/2018 (nms). (Entered: 11/26/2018) |
| 11/26/2018 | 655 | REDACTED VERSION of 644 Declaration of Victoria L. Reines, Volume 3, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 11/26/2018 (nms). (Entered: 11/26/2018) |
| 11/26/2018 | 654 | REDACTED VERSION of 643 Declaration of Victoria L. Reines, Volume 2, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 11/26/2018 (nms). (Entered: 11/26/2018) |
| 11/26/2018 | 653 | REDACTED VERSION of 642 Declaration of Victoria L. Reines, Volume 1, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 1-6)(Czerwonka, Scott) Modified on 11/26/2018 (nms). (Entered: 11/26/2018) |
| 11/26/2018 | 652 | REDACTED VERSION of 631 MEMORANDUM in Support, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 11/26/2018 (nms). (Entered: 11/26/2018) |
| 11/26/2018 | 651 | REDACTED VERSION of 628 Letter by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A-C)(Wilks, David) (Entered: 11/26/2018) |
| 11/21/2018 | 650 | REDACTED VERSION of 626 Response, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A)(Czerwonka, Scott) Modified on 11/25/2018 (nms). (Entered: 11/21/2018) |
| 11/19/2018 | 649 | [SEALED] Declaration of Victoria L. Reines, Volume 8, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 11/19/2018 (nms). (Entered: 11/19/2018) |
| 11/19/2018 | 648 | [SEALED] Declaration of Victoria L. Reines, Volume 7, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 11/19/2018 (nms). (Entered: 11/19/2018) |
| 11/19/2018 | 647 | [SEALED] Declaration of Victoria L. Reines, Volume 6, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 11/19/2018 (nms). (Entered: 11/19/2018) |
| 11/19/2018 | 646 | [SEALED] Declaration of Victoria L. Reines, Volume 5, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 11/19/2018 (nms). (Entered: 11/19/2018) |
| 11/19/2018 | 645 | [SEALED] Declaration of Victoria L. Reines, Volume 4, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 11/19/2018 (nms). (Entered: 11/19/2018) |
| 11/19/2018 | 644 | [SEALED] Declaration of Victoria L. Reines, Volume 3, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 11/19/2018 (nms). (Entered: 11/19/2018) |
| 11/19/2018 | 643 | [SEALED] Declaration of Victoria L. Reines, Volume 2, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 11/19/2018 (nms). (Entered: 11/19/2018) |
| 11/19/2018 | 642 | [SEALED] DECLARATION of Victoria L. Reines, Volume 1 re 631 MEMORANDUM in Support, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 1-6, # 2 Certificate of Service)(Czerwonka, Scott) Modified on 11/19/2018 (nms). (Entered: 11/19/2018) |
| 11/19/2018 | CORRECTING ENTRY: The declaration filed at D.I. 632 has been removed from the docket, as have the exhibits at D.I. 633. Counsel shall refile the declaration and its exhibits in a multi-volume set, with the expectation that everything filed at one docket item transaction needs to be bound together as one. Filings also need to be formatted appropriately with cover pages. (nms) (Entered: 11/19/2018) | |
| 11/19/2018 | CORRECTING ENTRY: The docket text for D.I. 628 has been corrected to reflect the filing is a letter and not a motion. (nms) (Entered: 11/19/2018) | |
| 11/16/2018 | 641 | [SEALED] Declaration of Michelle M. Ovanesian, Volume 6, re 635 Opening Brief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Ovanesian, Michelle) Modified on 11/19/2018 (nms). (Entered: 11/16/2018) |
| 11/16/2018 | 640 | [SEALED] Declaration of Michelle M. Ovanesian, Volume 5, re 635 Opening Brief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Ovanesian, Michelle) Modified on 11/19/2018 (nms). (Entered: 11/16/2018) |
| 11/16/2018 | 639 | [SEALED] Declaration of Michelle M. Ovanesian, Volume 4, re 635 Opening Brief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Ovanesian, Michelle) Modified on 11/19/2018 (nms). (Entered: 11/16/2018) |
| 11/16/2018 | 638 | [SEALED] Declaration of Michelle M. Ovanesian, Volume 3, re 635 Opening Brief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Ovanesian, Michelle) Modified on 11/19/2018 (nms). (Entered: 11/16/2018) |
| 11/16/2018 | 637 | [SEALED] Declaration of Michelle M. Ovanesian, Volume 2, re 635 Opening Brief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Ovanesian, Michelle) Modified on 11/19/2018 (nms). (Entered: 11/16/2018) |
| 11/16/2018 | 636 | [SEALED] DECLARATION of Michelle M. Ovanesian, Volume 1 re 635 Opening Brief in Support, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits 1-13, # 2 Certificate of Service)(Ovanesian, Michelle) Modified on 11/19/2018 (nms). (Entered: 11/16/2018) |
| 11/16/2018 | 635 | [SEALED] OPENING BRIEF in Support re 634 MOTION for Partial Summary Judgment to Estop Defendants from Asserting Written Description and Enablement Defenses that Contradict Defendants' Own PTO Filings, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..Answering Brief/Response due date per Local Rules is 11/30/2018. (Attachments: # 1 Certificate of Service)(Higgins, James) Modified on 11/19/2018 (nms). (Entered: 11/16/2018) |
| 11/16/2018 | 634 | MOTION for Partial Summary Judgment to Estop Defendants from Asserting Written Description and Enablement Defenses that Contradict Defendants' Own PTO Filings - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Proposed Order)(Higgins, James) Modified on 11/19/2018 (nms). (Entered: 11/16/2018) |
| 11/16/2018 | 631 | [SEALED] MEMORANDUM in Support re 630 MOTION for Summary Judgment of Patent Invalidity, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Answering Brief/Response due date per Local Rules is 11/30/2018. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 11/19/2018 (nms). (Entered: 11/16/2018) |
| 11/16/2018 | 630 | MOTION for Summary Judgment of Patent Invalidity - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Proposed Order)(Czerwonka, Scott) Modified on 11/19/2018 (nms). (Entered: 11/16/2018) |
| 11/16/2018 | 629 | [SEALED] Letter to The Honorable Richard G. Andrews from Melanie K. Sharp, Esq. regarding Amgen's Request for Leave to File Pre-Trial Daubert Motions. (Attachments: # 1 Exhibit A - H)(Sharp, Melanie) (Entered: 11/16/2018) |
| 11/16/2018 | 628 | [SEALED] Letter, to the Court, from David Wilks, Esq., regarding Defendants request for leave to file daubert motions. (Attachments: # 1 Exhibits A-C, # 2 Certificate of Service)(Czerwonka, Scott) Modified on 11/16/2018 (nms). Modified on 11/19/2018 (nms). (Entered: 11/16/2018) |
| 11/15/2018 | 627 | MOTION to Strike - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 11/16/2018 (nms). (Entered: 11/15/2018) |
| 11/14/2018 | 626 | [SEALED] RESPONSE to 616 Objections, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Czerwonka, Scott) Modified on 11/15/2018 (nms). (Entered: 11/14/2018) |
| 11/13/2018 | 625 | REDACTED VERSION of 616 Objections, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 11/14/2018 (nms). (Entered: 11/13/2018) |
| 11/13/2018 | 624 | SO ORDERED, re 622 Joint Stipulation and Proposed Order to Extend Page Limitations of Summary Judgment Briefing. Signed by Judge Richard G. Andrews on 11/9/2018. (nms) (Entered: 11/13/2018) |
| 11/13/2018 | SO ORDERED, re 621 Joint Stipulation and Proposed Order to Extend Deadline to Seek Leave of Court to File Daubert Motions. Signed by Judge Richard G. Andrews on 11/13/2108. (nms) (Entered: 11/13/2018) | |
| 11/13/2018 | 623 | NOTICE OF SERVICE of Expert Reply Report of Michael Szarek, Ph.D. filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 11/13/2018) |
| 11/9/2018 | 622 | Joint STIPULATION to Extend Page Limitations of Summary Judgment Briefing by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) (Entered: 11/09/2018) |
| 11/9/2018 | 621 | Joint Stipulation and Proposed Order to Extend Deadline to Seek Leave of Court to File Daubert Motions - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 11/9/2018 (nms). (Entered: 11/09/2018) |
| 11/9/2018 | SO ORDERED, re 620 MOTION for Pro Hac Vice Appearance of Attorney Ryann M. Muir, Ph.D., filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Richard G. Andrews on 11/9/2018. (nms) (Entered: 11/09/2018) | |
| 11/9/2018 | 620 | MOTION for Pro Hac Vice Appearance of Attorney Ryann M. Muir, Ph.D. - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Text of Proposed Order, # 2 Certification)(Czerwonka, Scott) (Entered: 11/09/2018) |
| 11/9/2018 | 619 | NOTICE of Withdrawal of Pro Hac Vice Counsel, Jeffrey C. Lee, Siew Yen Chong, Cassandra Adams, and Margaret P. Kammerud by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC (Czerwonka, Scott) (Entered: 11/09/2018) |
| 11/7/2018 | CORRECTING ENTRY: The docket text for D.I. 616 has been modified to reflect the exhibits attached are A-N. (nms) (Entered: 11/07/2018) | |
| 11/6/2018 | 617 | Letter to The Honorable Richard G. Andrews, from James L. Higgins, Esq., enclosing an In Camera submission regarding Objections filed (D.I. 616 ). (Higgins, James) Modified on 11/7/2018 (nms). (Entered: 11/06/2018) |
| 11/6/2018 | 616 | [SEALED] OBJECTIONS to 618 Special Master Ruling Denying Claw Back of an Inadvertently Produced Privileged Document Pursuant to the Protective Order, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits A-N, # 2 Certificate of Service)(Higgins, James) Modified on 11/7/2018 (nms). Modified on 11/7/2018 (nms). Modified on 11/7/2018 (nms). (Entered: 11/06/2018) |
| 11/2/2018 | 615 | NOTICE to Take Deposition of Ernest R. Berndt, Ph.D. on Friday, November 9, 2018 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 11/02/2018) |
| 11/2/2018 | 614 | NOTICE to Take Deposition of Evan Stein, M.D., Ph.D. on Thursday, November 15, 2018 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 11/02/2018) |
| 11/1/2018 | 613 | ORAL ORDER AMENDING SCHEDULING ORDER (D.I. 458 ): Due to a scheduling conflict the hearing set for 1/4/2019, in paragraph 11 is CANCELED. Oral argument regarding motions for summary judgment is now reset to 1/3/2019, at 2:00 PM. Ordered by Judge Richard G. Andrews on 11/1/2018. (nms) (Entered: 11/01/2018) |
| 10/31/2018 | 612 | NOTICE to Take Deposition of Charles E. McCulloch, Ph.D. on November 29, 2018 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 10/31/2018) |
| 10/31/2018 | 611 | ORAL ORDER: Due to a scheduling conflict the hearing scheduled for 1/4/2019, is CANCELED. The hearing on the Motion for Judgment on the Pleadings Regarding Amgen's Willful Infringement Claim (D.I. 448 ) is now reset for 1/3/2019, at 2:00 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 10/31/2018. (nms) (Entered: 10/31/2018) |
| 10/26/2018 | 610 | NOTICE to Take Deposition of Paul K. Meyer on October 29, 2018 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 10/26/2018) |
| 10/24/2018 | 609 | NOTICE OF SERVICE of Expert Report of Charles E. McCulloch, Ph.D. filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 10/24/2018) |
| 10/23/2018 | SO ORDERED, re 608 MOTION for Pro Hac Vice Appearance of Attorney Michael A. Lynn, filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Richard G. Andrews on 10/23/2018. (nms) (Entered: 10/23/2018) | |
| 10/23/2018 | 608 | MOTION for Pro Hac Vice Appearance of Attorney Michael A. Lynn - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certification of Michael A. Lynn, # 2 Text of Proposed Order)(Czerwonka, Scott) (Entered: 10/23/2018) |
| 10/23/2018 | 607 | NOTICE to Take Deposition of Michael Szarek on November 30, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 10/23/2018) |
| 10/22/2018 | 606 | NOTICE to Take Deposition of Carla Mulhern on November 7, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 10/22/2018) |
| 10/22/2018 | 605 | NOTICE to Take Deposition of Sharon Oster on November 2, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 10/22/2018) |
| 10/22/2018 | 604 | NOTICE to Take Deposition of Robert Eckel on October 30, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 10/22/2018) |
| 10/22/2018 | 603 | NOTICE OF SERVICE of Reply Expert Report of Evan A. Stein, M.D., Ph.D., Supplemental Reply Expert Report of Ernst R. Berndt and Reply Expert Report of Paul K. Meyer filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 10/22/2018) |
| 10/22/2018 | 602 | NOTICE OF SERVICE of Supplemental Report of Scott Boyd, M.D., Ph.D. and Third Supplemental Report of Michael J. Eck, M.D., Ph.D. filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 10/22/2018) |
| 10/19/2018 | SO ORDERED, re 601 MOTION for Pro Hac Vice Appearance of Attorney Amal El-bakhar. filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. Signed by Judge Richard G. Andrews on 10/19/2018. (nms) (Entered: 10/19/2018) | |
| 10/18/2018 | 601 | MOTION for Pro Hac Vice Appearance of Attorney Amal El-bakhar - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certification)(Higgins, James) Modified on 10/19/2018 (nms). (Entered: 10/18/2018) |
| 10/17/2018 | SO ORDERED, re 600 Stipulation and Order to Extend Liability Fact Discovery Deadline. Signed by Judge Richard G. Andrews on 10/16/2018. (nms) (Entered: 10/17/2018) | |
| 10/16/2018 | 618 | Letter/ORDER regarding Plaintiff Amgens' motion to compel. Signed by Special Master Yvonne Takvorian Saville on 10/16/2018. (nms) (Entered: 11/07/2018) |
| 10/16/2018 | 600 | Joint Stipulation and Order to Extend Liability Fact Discovery Deadline, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 10/16/2018 (nms). (Entered: 10/16/2018) |
| 10/15/2018 | 599 | REDACTED VERSION of 591 Notice to Take Deposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 10/15/2018 (nms). (Entered: 10/15/2018) |
| 10/15/2018 | 598 | REDACTED VERSION of 592 Notice to Take Deposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 10/15/2018 (nms). (Entered: 10/15/2018) |
| 10/15/2018 | 597 | NOTICE to Take Deposition of Eric Besse on October 18, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Ovanesian, Michelle) (Entered: 10/15/2018) |
| 10/12/2018 | 596 | NOTICE to Take Deposition of Michael J. Eck, M.D., Ph.D. on October 30, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 10/12/2018) |
| 10/12/2018 | 595 | NOTICE to Take Deposition of Mark G. Duggan, Ph.D. on November 1, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 10/12/2018) |
| 10/12/2018 | 594 | NOTICE to Take Deposition of Gregory A. Petsko, D.Phil on November 2, 2018 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 10/12/2018) |
| 10/12/2018 | 593 | NOTICE to Take Deposition of Anthony Robert Rees, D.Phil on November 1, 2018 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 10/12/2018) |
| 10/10/2018 | 592 | [SEALED] Second NOTICE to Take Deposition of Defendant Regeneron Pharmaceuticals, Inc. on October 17, 2018, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) Modified on 10/11/2018 (nms). (Entered: 10/10/2018) |
| 10/10/2018 | 591 | [SEALED] Second NOTICE to Take Deposition of Defendants Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC f/d/b/a Aventis Pharmaceuticals Inc. on October 17, 2018, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) Modified on 10/11/2018 (nms). (Entered: 10/10/2018) |
| 10/10/2018 | 590 | NOTICE to Take Deposition of Scott Boyd, M.D., Ph.D. on October 24 and 25, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 10/10/2018) |
| 10/9/2018 | 589 | NOTICE OF SERVICE of Rebuttal Expert Report of Carla S. Mulher; Expert Report of Sharon M. Oster; Expert Report of Michael Szarek, PhD; Rebuttal Expert Report of Robert H. Eckel, M.D. and Expert Report of Mark G. Duggan, PhD filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 10/09/2018) |
| 10/9/2018 | 588 | NOTICE OF SERVICE of Supplemental Rebuttal Expert Report of Gregory A. Petsko, D. Phil. Regarding Alleged Invalidity of the Selected Claims of the Patents-At-Issue and the Rebuttal Expert Report of Anthony Robert Ress, D. Phil. filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 10/09/2018) |
| 10/4/2018 | 587 | NOTICE to Take Deposition of Andrew Murphy on October 5, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 10/04/2018) |
| 10/4/2018 | 586 | NOTICE to Take Deposition of Umesh Chaudhari on October 5, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 10/04/2018) |
| 10/2/2018 | 585 | REDACTED VERSION of 579 Response to Objections, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 10/3/2018 (nms). (Entered: 10/02/2018) |
| 9/28/2018 | 584 | NOTICE OF SERVICE of Subpoena to Testify at a Deposition in a Civil Action directed to Dr. Florin Moisiuc filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 09/28/2018) |
| 9/28/2018 | 583 | SO ORDERED Granting 582 Joint Stipulation and Order to Extend Liability Fact Discovery Deadline. Signed by Judge Richard G. Andrews on 9/28/2018. (nms) (Entered: 09/28/2018) |
| 9/27/2018 | 582 | STIPULATION and Proposed Order to Extend Liability Fact Discovery Deadline, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 9/28/2018 (nms). (Entered: 09/27/2018) |
| 9/26/2018 | 581 | REDACTED VERSION of 575 Second Amended Notice to Take Deposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 9/27/2018 (nms). (Entered: 09/26/2018) |
| 9/26/2018 | 580 | REDACTED VERSION of 574 Second Amended Notice to Take Deposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 9/27/2018 (nms). (Entered: 09/26/2018) |
| 9/24/2018 | 579 | [SEALED] RESPONSE to 564 Objections, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits A-H)(Sharp, Melanie) Modified on 9/25/2018 (nms). (Entered: 09/24/2018) |
| 9/24/2018 | 578 | NOTICE OF SERVICE of Subpoena to Testify at a Deposition in a Civil Action directed to Dr. Michael S. Doyle filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 09/24/2018) |
| 9/21/2018 | 577 | NOTICE OF SERVICE of Subpoena to Testify at a Deposition in a Civil Action directed to Dr. Rakesh R. Shah filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Wilks, David) (Entered: 09/21/2018) |
| 9/20/2018 | 576 | REDACTED VERSION of 564 Objections, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits A-I)(Czerwonka, Scott) Modified on 9/20/2018 (nms). (Entered: 09/20/2018) |
| 9/19/2018 | 575 | [SEALED] Second Amended Notice to Take Deposition of Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC f/d/b/a Aventis Pharmaceuticals Inc. on September 21, 2018 Pursuant to Fed. R. Civ. P. 30(b)(6), filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) Modified on 9/27/2018 (nms). (Entered: 09/19/2018) |
| 9/19/2018 | 574 | [SEALED] Second Amended Notice to Take Deposition of Regeneron Pharmaceuticals, Inc. on September 21, 2018, Pursuant to Fed. R. Civ. P. 30(b)(6), filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) Modified on 9/27/2018 (nms). (Entered: 09/19/2018) |
| 9/18/2018 | 573 | REDACTED VERSION of 566 Notice to Take Deposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 9/19/2018 (nms). (Entered: 09/18/2018) |
| 9/18/2018 | 572 | REDACTED VERSION of 565 Notice to Take Deposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 9/19/2018 (nms). (Entered: 09/18/2018) |
| 9/17/2018 | 571 | NOTICE of Withdrawal of the Notice of Intent to Redact the Transcript of the August 21, 2018 Special Master Hearing (D.I. 552 ), by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 9/18/2018 (nms). (Entered: 09/17/2018) |
| 9/14/2018 | 570 | Amended NOTICE to Take Deposition of Ergang Shi on September 25, 2018, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) Modified on 9/17/2018 (nms). (Entered: 09/14/2018) |
| 9/14/2018 | 569 | Amended NOTICE to Take Deposition of Nicholas Papadopoulos on September 26, 2018, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) Modified on 9/17/2018 (nms). (Entered: 09/14/2018) |
| 9/14/2018 | 568 | Amended NOTICE to Take Deposition of Tammy Huang on September 28, 2018, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) Modified on 9/17/2018 (nms). (Entered: 09/14/2018) |
| 9/14/2018 | 567 | Amended NOTICE to Take Deposition of Jeanette Fairhurst on September 18, 2018, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) Modified on 9/17/2018 (nms). (Entered: 09/14/2018) |
| 9/14/2018 | 566 | [SEALED] Amended NOTICE to Take Deposition of Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC f/d/b/a Aventis Pharmaceuticals Inc. on September 26, 2018 (Pursuant to Fed. R. Civ. P. 30(b)(6)) filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) Modified on 9/17/2018 (nms). (Entered: 09/14/2018) |
| 9/14/2018 | 565 | [SEALED] NOTICE to Take Deposition of Regeneron Pharmaceuticals, Inc. on September 26, 2018 (Pursuant to Fed. R. Civ. P. 30(b)(6)) filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 09/14/2018) |
| 9/13/2018 | 564 | [SEALED] OBJECTIONS to 550 Special Master's Ruling Denying Discovery of Amgen's Pricing and Access Restrictions, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC . (Attachments: # 1 Exhibits A-I, # 2 Certificate of Service)(Czerwonka, Scott) Modified on 9/13/2018 (nms). (Entered: 09/13/2018) |
| 9/12/2018 | 563 | NOTICE OF SERVICE of Notice of Subpoena to Testify at a Deposition in a Civil Action Directed to Dr. Mary P. McGowan filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 09/12/2018) |
| 9/11/2018 | 562 | NOTICE to Take Deposition of Umesh Chaudhari on September 18, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 09/11/2018) |
| 9/11/2018 | 561 | NOTICE to Take Deposition of Andrew Murphy on September 18, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 09/11/2018) |
| 9/10/2018 | 560 | NOTICE OF SERVICE of Expert Report of Paul K. Meyer, Expert Report of Ernst R. Berndt and Supplemental Expert Report of Evan A. Stein, M.D., Ph.D. filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 09/10/2018) |
| 9/7/2018 | 559 | NOTICE of Service of Defendant Regeneron Pharmaceuticals, Inc.'s September 7, 2018 Supplemental Objections and Responses to Plaintiffs First Set of Interrogatories to Regeneron, Defendants Post-remand September 7, 2018 Supplemental Objections and Responses to Plaintiffs Joint Interrogatory No. 4, Defendants Post-remand September 7, 2018 Supplemental Invalidity Contentions, and Sanofis September 7, 2018 Supplemental Objections and Responses to Plaintiffs First Set of Interrogatories to Sanofi, Sanofi Aventis U.s. LLC, and Aventisub LLC F/d/b/a Aventis Pharmaceuticals Inc., filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) Modified on 9/10/2018 (nms). (Entered: 09/07/2018) |
| 9/7/2018 | 558 | NOTICE OF SERVICE of Second Supplemental Report of Michael L. Eck, M.D., Ph.D and Opening Report of Scott Boyd, M.D., Ph.D filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 09/07/2018) |
| 9/5/2018 | 557 | NOTICE to Take Deposition of Ergang Shi on September 20, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Ovanesian, Michelle) (Entered: 09/05/2018) |
| 9/5/2018 | 556 | NOTICE to Take Deposition of Nicholas Papadopoulos on September 14, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Ovanesian, Michelle) (Entered: 09/05/2018) |
| 9/5/2018 | 555 | NOTICE to Take Deposition of Tammy Huang on September 17, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Ovanesian, Michelle) (Entered: 09/05/2018) |
| 9/5/2018 | 554 | NOTICE to Take Deposition of Jeanette Fairhurst on September 12, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Ovanesian, Michelle) (Entered: 09/05/2018) |
| 9/5/2018 | 553 | NOTICE to Take Deposition of David Buckler on September 21, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Ovanesian, Michelle) (Entered: 09/05/2018) |
| 9/4/2018 | 552 | NOTICE of Intent to Request Redaction by Michelle Marie Ovanesian re 549 Transcript,, (Ovanesian, Michelle) (Entered: 09/04/2018) |
| 8/29/2018 | 551 | NOTICE Of Service of Defendants Post-remand Fourth Supplemental Objections and Responses to Plaintiffs Joint Interrogatories (No. 5, 6, 7, 16, 19, 22, 25) and Sanofis Second Supplemental Objections and Responses to Plaintiffs First Set of Interrogatories to Sanofi, Sanofi-Aventis U.S. LLC, and Aventisub LLC f/d/b/a Aventis Pharmaceuticals Inc., filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) Modified on 8/29/2018 (nms). (Entered: 08/29/2018) |
| 8/27/2018 | 550 | Letter to Counsel, dated 8/23/2018, from Special Master Yvonne Takvorian Saville, regarding ruling on Defendant's motion. (nms) (Entered: 08/27/2018) |
| 8/27/2018 | 549 | Official Transcript of hearing held on 8/21/2018, before Special Master Yvonne Takvorian Saville. Court Reporter/Transcriber Basye Santiago Reporting, Telephone number 302-573-2300. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 9/17/2018. Redacted Transcript Deadline set for 9/27/2018. Release of Transcript Restriction set for 11/26/2018. (nms) (Entered: 08/27/2018) |
| 8/21/2018 | 548 | NOTICE to Take Deposition of Jeremy Grunstein on 08-24-18 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 08/21/2018) |
| 8/21/2018 | 547 | Amended NOTICE to Take Deposition of Michelle Carnahan on August 28, 2018, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) Modified on 8/22/2018 (nms). (Entered: 08/21/2018) |
| 8/21/2018 | 546 | Amended NOTICE to Take Deposition of Marion McCourt on August 23, 2018, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) Modified on 8/22/2018 (nms). (Entered: 08/21/2018) |
| 8/21/2018 | 545 | Amended NOTICE to Take Deposition of Rich O'Neal on August 23, 2018, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) Modified on 8/22/2018 (nms). (Entered: 08/21/2018) |
| 8/21/2018 | 544 | NOTICE OF SERVICE of Plaintiffs Amgen Inc., Amgen Manufacturing, Ltd. and Amgen USA Inc.'s Amended Witness Disclosure filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 08/21/2018) |
| 8/20/2018 | 543 | NOTICE to Take Deposition of Hank Kessler on 08-23-18 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 08/20/2018) |
| 8/20/2018 | 542 | NOTICE to Take Deposition of Hank Kessler on 08-23-18 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 08/20/2018) |
| 8/20/2018 | SO ORDERED, re 539 STIPULATION TO EXTEND Fact Discovery Deadline. Signed by Judge Richard G. Andrews on 8/20/2018. (nms) (Entered: 08/20/2018) | |
| 8/17/2018 | 541 | NOTICE OF SERVICE of Plaintiff Amgen's Second Supplemental Objections and Responses to Defendants' Identified Existing Liability Interrogatories (Joint Nos. 2, 4, 5, 6, 17, 18 and 19; Sanofi Nos. 2, 5, 8, and 15; and Regn Nos. 6, 7, and 9) in Accordance with the Court's Order of April 9, 2018 (D.I. 441) filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 08/17/2018) |
| 8/17/2018 | 540 | MOTION for Discovery - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 8/20/2018 (nms). (Entered: 08/17/2018) |
| 8/17/2018 | 539 | STIPULATION TO EXTEND Fact Discovery Deadline - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Ovanesian, Michelle) Modified on 8/20/2018 (nms). (Entered: 08/17/2018) |
| 8/17/2018 | 538 | NOTICE OF SERVICE of Defendants' Post-Remand August 17, 2018 Supplemental Objections and Responses to Plaintiffs' Joint Interrogatory No. 4, Defendants' Post-Remand August 17, 2018 Supplemental Invalidity Contentions, Sanofi's August 17, 2018 Supplemental Objections and Responses to Plaintiffs' First Set of Interrogatories to Sanofi, Sanofi-Aventis U.S. LLC, and Aventisub LLC f/d/b/a Aventis Pharmaceuticals, Inc., and Defendant Regeneron Pharmaceuticals, Inc.'s August 17, 2018 Supplemental Objections and Responses to Plaintiffs' First Set of Interrogatories to Regeneron, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) Modified on 8/20/2018 (nms). (Entered: 08/17/2018) |
| 8/17/2018 | 537 | NOTICE OF SERVICE of Defendants' Amended Disclosure of Witnesses, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) Modified on 8/20/2018 (nms). (Entered: 08/17/2018) |
| 8/17/2018 | Pro Hac Vice Attorney Victoria L. Reines for Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (crb) (Entered: 08/17/2018) | |
| 8/16/2018 | SO ORDERED, re 536 MOTION for Pro Hac Vice Appearance of Attorney Victoria L. Reines, filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Richard G. Andrews on 8/16/2018. (nms) (Entered: 08/16/2018) | |
| 8/16/2018 | 536 | MOTION for Pro Hac Vice Appearance of Attorney Victoria L. Reines - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Victoria L. Reines)(Czerwonka, Scott) (Entered: 08/16/2018) |
| 8/16/2018 | 535 | ORAL ORDER: The Motion for Pro Hac Vice Appearance of Attorney Victoria L. Reines (D.I. 534 ) is DENIED without prejudice as it did not contain a certification page. Ordered by Judge Richard G. Andrews on 8/16/2018. (nms) (Entered: 08/16/2018) |
| 8/16/2018 | 534 | MOTION for Pro Hac Vice Appearance of Attorney Victoria L. Reines - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Text of Proposed Order)(Czerwonka, Scott) (Entered: 08/16/2018) |
| 8/16/2018 | 533 | Corrected NOTICE to Take Deposition of Jeremy Grunstein on 08-24-18, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) Modified on 8/16/2018 (nms). (Entered: 08/16/2018) |
| 8/16/2018 | 532 | Corrected NOTICE to Take Deposition of Laura Hamill on 08-23-18, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) Modified on 8/16/2018 (nms). (Entered: 08/16/2018) |
| 8/9/2018 | 531 | MOTION for Protective Order - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Entered: 08/09/2018) |
| 8/9/2018 | Pro Hac Vice Attorney David Giroux for Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (crb) (Entered: 08/09/2018) | |
| 8/8/2018 | 530 | NOTICE to Take Deposition of Rich O'Neal on August 17, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 08/08/2018) |
| 8/8/2018 | 529 | NOTICE to Take Deposition of Marion McCourt on August 17, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 08/08/2018) |
| 8/7/2018 | 528 | OBJECTIONS to the Disclosure of Confidential Discovery Material Under the Protective Order, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Sharp, Melanie) Modified on 8/8/2018 (nms). (Entered: 08/07/2018) |
| 8/6/2018 | 527 | Corrected NOTICE to Take Deposition of Wei Wang on 8-16-18, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) Modified on 8/7/2018 (nms). (Entered: 08/06/2018) |
| 8/6/2018 | 526 | Corrected NOTICE to Take Deposition of Derek Piper on 8-15-18, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) Modified on 8/7/2018 (nms). (Entered: 08/06/2018) |
| 8/6/2018 | 525 | NOTICE OF SERVICE of Plaintiffs Supplemental Response to Defendants Joint Interrogatory No. 8 and Corrected Supplemental Responses to Joint Interrogatories Nos. 11-12, 14 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Ovanesian, Michelle) (Entered: 08/06/2018) |
| 8/6/2018 | SO ORDERED, re 523 MOTION for Pro Hac Vice Appearance of Attorney Deborah Fishman, filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC, and 524 MOTION for Pro Hac Vice Appearance of Attorney David A. Giroux, filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Richard G. Andrews on 8/6/2018. (nms) (Entered: 08/06/2018) | |
| 8/6/2018 | 524 | MOTION for Pro Hac Vice Appearance of Attorney David A. Giroux - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Text of Proposed Order, # 2 Certification of David A. Giroux)(Czerwonka, Scott) (Entered: 08/06/2018) |
| 8/6/2018 | 523 | MOTION for Pro Hac Vice Appearance of Attorney Deborah Fishman - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Deborah Fishman)(Czerwonka, Scott) (Entered: 08/06/2018) |
| 8/6/2018 | 522 | Corrected NOTICE to Take Deposition of Steven Pieri on 08-08-18, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) Modified on 8/6/2018 (nms). (Entered: 08/06/2018) |
| 8/6/2018 | 521 | Corrected NOTICE to Take Deposition of Laura Hamill on 08-17-18, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) Modified on 8/6/2018 (nms). (Entered: 08/06/2018) |
| 8/6/2018 | 520 | Corrected NOTICE to Take Deposition of Som Chattopadhyay on 08-08-18, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) Modified on 8/6/2018 (nms). (Entered: 08/06/2018) |
| 8/6/2018 | 519 | Corrected NOTICE to Take Deposition of Scott Wasserman on 08-15-18, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) Modified on 8/6/2018 (nms). (Entered: 08/06/2018) |
| 8/6/2018 | 518 | NOTICE to Take Deposition of Gwen Cummings on 08-07-18, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) Modified on 8/6/2018 (nms). (Entered: 08/06/2018) |
| 8/6/2018 | 517 | NOTICE to Take Deposition of Jeremy Grunstein on 08-17-18 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 08/06/2018) |
| 8/3/2018 | 516 | REDACTED VERSION of 506 Objections & Responses, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 8/6/2018 (nms). (Entered: 08/03/2018) |
| 8/1/2018 | 515 | ORDER Appointing Special Master: Yvonne Takvorian Saville, SM appointed. Signed by Judge Richard G. Andrews on 8/1/2018. (nms) (Entered: 08/01/2018) |
| 7/31/2018 | 514 | NOTICE of Withdrawal of Pro Hac Vice Counsel, Daryl L. Joseffer by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. (Higgins, James) (Entered: 07/31/2018) |
| 7/30/2018 | 513 | NOTICE OF SERVICE of Defendants' Post-Remand Supplemental Invalidity Contentions filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 07/30/2018) |
| 7/30/2018 | 512 | Corrected NOTICE to Take Deposition of Maximiliano Waschbusch on August 10, 2018, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Ovanesian, Michelle) Modified on 7/30/2018 (nms). (Entered: 07/30/2018) |
| 7/30/2018 | 511 | Corrected NOTICE to Take Deposition of Tiffany Stout on August 10, 2018, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Ovanesian, Michelle) Modified on 7/30/2018 (nms). (Entered: 07/30/2018) |
| 7/30/2018 | 510 | Corrected NOTICE to Take Deposition of Jonathan Bruce on August 10, 2018, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Ovanesian, Michelle) Modified on 7/30/2018 (nms). (Entered: 07/30/2018) |
| 7/30/2018 | 509 | Corrected NOTICE to Take Deposition of Sheldon Koenig on August 9, 2018, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Ovanesian, Michelle) Modified on 7/30/2018 (nms). (Entered: 07/30/2018) |
| 7/30/2018 | 508 | Corrected NOTICE to Take Deposition of Kevin Buckle on August 9, 2018, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Ovanesian, Michelle) Modified on 7/30/2018 (nms). (Entered: 07/30/2018) |
| 7/30/2018 | 507 | Corrected NOTICE to Take Deposition of Michelle Carnahan on August 9, 2018, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Ovanesian, Michelle) Modified on 7/30/2018 (nms). (Entered: 07/30/2018) |
| 7/30/2018 | 506 | [SEALED] OBJECTIONS to 477 Notice to Take Deposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Higgins, James) Modified on 7/30/2018 (nms). (Entered: 07/30/2018) |
| 7/26/2018 | 505 | ORDER REFERRING CASE to Clerk for assignment of a Special Master. Signed by Judge Richard G. Andrews on 7/26/2018. (nms) (Entered: 07/26/2018) |
| 7/25/2018 | 504 | NOTICE to Take Deposition of Maximiliano Waschbusch on August 9, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Sharp, Melanie) (Entered: 07/25/2018) |
| 7/25/2018 | 503 | NOTICE to Take Deposition of Tiffany Stout on August 9, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Sharp, Melanie) (Entered: 07/25/2018) |
| 7/25/2018 | 502 | NOTICE to Take Deposition of Sheldon Koenig on August 8, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Sharp, Melanie) (Entered: 07/25/2018) |
| 7/25/2018 | 501 | NOTICE to Take Deposition of Michelle Carnahan on August 8, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Sharp, Melanie) (Entered: 07/25/2018) |
| 7/25/2018 | 500 | NOTICE to Take Deposition of Kevin Buckle on August 8, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Sharp, Melanie) (Entered: 07/25/2018) |
| 7/25/2018 | 499 | NOTICE to Take Deposition of Jonathan Bruce on August 9, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Sharp, Melanie) (Entered: 07/25/2018) |
| 7/25/2018 | 498 | NOTICE to Take Deposition of Shannon Faught on August 15, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Sharp, Melanie) (Entered: 07/25/2018) |
| 7/25/2018 | 497 | NOTICE to Take Deposition of Jay Edelberg on August 9, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Sharp, Melanie) (Entered: 07/25/2018) |
| 7/25/2018 | 496 | NOTICE to Take Deposition of Eric Warren on August 8, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Sharp, Melanie) (Entered: 07/25/2018) |
| 7/25/2018 | 495 | NOTICE to Take Deposition of Genie Dubuk on August 3, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Sharp, Melanie) (Entered: 07/25/2018) |
| 7/25/2018 | 494 | NOTICE to Take Deposition of Aaron Ondrey on August 1, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Sharp, Melanie) (Entered: 07/25/2018) |
| 7/25/2018 | 493 | NOTICE to Take Deposition of Robert Sanchez on July 27, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Sharp, Melanie) (Entered: 07/25/2018) |
| 7/23/2018 | 492 | NOTICE to Take Deposition of Simon Jackson on 08-08-18 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 07/23/2018) |
| 7/23/2018 | 491 | NOTICE to Take Deposition of Derek Piper on 08-09-18 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 07/23/2018) |
| 7/23/2018 | 490 | NOTICE to Take Deposition of Sasha Kamb on 08-14-18 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 07/23/2018) |
| 7/23/2018 | 489 | NOTICE to Take Deposition of Chad King on 08-10-18 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 07/23/2018) |
| 7/23/2018 | 488 | NOTICE to Take Deposition of Margaret Karow on 08-15-18 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 07/23/2018) |
| 7/23/2018 | 487 | NOTICE to Take Deposition of Wei Wang on 08-16-18 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 07/23/2018) |
| 7/20/2018 | 486 | NOTICE to Take Deposition of Laura Hamill on 08/14/18 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 07/20/2018) |
| 7/20/2018 | 485 | NOTICE to Take Deposition of Sam Chattopadhyay on 08/13/18 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) Modified on 7/23/2018 (nms). (Entered: 07/20/2018) |
| 7/20/2018 | 484 | NOTICE to Take Deposition of Steve Pieri on 08/16/18 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 07/20/2018) |
| 7/20/2018 | 483 | NOTICE to Take Deposition of Scott Wasserman on 08/17/18 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 07/20/2018) |
| 7/20/2018 | 482 | REDACTED VERSION of 480 Objections, by Regeneron Pharmaceuticals Inc.. (Czerwonka, Scott) Modified on 7/20/2018 (nms). (Entered: 07/20/2018) |
| 7/20/2018 | 481 | REDACTED VERSION of 479 Objections, by Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 7/20/2018 (nms). (Entered: 07/20/2018) |
| 7/13/2018 | 480 | [SEALED] OBJECTIONS to 470 Notice to Take Deposition, by Regeneron Pharmaceuticals Inc.. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 7/17/2018 (nms). (Entered: 07/13/2018) |
| 7/13/2018 | 479 | [SEALED] OBJECTIONS to 471 Notice to Take Deposition, by Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 7/17/2018 (nms). (Entered: 07/13/2018) |
| 7/13/2018 | 478 | NOTICE OF SERVICE of Defendant Regeneron Pharmaceuticals, Inc.s Second Supplemental Objections and Responses to Plaintiffs First Set of Interrogatories to Regeneron and Defendants Post-Remand Third Supplemental Objections and Responses to Plaintiffs Joint Interrogatory No. 4 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 07/13/2018) |
| 7/11/2018 | 477 | NOTICE to Take Deposition of Amgen Inc., Amgen Manufacturing Ltd., and Amgen USA Inc. on 08/06/18 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 07/11/2018) |
| 7/11/2018 | CORRECTING ENTRY: The pdfs for D.I. 475 and D.I. 476 have been replaced with amended versions. The pdfs are now viewable. (nms) (Entered: 07/11/2018) | |
| 7/9/2018 | 476 | REDACTED VERSION of 471 Notice to Take Deposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 7/10/2018 (nms). (Main Document 476 replaced on 7/11/2018) (nms). (Entered: 07/09/2018) |
| 7/9/2018 | 475 | REDACTED VERSION of 470 Notice to Take Deposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 7/10/2018 (nms). (Main Document 475 replaced on 7/11/2018) (nms). (Entered: 07/09/2018) |
| 7/9/2018 | CORRECTING ENTRY: The redacted documents filed at D.I. 475 and D.I. 476 have been removed from the docket as the pdfs were not readable. Counsel shall refile the redactions. (nms) (Entered: 07/09/2018) | |
| 7/5/2018 | 474 | REDACTED VERSION of 469 Letter, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Czerwonka, Scott) Modified on 7/6/2018 (nms). (Entered: 07/05/2018) |
| 7/3/2018 | 473 | REDACTED VERSION of 467 Letter, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 7/5/2018 (nms). (Entered: 07/03/2018) |
| 7/3/2018 | 472 | Official Transcript of Discovery Dispute held on 06-28-18 before Judge Richard G. Andrews. Court Reporter/Transcriber Leonard A. Dibbs. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 7/24/2018. Redacted Transcript Deadline set for 8/3/2018. Release of Transcript Restriction set for 10/1/2018. (lad) (Entered: 07/03/2018) |
| 6/29/2018 | 471 | [SEALED] NOTICE to Take Deposition of Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC f/d/b/a Aventis Pharmaceuticals Inc. on July 27, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) (Entered: 06/29/2018) |
| 6/29/2018 | 470 | [SEALED] NOTICE to Take Deposition of Regeneron Pharmaceuticals, Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) on July 26, 2018 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) (Entered: 06/29/2018) |
| 6/28/2018 | Minute Entry for proceedings held before Judge Richard G. Andrews - Discovery Conference held on 6/28/2018. (Court Reporter Leonard Dibbs.) (ksr, ) (Entered: 06/28/2018) | |
| 6/27/2018 | 469 | [SEALED] Letter to The Honorable Richard G. Andrews, from Scott B. Czerwonka, regarding discovery dispute. (Attachments: # 1 Exhibits A-F, # 2 Certificate of Service)(Czerwonka, Scott) Modified on 6/27/2018 (nms). (Entered: 06/27/2018) |
| 6/26/2018 | 468 | NOTICE OF SERVICE of Amgen's Disclosure of Selected Claims Per Scheduling Order filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 06/26/2018) |
| 6/26/2018 | 467 | [SEALED] Letter to The Honorable Richard G. Andrews from Melanie K. Sharp, Esq. regarding Disputed Discovery Issues - re 461 Oral Order,, Set Hearings,. (Attachments: # 1 Exhibit A - L, # 2 Certificate of Service)(Sharp, Melanie) (Entered: 06/26/2018) |
| 6/22/2018 | SO ORDERED, re 466 MOTION for Pro Hac Vice Appearance of Attorney Lauren A. Moskowitz, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. Signed by Judge Richard G. Andrews on 6/22/2018. (nms) (Entered: 06/22/2018) | |
| 6/22/2018 | 466 | MOTION for Pro Hac Vice Appearance of Attorney Lauren A. Moskowitz - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certification by Counsel)(Higgins, James) (Entered: 06/22/2018) |
| 6/21/2018 | Pro Hac Vice Attorney Paul Margulies for Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, and Sanofi-Aventis U.S. LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (ceg) (Entered: 06/21/2018) | |
| 6/21/2018 | SO ORDERED, re 465 MOTION for Pro Hac Vice Appearance of Attorney Paul Margulies, filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Richard G. Andrews on 6/21/2018. (nms) (Entered: 06/21/2018) | |
| 6/20/2018 | 465 | MOTION for Pro Hac Vice Appearance of Attorney Paul Margulies - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Certification of Counsel, # 2 Proposed Order)(Wilks, David) (Entered: 06/20/2018) |
| 6/15/2018 | 464 | NOTICE OF SERVICE of (1) Plaintiff Amgen Inc.'s Supplemental Objections and Responses to Defendants' Identified Existing Liability Interrogatories (Joint Nos. 2, 3, 4, 5, 6, 17, 18 and 19; Sanofi Nos. 1, 2, 3, 4, 5, 6, 7, 8, 11 and 15; and Regn Nos. 6, 7, 8 and 9) in Accordance with the Court's Order of April 9, 2018 (D.I. 441); (2) Plaintiffs' Supplemental Responses and Objections to Regeneron's First Set of Interrogatories (Nos. 1-4); (3) Plaintiffs' Supplemental Responses and Objections to Sanofi's First Set of Interrogatories (No. 14); (4) Plaintiffs' Supplemental Responses and Objections to Defendants' Selected Joint Interrogatories (Nos. 8-16, 20-24) filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Sharp, Melanie) (Entered: 06/15/2018) |
| 6/15/2018 | 463 | NOTICE OF SERVICE of Plaintiff Amgen Inc.'s Supplemental Objections and Responses to Defendants' Identified Existing Liability Requests for Admission (Nos. 26 And 27) in Accordance with the Court's Order of April 9, 2018 (D.I. 441) filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Sharp, Melanie) (Entered: 06/15/2018) |
| 6/15/2018 | 462 | NOTICE OF SERVICE of Defendants Post-Remand Supplemental Objections and Responses to Plaintiffs Joint Interrogatories, Defendant Regeneron Pharmaceuticals, Inc.s First Supplemental Objections and Responses to Plaintiffs First Set of Interrogatories to Regeneron, and Sanofis Supplemental Objections and Responses to Plaintiffs First Set of Interrogatories to Sanofi, Sanofi-Aventis U.S. LLC, and Aventisub LLC f/d/b/a Aventis Pharmaceuticals Inc. filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Wilks, David) (Entered: 06/15/2018) |
| 6/14/2018 | 461 | ORAL ORDER: The parties have advised that a dispute has arisen requiring judicial attention. The Court will hold a discovery conference on 6/28/2018, at 9:00 AM in Courtroom 6A before Judge Richard G. Andrews to take up this issue. In preparation for this hearing the parties shall follow the Discovery. Ordered by Judge Richard G. Andrews on 6/14/2018. (nms) (Entered: 06/14/2018) |
| 5/22/2018 | 460 | NOTICE OF SERVICE of Defendants' Disclosure of Witnesses filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Czerwonka, Scott) (Entered: 05/22/2018) |
| 5/21/2018 | 459 | NOTICE OF SERVICE of Plaintiffs Witness Disclosure filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 05/21/2018) |
| 5/16/2018 | 458 | SCHEDULING ORDER: The previous referral to the Magistrate Judge Fallon for the purpose of exploring ADR (D.I. 52 ) remains operative. Fact Discovery completed by 8/17/2018. Dispositive Motions due by 11/16/2018. A Pretrial Conference is set for 1/25/2019, at 9:00 AM in Courtroom 6A before Judge Richard G. Andrews. A three day Jury Trial is set for 2/19/2019, at 9:30 AM in Courtroom 6A before Judge Richard G. Andrews (see Order for further details). Signed by Judge Richard G. Andrews on 5/16/2018. (nms) (Entered: 05/16/2018) |
| 5/14/2018 | Pro Hac Vice Attorney Arunabha Bhoumik for Regeneron Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (crb) (Entered: 05/14/2018) | |
| 5/14/2018 | SO ORDERED, re 456 MOTION for Pro Hac Vice Appearance of Attorney Arunabha Bhoumik, filed by Regeneron Pharmaceuticals Inc.. Signed by Judge Richard G. Andrews on 5/14/2018. (nms) (Entered: 05/14/2018) | |
| 5/11/2018 | 457 | REDACTED VERSION of 452 Answering Brief in Opposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 5/14/2018 (nms). (Entered: 05/11/2018) |
| 5/11/2018 | 456 | MOTION for Pro Hac Vice Appearance of Attorney Arunabha Bhoumik - filed by Regeneron Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order, # 2 Certification)(Czerwonka, Scott) (Entered: 05/11/2018) |
| 5/10/2018 | 455 | ORAL ORDER: A hearing on the Motion for Judgment on the Pleadings Regarding Amgen's Willful Infringement Claim (D.I. 448 ) is now set for 1/4/2019, at 10:30 AM in Courtroom 6A before Judge Richard G. Andrews. Ordered by Judge Richard G. Andrews on 5/10/2018. (nms) (Entered: 05/10/2018) |
| 5/10/2018 | 454 | Official Transcript of discovery/scheduling conference held on April 20, 2018 before Judge Andrews. Court Reporter/Transcriber Valerie Gunning,Telephone number (302) 573-6194. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 5/31/2018. Redacted Transcript Deadline set for 6/11/2018. Release of Transcript Restriction set for 8/8/2018. (vjg) (Entered: 05/10/2018) |
| 5/9/2018 | 453 | REPLY BRIEF re 448 MOTION for Judgment on the Pleadings Regarding Amgen's Willful Infringement Claim filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Wilks, David) (Entered: 05/09/2018) |
| 5/4/2018 | 452 | [SEALED] ANSWERING BRIEF in Opposition re 448 MOTION for Judgment on the Pleadings Regarding Amgen's Willful Infringement Claim filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..Reply Brief due date per Local Rules is 5/11/2018. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) (Entered: 05/04/2018) |
| 5/4/2018 | 451 | NOTICE OF SERVICE of Plaintiff Amgen's Supplemental Objections and Responses to Defendants' Identified Existing Liability Requests for the Production of Documents & Things (Nos. 1-8, 10, 12, 17, 45-47, 62, 63, 70, 71) filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 05/04/2018) |
| 5/4/2018 | 450 | PROPOSED Scheduling Order, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Letter)(Higgins, James) Modified on 5/7/2018 (nms). (Entered: 05/04/2018) |
| 4/27/2018 | 449 | OPENING BRIEF in Support re 448 MOTION for Judgment on the Pleadings Regarding Amgen's Willful Infringement Claim, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Answering Brief/Response due date per Local Rules is 5/11/2018. (Wilks, David) Modified on 4/30/2018 (nms). (Entered: 04/27/2018) |
| 4/27/2018 | 448 | MOTION for Judgment on the Pleadings Regarding Amgen's Willful Infringement Claim - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Proposed Order)(Wilks, David) Modified on 4/30/2018 (nms). (Entered: 04/27/2018) |
| 4/27/2018 | Pro Hac Vice Attorney Larry Coury and Lynda Q. Nguyen for Regeneron Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (ceg) (Entered: 04/27/2018) | |
| 4/26/2018 | 447 | NOTICE of Appearance by Michelle Marie Ovanesian on behalf of Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. (Ovanesian, Michelle) (Entered: 04/26/2018) |
| 4/20/2018 | Minute Entry for proceedings held before Judge Richard G. Andrews - Discovery/Scheduling Conference held on 4/20/2018. (Court Reporter Valerie Gunning.) (ksr, ) (Entered: 04/27/2018) | |
| 4/19/2018 | 446 | Letter to The Honorable Richard G. Andrews from James L. Higgins, Esq. regarding Summary Chart of the Parties' Proposals from Proposed Scheduling Order. (Attachments: # 1 Chart)(Higgins, James) Modified on 4/20/2018 (nms). (Entered: 04/19/2018) |
| 4/19/2018 | 445 | Letter to the Honorable Richard G. Andrews, from Melanie K. Sharp, Esq., responding to Defendants letter dated April 18, 2018. (Attachments: # 1 Exhibits A-B)(Sharp, Melanie) Modified on 4/19/2018 (nms). (Entered: 04/19/2018) |
| 4/18/2018 | 444 | PROPOSED Scheduling Order, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Letter)(Sharp, Melanie) Modified on 4/18/2018 (nms). (Entered: 04/18/2018) |
| 4/18/2018 | 443 | Letter to The Honorable Richard G. Andrews, from David E. Wilks, regarding discovery disputes. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Wilks, David) Modified on 4/18/2018 (nms). (Entered: 04/18/2018) |
| 4/16/2018 | 442 | NOTICE of Withdrawal of Pro Hac Vice Counsel Evan Boetticher, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 4/17/2018 (nms). (Entered: 04/16/2018) |
| 4/9/2018 | 441 | ORAL ORDER: The Court has reviewed the Joint Status Report. (D.I. 437 ). The Court will allow additional fact discovery between the parties (but not with third parties) relating to post-priority date antibody evidence, and related additional expert discovery. The Court expects to allow Defendants to replace Dr. Siegel with Dr. Boyd, with Dr. Boyd being limited to the substance of opinions expressed by Dr. Siegel except to the extent any opinions are based on additional post-priority date antibody evidence. I expect to allow Defendants to file one summary judgment motion. There is no reason for any Daubert motions except to the extent they relate to opinions based on the additional post-priority antibody evidence. The parties should plan on the written description/enablement trial being limited to three days, and should agree to a schedule that will permit trial to start on February 19, 2019. Defendants should promptly identify for Plaintiff any existing discovery requests that seek post-priority date antibody evidence, and Plaintiffs should start producing such discovery without waiting for the Rule 16 conference. Ordered by Judge Richard G. Andrews on 4/9/2018. (nms) (Entered: 04/09/2018) |
| 3/29/2018 | 440 | ORAL ORDER: The parties have advised that a dispute has arisen requiring judicial attention. The Court will hold a discovery conference on 4/20/2018, at 3:30 PM in Courtroom 6A before Judge Richard G. Andrews to take up this issue. In preparation for this hearing the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Courts form Scheduling Order for patent cases. At this hearing the Court will also hear the parties on the matter of a case schedule to be put in place. In that regard, the parties are directed to meet and confer about scheduling, and attempt to reach agreement. The parties shall use as a basis for discussion the Courts Rule 16 Scheduling Order patent, available on the Courts website. No later than 48 hours before the conference, the parties shall file a proposed scheduling order using the Rule 16 Scheduling Order - patent. Ordered by Judge Richard G. Andrews on 3/29/2018. (nms) (Entered: 03/29/2018) |
| 3/26/2018 | Pro Hac Vice Attorney Lauren N. Martin for Amgen Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (ceg) (Entered: 03/26/2018) | |
| 3/22/2018 | 439 | NOTICE of Change of Firm Affiliation for Lauren Martin by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. (Higgins, James) (Entered: 03/22/2018) |
| 3/22/2018 | 438 | NOTICE of Withdrawal of Pro Hac Vice Counsel (Terry W. Ahearn and Michael V. O'Shaughnessy) by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. (Higgins, James) (Entered: 03/22/2018) |
| 3/12/2018 | 437 | Joint Status Report, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Sharp, Melanie) Modified on 3/13/2018 (nms). (Entered: 03/12/2018) |
| 3/8/2018 | Pro Hac Vice Attorney David K. Barr for Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (crb) (Entered: 03/08/2018) | |
| 3/8/2018 | Pro Hac Vice Attorney Daniel L. Reisner for Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (crb) (Entered: 03/08/2018) | |
| 3/6/2018 | Pro Hac Vice Attorney Matthew M. Wolf for Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, and Sanofi-Aventis U.S. LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (ceg) (Entered: 03/06/2018) | |
| 3/5/2018 | 436 | ORAL ORDER: The parties shall file a joint status report within seven days of the date of this Order. Ordered by Judge Richard G. Andrews on 3/5/2018. (nms) (Entered: 03/05/2018) |
| 3/2/2018 | 435 | MANDATE of USCA as to 402 Notice of Appeal (Federal Circuit) filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. USCA Decision: reversed in part, affirmed in part, vacated in part, and remanded. (Attachments: # 1 Opinion and Judgment)(nmfn) (Entered: 03/05/2018) |
| 3/2/2018 | SO ORDERED, re 434 MOTION for Pro Hac Vice Appearance of Attorney Keith R. Hummel, David N. Greenwald, Sharonmoyee Goswami and Geoffrey G. Hu, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. Signed by Judge Richard G. Andrews on 3/2/2018. (nms) (Entered: 03/02/2018) | |
| 3/2/2018 | 434 | MOTION for Pro Hac Vice Appearance of Attorney Keith R. Hummel, David N. Greenwald, Sharonmoyee Goswami and Geoffrey G. Hu - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certifications by Counsel)(Higgins, James) (Entered: 03/02/2018) |
| 3/1/2018 | SO ORDERED, re 433 MOTION for Pro Hac Vice Appearance of Attorney Matthew M. Wolf, David Barr and Daniel Reisner, filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Richard G. Andrews on 3/1/2018. (nms) (Entered: 03/01/2018) | |
| 3/1/2018 | 433 | MOTION for Pro Hac Vice Appearance of Attorney Matthew M. Wolf, David Barr and Daniel Reisner - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Proposed Order, # 2 Certification of Matthew M. Wolf, # 3 Certification of David Barr, # 4 Certification of Daniel Reisner)(Wilks, David) (Entered: 03/01/2018) |
| 2/28/2018 | Case Reassigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:14-cv-01317-RGA, 1:14-cv-01349-RGA, 1:14-cv-01393-RGA, 1:14-cv-01414-RGA (rjb) (Entered: 02/28/2018) | |
| 2/27/2018 | 432 | Letter to the Honorable Leonard P. Stark from David E. Wilks, Esquire regarding response to February 23, 2018 letter from Melanie K. Sharp Esquire. - re 431 Letter. (Wilks, David) (Entered: 02/27/2018) |
| 2/23/2018 | 431 | Letter to The Honorable Leonard P. Stark from Melanie K. Sharp, Esq. regarding Status of Mandate/Remand and Assignment for Re-Trial of SLR Case. (Sharp, Melanie) (Entered: 02/23/2018) |
| 12/14/2017 | 430 | NOTICE of Appearance of Additional Counsel for Plaintiffs by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. (Higgins, James) (Entered: 12/14/2017) |
| 10/17/2017 | 429 | NOTICE OF SUBSTITUTION OF COUNSEL re All Defendants : Entry of appearance of attorney David E. Wilks. Attorney Steven J. Balick terminated. (Attachments: # 1 Certificate of Service)(Wilks, David) (Entered: 10/17/2017) |
| 8/31/2017 | 428 | NOTICE of Appearance of Additional Counsel for Defendants, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC (Balick, Steven) (Entered: 08/31/2017) |
| 4/19/2017 | 427 | ORDER granting 406 Motion to Alter Judgment. Signed by Judge Sue L. Robinson on 4/19/2017. (nmfn) (Entered: 04/19/2017) |
| 2/24/2017 | 426 | REDACTED VERSION of 423 Declaration of James L. Higgins, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 02/24/2017) |
| 2/24/2017 | 425 | REDACTED VERSION of 422 Reply Brief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 02/24/2017) |
| 2/23/2017 | 424 | NOTICE of Withdrawal of Pro Hac Vice Counsel, Esther Lin by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. (Higgins, James) (Entered: 02/23/2017) |
| 2/21/2017 | 423 | [SEALED] DECLARATION of James L. Higgins re 406 MOTION to Alter Judgment, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits A-C, # 2 Certificate of Service)(Higgins, James) Modified on 3/13/2018 (nms). (Entered: 02/21/2017) |
| 2/21/2017 | 422 | [SEALED] REPLY BRIEF re 406 MOTION to Alter Judgment, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) Modified on 3/13/2018 (nms). (Entered: 02/21/2017) |
| 2/20/2017 | 421 | REDACTED VERSION of 399 Declaration of Sharon M. Oster, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) Modified on 3/13/2018 (nms). (Entered: 02/20/2017) |
| 2/20/2017 | 420 | REDACTED VERSION of 398 Declaration of Robert Terifay, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) Modified on 3/13/2018 (nms). (Entered: 02/20/2017) |
| 2/20/2017 | 419 | REDACTED VERSION of 397 Declaration of Victoria Carey, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) Modified on 3/13/2018 (nms). (Entered: 02/20/2017) |
| 2/20/2017 | 418 | REDACTED VERSION of 396 Declaration of Robert H. Eckel, M.D., by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) Modified on 3/13/2018 (nms). (Entered: 02/20/2017) |
| 2/20/2017 | 417 | REDACTED VERSION of 395 Opening Brief in Support, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 02/20/2017) |
| 2/16/2017 | REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # 395, 396, 397, 398, 399. (fms) (Entered: 02/16/2017) | |
| 2/14/2017 | 416 | ANSWERING BRIEF in Opposition re 406 MOTION to Alter Judgment, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Reply Brief due date per Local Rules is 2/21/2017. (Balick, Steven) Modified on 3/13/2018 (nms). (Entered: 02/14/2017) |
| 2/8/2017 | 415 | Official Transcript of telephone conference held on March 15, 2016 before Judge Robinson. Court Reporter/Transcriber Valerie Gunning,Telephone number (302) 573-6194. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 3/1/2017. Redacted Transcript Deadline set for 3/13/2017. Release of Transcript Restriction set for 5/9/2017. (vjg) (Entered: 02/08/2017) |
| 2/8/2017 | 414 | Official Transcript of status conference held on March 4, 2016 before Judge Robinson. Court Reporter/Transcriber Valerie Gunning,Telephone number (302) 573-6194. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 3/1/2017. Redacted Transcript Deadline set for 3/13/2017. Release of Transcript Restriction set for 5/9/2017. (vjg) (Entered: 02/08/2017) |
| 2/8/2017 | 413 | Official Transcript of status conference held on January 27, 2016 before Judge Robinson. Court Reporter/Transcriber Valerie Gunning,Telephone number (302) 573-6194. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 3/1/2017. Redacted Transcript Deadline set for 3/13/2017. Release of Transcript Restriction set for 5/9/2017. (vjg) (Entered: 02/08/2017) |
| 2/8/2017 | 412 | Official Transcript of status conference held on October 26, 2015 before Judge Robinson. Court Reporter/Transcriber Valerie Gunning,Telephone number (302) 573-6194. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 3/1/2017. Redacted Transcript Deadline set for 3/13/2017. Release of Transcript Restriction set for 5/9/2017. (vjg) (Entered: 02/08/2017) |
| 2/8/2017 | 411 | Official Transcript of Markman hearing held on September 17, 2015 before Judge Robinson. Court Reporter/Transcriber Valerie Gunning,Telephone number ((302) 573-6194. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 3/1/2017. Redacted Transcript Deadline set for 3/13/2017. Release of Transcript Restriction set for 5/9/2017. (vjg) (Entered: 02/08/2017) |
| 2/8/2017 | 410 | Official Transcript of scheduling conference held on April 9, 2015 before Judge Robinson. Court Reporter/Transcriber Valerie Gunning,Telephone number (302) 573-6194. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 3/1/2017. Redacted Transcript Deadline set for 3/13/2017. Release of Transcript Restriction set for 5/9/2017. (vjg) (Entered: 02/08/2017) |
| 2/8/2017 | 409 | Official Transcript of scheduling conference held on February 24, 2015 before Judge Robinson. Court Reporter/Transcriber Valerie Gunning,Telephone number (302) 573-6194. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 3/1/2017. Redacted Transcript Deadline set for 3/13/2017. Release of Transcript Restriction set for 5/9/2017. (vjg) (Entered: 02/08/2017) |
| 2/6/2017 | 408 | REDACTED VERSION of 406 MOTION to Alter Judgment, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 02/06/2017) |
| 1/31/2017 | 407 | PROPOSED Order re 406 MOTION to Alter Judgment, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Sharp, Melanie) Modified on 3/13/2018 (nms). (Entered: 01/31/2017) |
| 1/31/2017 | 406 | [SEALED] MOTION to Alter Judgment - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certificate of Service)(Sharp, Melanie) Modified on 3/13/2018 (nms). (Entered: 01/31/2017) |
| 1/23/2017 | 405 | TRANSCRIPT REQUEST by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC for proceedings held on various dates before Judge Sue L. Robinson (list of dates attached to request), (Mayo, Andrew) (Entered: 01/23/2017) |
| 1/12/2017 | 404 | NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re 402 Notice of Appeal (Federal Circuit) filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. USCA Case Number 17-1480. (fms) (Entered: 01/13/2017) |
| 1/12/2017 | Notification regarding 402 Notice of Appeal (Federal Circuit) sent to Reporter Gunning (nmg) (Entered: 01/12/2017) | |
| 1/12/2017 | Notice of Appeal and Docket Sheet to US Court of Appeals for the Federal Circuit re 402 Notice of Appeal (Federal Circuit). (nmg) (Entered: 01/12/2017) | |
| 1/12/2017 | APPEAL - Credit Card Payment of $505.00 received re 402 Notice of Appeal (Federal Circuit) filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. ( Filing fee $505, receipt number 0311-2063770.) (Balick, Steven) (Entered: 01/12/2017) | |
| 1/12/2017 | 403 | NOTICE requesting Clerk to remove Akin Gump Strauss Hauer & Feld LLP, Dianne B. Elderkin, Steven D. Maslowski, Michael P. Kahn, Matthew A. Pearson, Angela Verrecchio, Jenna M. Pellecchia, Matthew G. Hartman, Michael N. Petegorsky, and Jonathan J. Underwood as co-counsel.. (Balick, Steven) (Entered: 01/12/2017) |
| 1/12/2017 | 402 | NOTICE OF APPEAL to the Federal Circuit of 392 Memorandum and Order, 391 Judgment, . Appeal filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Balick, Steven) (Entered: 01/12/2017) |
| 1/9/2017 | 401 | MEMORANDUM ORDER denying 394 MOTION to Stay Issuance of Permanent Injunction Pending Appeal. The permanent injunction is stayed for 45 days. Signed by Judge Sue L. Robinson on 1/9/2017. (nmfn) (Entered: 01/09/2017) |
| 1/6/2017 | 400 | [SEALED] Email Request for Emergency Relief and Opposing Counsel's Response to E-Mail Request for Emergency Relief. (nmfn) (Entered: 01/06/2017) |
| 1/6/2017 | 399 | [SEALED] DECLARATION of Sharon M. Oster re 395 Opening Brief in Support, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Balick, Steven) Modified on 3/13/2018 (nms). (Entered: 01/06/2017) |
| 1/6/2017 | 398 | [SEALED] DECLARATION of Robert Terifay re 395 Opening Brief in Support, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Balick, Steven) Modified on 3/13/2018 (nms). (Entered: 01/06/2017) |
| 1/6/2017 | 397 | [SEALED] DECLARATION of Victoria Carey re 395 Opening Brief in Support, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Balick, Steven) Modified on 3/13/2018 (nms). (Entered: 01/06/2017) |
| 1/6/2017 | 396 | [SEALED] DECLARATION of Robert H. Eckel, M.D. re 395 Opening Brief in Support, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Balick, Steven) Modified on 3/13/2018 (nms). (Entered: 01/06/2017) |
| 1/6/2017 | 395 | [SEALED] OPENING BRIEF in Support re 394 MOTION to Stay Issuance of Permanent Injunction Pending Appeal, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Answering Brief/Response due date per Local Rules is 1/20/2017. (Balick, Steven) Modified on 3/13/2018 (nms). (Entered: 01/06/2017) |
| 1/6/2017 | 394 | MOTION to Stay Issuance of Permanent Injunction Pending Appeal - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Balick, Steven) Modified on 3/13/2018 (nms). (Entered: 01/06/2017) |
| 1/5/2017 | 393 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,563,698; 8,829,165; 8,859,741. (Attachments: # 1 Judgment)(nmfn) (Entered: 01/05/2017) |
| 1/5/2017 | CASE CLOSED per D.I. 389 , 390 , 391 , and 392 . (nmfn) (Entered: 01/05/2017) | |
| 1/5/2017 | 392 | MEMORANDUM ORDER granting 336 MOTION for Permanent Injunction filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. Signed by Judge Sue L. Robinson on 1/5/2017. (nmfn) (Entered: 01/05/2017) |
| 1/3/2017 | 391 | FINAL JUDGMENT FOLLOWING POST TRIAL MOTION PRACTICE PURSUANT TO FED. R. CIV. P. 54(b) in favor of Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. against Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Sue L. Robinson on 1/3/2017. (nmfn) (Entered: 01/03/2017) |
| 1/3/2017 | 390 | ORDER denying 331 Motion for New Trial; denying 332 Motion for Judgment as a Matter of Law ; finding as moot 338 Motion to Strike. Signed by Judge Sue L. Robinson on 1/3/2017. (nmfn) (Entered: 01/03/2017) |
| 1/3/2017 | 389 | MEMORANDUM OPINION. Signed by Judge Sue L. Robinson on 1/3/2017. (nmfn) (Entered: 01/03/2017) |
| 12/21/2016 | 388 | NOTICE of Withdrawal of Pro Hac Vice Counsel - Adam M. Conrad by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. (Higgins, James) (Entered: 12/21/2016) |
| 9/6/2016 | 387 | NOTICE of Withdrawal of Pro Hac Vice Counsel, Joshua Mack by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. re SO ORDERED (Higgins, James) (Entered: 09/06/2016) |
| 8/17/2016 | Pro Hac Vice Attorney Daryl L. Joseffer, Adam M. Conrad for Amgen Inc., Amgen Manufacturing Limited, and for Amgen USA Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (klc) (Entered: 08/17/2016) | |
| 7/27/2016 | 386 | NOTICE of Supplemental Authority Under L.R. 7.1.2(B) by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. (Attachments: # 1 Exhibit A)(Higgins, James) (Entered: 07/27/2016) |
| 7/5/2016 | SO ORDERED, re 385 MOTION for Pro Hac Vice Appearance of Attorney Daryl L. Joseffer and Adam M. Conrad filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. Signed by Judge Sue L. Robinson on 7/5/2016. (fms) (Entered: 07/05/2016) | |
| 7/1/2016 | 385 | MOTION for Pro Hac Vice Appearance of Attorney Daryl L. Joseffer and Adam M. Conrad - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certifications by Counsel)(Higgins, James) (Entered: 07/01/2016) |
| 6/16/2016 | CORRECTING ENTRY: Per request of filer, the pdf at D.I. 384 has been removed and replaced. (fms) (Entered: 06/16/2016) | |
| 6/15/2016 | 384 | REDACTED VERSION of 383 Joint Exhibit List, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Main Document 384 replaced on 6/16/2016) (fms). Modified on 3/13/2018 (nms). (Entered: 06/15/2016) |
| 6/9/2016 | CORRECTING ENTRY: Per request of filer, D.I. 382 has been removed and replaced with a version that contains redactions to the Plaintiffs' Corrected Opening Brief. (fms) (Entered: 06/09/2016) | |
| 6/8/2016 | 383 | [SEALED] Joint Exhibit List, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 06/08/2016) |
| 6/6/2016 | 382 | REDACTED VERSION of 362 Opening Brief in Support, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Main Document 382 replaced on 6/9/2016) (fms). Modified on 3/13/2018 (nms). (Entered: 06/06/2016) |
| 6/6/2016 | REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # 362. (fms) (Entered: 06/06/2016) | |
| 6/2/2016 | 381 | REDACTED VERSION of 376 Reply Brief, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 06/02/2016) |
| 6/1/2016 | 380 | REDACTED VERSION of 374 Reply Brief by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 06/01/2016) |
| 5/26/2016 | 379 | Letter to The Honorable Sue L. Robinson from James L. Higgins, Esq. regarding Enclosing Hyperlinked Versions Amgen's Post-Trial Briefing at D.I. 362, D.I. 376, D.I. 359 and D.I. 352 - re 359 Answering Brief in Opposition, 376 Reply Brief, 362 Opening Brief in Support, 352 Answering Brief in Opposition,,. (Higgins, James) (Entered: 05/26/2016) |
| 5/26/2016 | 378 | Letter to The Honorable Sue L. Robinson from Tiffany Geyer Lydon regarding hyperlinked briefs for D.I. 367, 371 and 374. (Lydon, Tiffany) (Entered: 05/26/2016) |
| 5/26/2016 | 377 | Letter to The Honorable Sue L. Robinson from Tiffany Geyer Lydon regarding hyperlinked briefs for D.I. 368, 369, 370. (Lydon, Tiffany) (Entered: 05/26/2016) |
| 5/25/2016 | 376 | [SEALED] Corrected REPLY BRIEF re 336 MOTION for Permanent Injunction, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Sharp, Melanie) Modified on 3/13/2018 (nms) (Entered: 05/25/2016) |
| 5/25/2016 | 375 | [SEALED] REPLY BRIEF re 336 MOTION for Permanent Injunction filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Sharp, Melanie) (Entered: 05/25/2016) |
| 5/25/2016 | 374 | [SEALED] REPLY BRIEF re 331 MOTION for New Trial filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Balick, Steven) (Entered: 05/25/2016) |
| 5/25/2016 | CORRECTING ENTRY: The pdfs of D.I. 367 and 369 have been replaced with corrected versions per request of filer. (nmfn) (Entered: 05/25/2016) | |
| 5/25/2016 | CORRECTING ENTRY: The pdf of D.I. 371 has been replaced with a corrected version per request of filer. (nmfn) (Entered: 05/25/2016) | |
| 5/24/2016 | 373 | REDACTED VERSION of 369 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 05/24/2016) |
| 5/24/2016 | 372 | REDACTED VERSION of 368 Opening Brief in Support, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 05/24/2016) |
| 5/23/2016 | 371 | ANSWERING BRIEF in Opposition re 338 MOTION to Strike 333 Opening Brief in Support, 332 MOTION for Judgment as a Matter of Law on Written Description and Enablement (CORRECTED) filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Reply Brief due date per Local Rules is 6/3/2016. (Balick, Steven) (Main Document 371 replaced on 5/25/2016) (nmfn, ). (Entered: 05/23/2016) |
| 5/23/2016 | 370 | Corrected REPLY BRIEF re 332 MOTION for Judgment as a Matter of Law, filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Balick, Steven) Modified on 3/13/2018 (nms). (Entered: 05/23/2016) |
| 5/23/2016 | 369 | [SEALED] ANSWERING BRIEF in Opposition re 336 MOTION for Permanent Injunction (CORRECTED) filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Reply Brief due date per Local Rules is 6/3/2016. (Balick, Steven) (Main Document 369 replaced on 5/25/2016) (nmfn, ). (Entered: 05/23/2016) |
| 5/23/2016 | 368 | [SEALED] OPENING BRIEF in Support re 331 MOTION for New Trial (Corrected) filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Answering Brief/Response due date per Local Rules is 6/9/2016. (Balick, Steven) (Entered: 05/23/2016) |
| 5/23/2016 | 367 | OPENING BRIEF in Support re 332 MOTION for Judgment as a Matter of Law on Written Description and Enablement (Corrected) filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Answering Brief/Response due date per Local Rules is 6/9/2016. (Balick, Steven) (Main Document 367 replaced on 5/25/2016) (nmfn, ). (Entered: 05/23/2016) |
| 5/19/2016 | 366 | REPLY BRIEF re 338 MOTION to Strike, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibits A-C)(Higgins, James) Modified on 3/13/2018 (nms). (Entered: 05/19/2016) |
| 5/18/2016 | 365 | REDACTED VERSION of 360 Appendix, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 05/18/2016) |
| 5/18/2016 | 364 | REDACTED VERSION of 359 Answering Brief in Opposition to Defendants' Motion for a New Trial by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Entered: 05/18/2016) |
| 5/18/2016 | 363 | REDACTED VERSION of 358 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) Modified on 3/13/2018 (nms). (Entered: 05/18/2016) |
| 5/13/2016 | 362 | [SEALED] OPENING BRIEF in Support re 336 MOTION for Permanent Injunction [CORRECTED] filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..Answering Brief/Response due date per Local Rules is 5/31/2016. (Sharp, Melanie) (Entered: 05/13/2016) |
| 5/12/2016 | 361 | REPLY BRIEF re 332 MOTION for Judgment as a Matter of Law on Written Description and Enablement filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Balick, Steven) (Entered: 05/12/2016) |
| 5/11/2016 | 360 | [SEALED] APPENDIX re 359 Answering Brief in Opposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Tab 1, Part 1, # 2 Tab 1, Part 2, # 3 Tab 1, Part 3, # 4 Tab 1, Part 4, # 5 Tab 1, Part 5, # 6 Tab 1, Part 6, # 7 Tab 1, Part 7, # 8 Tab 1, Part 8, # 9 Tab 1, Part 9, # 10 Tab 1, Part 10, # 11 Tab 1, Part 11, # 12 Tab 1, Part 12, # 13 Tab 1, Part 13, # 14 Tab 2, Part 1, # 15 Tab 2, Part 2, # 16 Tab 2, Part 3, # 17 Tab 2, Part 4, # 18 Tab 2, Part 5, # 19 Tab 2, Part 6, # 20 Tab 2, Part 7, # 21 Tab 2, Part 8, # 22 Tab 2, Part 9, # 23 Tab 2, Part 10, # 24 Tab 2, Part 11, # 25 Tab 3, # 26 Tab 4, Part 1, # 27 Tab 4, Part 2, # 28 Tab 4, Part 3, # 29 Tab 4, Part 4, # 30 Tab 4, Part 5, # 31 Tab 4, Part 6, # 32 Tab 4, Part 7, # 33 Tab 4, Part 8, # 34 Tab 4, Part 9, # 35 Tab 5, # 36 Tab 6)(Sharp, Melanie) Modified on 3/13/2018 (nms). (Entered: 05/11/2016) |
| 5/11/2016 | 359 | [SEALED] ANSWERING BRIEF in Opposition re 331 MOTION for New Trial filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..Reply Brief due date per Local Rules is 5/23/2016. (Sharp, Melanie) (Entered: 05/11/2016) |
| 5/11/2016 | 358 | [SEALED] ANSWERING BRIEF in Opposition re 336 MOTION for Permanent Injunction filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Reply Brief due date per Local Rules is 5/23/2016. (Balick, Steven) (Entered: 05/11/2016) |
| 5/9/2016 | 357 | ANSWERING BRIEF in Opposition re 338 MOTION to Strike 333 Opening Brief in Support, 332 MOTION for Judgment as a Matter of Law on Written Description and Enablement filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Reply Brief due date per Local Rules is 5/19/2016. (Attachments: # 1 Exhibit A)(Balick, Steven) (Entered: 05/09/2016) |
| 5/6/2016 | 356 | [SEALED] Transcript of telephone conference held on March 15, 2016 before Judge Robinson.. (vjg) (Entered: 05/06/2016) |
| 5/6/2016 | Pro Hac Vice Attorney Stephanie L. Donahue for Sanofi added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (dmp, ) (Entered: 05/06/2016) | |
| 5/5/2016 | 355 | REDACTED VERSION of 334 Opening Brief in Support, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 05/05/2016) |
| 5/4/2016 | CORRECTING ENTRY: The under seal PDF at D.I. 352 has been replaced with a new PDF now designated as public. The new PDF also includes a corrected citation at the end of the footnote on page 11, and the confidentiality designation previously placed on all pages of the document has been removed. (fms) (Entered: 05/04/2016) | |
| 5/2/2016 | 354 | APPENDIX re 352 Answering Brief in Opposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Tab 1, part 1, # 2 Tab 1, part 2, # 3 Tab 1, part 3, # 4 Tab 1, part 4, # 5 Tab 1, part 5, # 6 Tab 1, part 6, # 7 Tab 1, part 7, # 8 Tab 1, part 8, # 9 Tab 1, part 9, # 10 Tab 1, part 10, # 11 Tab 1, part 11, # 12 Tab 1, part 12, # 13 Tab 1, part 13, # 14 Tab 1, part 14, # 15 Tab 1, part 15, # 16 Tab 2, part 1, # 17 Tab 2, part 2, # 18 Tab 2, part 3, # 19 Tab 2, part 4, # 20 Tab 2, part 5, # 21 Tab 2, part 6, # 22 Tab 2, part 7, # 23 Tab 2, part 8, # 24 Tab 2, part 9, # 25 Tab 2, part 10, # 26 Tab 2, part 11, # 27 Tab 2, part 12, # 28 Tab 2, part 13, # 29 Tab 3, part 1, # 30 Tab 3, part 2, # 31 Tab 3, part 3, # 32 Tab 3, part 4, # 33 Tab 3, part 5, # 34 Tab 3, part 6, # 35 Tab 3, part 7, # 36 Tab 3, part 8, # 37 Tab 3, part 9, # 38 Tab 3, part 10, # 39 Tab 3, part 11, # 40 Tab 3, part 12, # 41 Tab 3, part 13, # 42 Tab 3, part 14, # 43 Tab 3, part 15, # 44 Tab 3, part 16)(Sharp, Melanie) Modified on 3/13/2018 (nms). (Entered: 05/02/2016) |
| 5/2/2016 | 353 | PROPOSED ORDER Granting Plaintiffs' Motion and Memorandum to Strike Defendants' Rule 50(b) Motion for Judgment As a Matter of Law For Failure to Preserve the Issues Pursuant to Rule 50(a) re 338 MOTION to Strike 333 Opening Brief in Support, 332 MOTION for Judgment as a Matter of Law on Written Description and Enablement , 332 MOTION for Judgment as a Matter of Law on Written Description and Enablement, 352 Answering Brief in Opposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Sharp, Melanie) (Entered: 05/02/2016) |
| 5/2/2016 | 352 | ANSWERING BRIEF in Opposition re 338 MOTION to Strike 333 Opening Brief in Support, 332 MOTION for Judgment as a Matter of Law on Written Description and Enablement , 332 MOTION for Judgment as a Matter of Law on Written Description and Enablement filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..Reply Brief due date per Local Rules is 5/12/2016. (Sharp, Melanie) (Main Document 352 replaced on 5/4/2016) (fms). Modified on 5/4/2016 (fms). (Entered: 05/02/2016) |
| 5/2/2016 | 351 | NOTICE of Withdrawal of Counsel, Shane G. Smith by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. (Higgins, James) (Entered: 05/02/2016) |
| 5/2/2016 | Set Transcript Deadlines re 349 Redacted Transcript, 350 Redacted Transcript. Release of Transcript Restriction set for 8/1/2016. (fms) (Entered: 05/02/2016) | |
| 5/2/2016 | 350 | Redaction of 348 Transcript. (fms) (Entered: 05/02/2016) |
| 5/2/2016 | 349 | Redaction of 347 Transcript. (fms) (Entered: 05/02/2016) |
| 5/2/2016 | 348 | [SEALED] Transcript of Hearing held on 3/24/2016 before Judge Robinson. (fms) (Entered: 05/02/2016) |
| 5/2/2016 | 347 | [SEALED] Transcript of Hearing held on 3/23/2016 before Judge Robinson. (fms) (Entered: 05/02/2016) |
| 5/1/2016 | 346 | Official Transcript of jury trial held on March 16, 2016 before Judge Robinson. Court Reporter/Transcriber Valerie Gunning,Telephone number (302) 573-6194. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 5/23/2016. Redacted Transcript Deadline set for 6/1/2016. Release of Transcript Restriction set for 8/1/2016. (vjg) (Entered: 05/01/2016) |
| 5/1/2016 | 345 | Official Transcript of jury trial held on March 14, 2016 before Judge Robinson. Court Reporter/Transcriber Valerie Gunning,Telephone number (302) 573-6194. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 5/23/2016. Redacted Transcript Deadline set for 6/1/2016. Release of Transcript Restriction set for 8/1/2016. (vjg) (Entered: 05/01/2016) |
| 5/1/2016 | 344 | Official Transcript of jury trial held on March 11, 2016 before Judge Robinson. Court Reporter/Transcriber Valerie Gunning,Telephone number (302) 573-6194. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 5/23/2016. Redacted Transcript Deadline set for 6/1/2016. Release of Transcript Restriction set for 8/1/2016. (vjg) (Entered: 05/01/2016) |
| 5/1/2016 | 343 | Official Transcript of jury trial held on March 10, 2016 before Judge Valerie Gunning. Court Reporter/Transcriber Valerie Gunning,Telephone number (302) 573-6194. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 5/23/2016. Redacted Transcript Deadline set for 6/1/2016. Release of Transcript Restriction set for 8/1/2016. (vjg) (Entered: 05/01/2016) |
| 5/1/2016 | 342 | Official Transcript of jury trial held on March 9, 2016 before Judge Robinson. Court Reporter/Transcriber Valerie Gunning,Telephone number (302) 573-6194. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 5/23/2016. Redacted Transcript Deadline set for 6/1/2016. Release of Transcript Restriction set for 8/1/2016. (vjg) (Entered: 05/01/2016) |
| 5/1/2016 | 341 | Official Transcript of jury trial held on March 8, 2016 before Judge Robinson. Court Reporter/Transcriber Valerie Gunning,Telephone number (302) 573-6194. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 5/23/2016. Redacted Transcript Deadline set for 6/1/2016. Release of Transcript Restriction set for 8/1/2016. (vjg) (Entered: 05/01/2016) |
| 4/27/2016 | CORRECTING ENTRY: D.I. 334 has been placed under seal per request of counsel. (nmfn) (Entered: 04/27/2016) | |
| 4/27/2016 | 340 | REDACTED VERSION of 337 Opening Brief in Support, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit A)(Sharp, Melanie) Modified on 3/18/2019 (nms). (Entered: 04/27/2016) |
| 4/22/2016 | 339 | DECLARATION re 338 MOTION to Strike 333 Opening Brief in Support, 332 MOTION for Judgment as a Matter of Law on Written Description and Enablement [Declaration of Bhanu K. Sadasivian] by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 1)(Higgins, James) (Entered: 04/22/2016) |
| 4/22/2016 | 338 | MOTION to Strike 333 Opening Brief in Support, 332 MOTION for Judgment as a Matter of Law on Written Description and Enablement - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Rule 7.1.1 Statement)(Higgins, James) (Entered: 04/22/2016) |
| 4/22/2016 | 337 | [SEALED] OPENING BRIEF in Support re 336 MOTION for Permanent Injunction filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..Answering Brief/Response due date per Local Rules is 5/9/2016. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Sharp, Melanie) (Entered: 04/22/2016) |
| 4/22/2016 | 336 | MOTION for Permanent Injunction - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Text of Proposed Order)(Sharp, Melanie) (Entered: 04/22/2016) |
| 4/22/2016 | 335 | DECLARATION of Jonathan J. Underwood re 331 MOTION for New Trial, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Balick, Steven) Modified on 3/13/2018 (nms). (Entered: 04/22/2016) |
| 4/22/2016 | 334 | SEALED OPENING BRIEF in Support re 331 MOTION for New Trial filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Answering Brief/Response due date per Local Rules is 5/9/2016. (Balick, Steven) Modified on 4/27/2016 (nmfn). (Main Document 334 replaced on 4/27/2016) (nmfn, ). (Entered: 04/22/2016) |
| 4/18/2016 | CORRECTING ENTRY: The redacted verdict (D.I. 304 ) has been removed and replaced with a version that contains all 4 pages with the juror signatures redacted from the 4th page. The pdf of the redacted version previously contained only the first 3 pages with the 4th page removed in its entirety. (fms) (Entered: 04/18/2016) | |
| 4/15/2016 | 333 | OPENING BRIEF in Support re 332 MOTION for Judgment as a Matter of Law on Written Description and Enablement filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Answering Brief/Response due date per Local Rules is 5/2/2016. (Balick, Steven) (Entered: 04/15/2016) |
| 4/15/2016 | 332 | MOTION for Judgment as a Matter of Law on Written Description and Enablement - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Balick, Steven) (Entered: 04/15/2016) |
| 4/15/2016 | 331 | MOTION for New Trial - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 04/15/2016) |
| 4/5/2016 | SO ORDERED, re 330 Stipulation and Proposed Order to Set a Briefing Schedule and Increase the Number of Briefing Pages filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. See Stipulation for details. By Judge Sue L. Robinson on 4/5/2016. (fms) (Entered: 04/05/2016) | |
| 4/4/2016 | 330 | STIPULATION regarding post-trial briefing, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Balick, Steven) (Entered: 04/04/2016) |
| 3/30/2016 | Pro Hac Vice Attorney George W. Hicks, Jr,Christopher G. Michel for Sanofi added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (dmp, ) (Entered: 03/30/2016) | |
| 3/29/2016 | SO ORDERED, re 329 MOTION for Pro Hac Vice Appearance of Attorney Paul D. Clement, George W. Hicks, Jr., and Christopher G. Michel filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Sue L. Robinson on 3/29/2016. (fms) (Entered: 03/29/2016) | |
| 3/29/2016 | 329 | MOTION for Pro Hac Vice Appearance of Attorney Paul D. Clement, George W. Hicks, Jr., and Christopher G. Michel - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 03/29/2016) |
| 3/24/2016 | Minute Entry for proceedings held before Judge Sue L. Robinson - Hearing completed on 3/24/2016 (DAY 2). (Court Reporter V. Gunning.) (fms) (Entered: 03/24/2016) | |
| 3/24/2016 | 328 | REDACTED VERSION of 307 Combinded Admitted Trial Exhibit List, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 03/24/2016) |
| 3/24/2016 | 327 | REDACTED VERSION of 307 Trial Exhibit List, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 03/24/2016) |
| 3/24/2016 | 326 | REDACTED VERSION of 307 Joint Trial Exhibit List, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 03/24/2016) |
| 3/24/2016 | 325 | REDACTED VERSION of 307 Final Trial Exhibit List, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) Modified on 3/13/2018 (nms). (Entered: 03/24/2016) |
| 3/23/2016 | Minute Entry for proceedings held before Judge Sue L. Robinson - Hearing held on 3/23/2016 (DAY 1). (Court Reporter V. Gunning.) (fms) (Entered: 03/23/2016) | |
| 3/22/2016 | 324 | REDACTED VERSION of 300 Memorandum in Opposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 03/22/2016) |
| 3/22/2016 | 323 | REDACTED VERSION of 296 Response to Defendants' Request for Admission of Evidence Related to Amgen's Post-Priority Date Efforts, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 03/22/2016) |
| 3/22/2016 | 322 | REDACTED VERSION of 294 Proffer Concerning Post-Priority Crystal Structure Evidence From Dr. Gregory Petsko, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 03/22/2016) |
| 3/22/2016 | 321 | REDACTED VERSION of 283 Bench Memorandum on the Relevance of Defendants' Inconsistent Statements to the United States Patent Office, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 03/22/2016) |
| 3/22/2016 | 320 | REDACTED VERSION of 271 MOTION to Preclude [Amgen's Motion to Exclude Supplemental Expert Report, Exclude Non-Prior Art References from Evidence, and Exclude Evidence of Obviousness] by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Entered: 03/22/2016) |
| 3/22/2016 | 319 | REDACTED VERSION of 260 Statement, [Plaintiffs' Response to Defendants' Evidentiary Issue 12 & 13] by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Entered: 03/22/2016) |
| 3/22/2016 | 318 | REDACTED VERSION of 268 Statement, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A-C)(Lydon, Tiffany) (Entered: 03/22/2016) |
| 3/22/2016 | 317 | REDACTED VERSION of 286 Statement, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A & B)(Lydon, Tiffany) (Entered: 03/22/2016) |
| 3/22/2016 | 316 | REDACTED VERSION of 267 Declaration, (of Jenna M. Pellecchia) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 03/22/2016) |
| 3/22/2016 | 315 | REDACTED VERSION of 266 Statement, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 03/22/2016) |
| 3/22/2016 | 314 | REDACTED VERSION of 298 MOTION for Judgment as a Matter of Law by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 03/22/2016) |
| 3/22/2016 | 313 | REDACTED VERSION of 285 Statement, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 03/22/2016) |
| 3/22/2016 | 312 | REDACTED VERSION of 278 Statement (Proffer of Donald Siegel, M.D., Ph.D) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 03/22/2016) |
| 3/22/2016 | 311 | REDACTED VERSION of 279 Statement (Proffer of Michael J. Eck, M.D., Ph.D) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 03/22/2016) |
| 3/22/2016 | 310 | REDACTED VERSION of 277 Statement, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 03/22/2016) |
| 3/22/2016 | 309 | REDACTED VERSION of 276 Letter by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 03/22/2016) |
| 3/18/2016 | 308 | JUDGMENT FOLLOWING A JURY VERDICT PURSUANT TO FED. R. CIV. P. 58(b) in favor of Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. against Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Sue L. Robinson on 3/18/2016. (nmfn) (Entered: 03/18/2016) |
| 3/16/2016 | 307 | [SEALED] Exhibit Lists for Jury Trial held 3/8/2016-3/16/2016. (Attachments: # 1 Joint Exhibit List, # 2 Defendants' Exhibit List, # 3 Plaintiffs' Exhibit List)(fms) (Entered: 03/17/2016) |
| 3/16/2016 | 306 | [SEALED] Jury Notes. (fms) (Entered: 03/16/2016) |
| 3/16/2016 | 305 | [SEALED] Jury List. (fms) (Entered: 03/16/2016) |
| 3/16/2016 | Minute Entry for proceedings held before Judge Sue L. Robinson - Jury Trial completed on 3/16/2016 (DAY 7); Jury Deliberations and Verdict. (Court Reporter V. Gunning.) (fms) (Entered: 03/16/2016) | |
| 3/16/2016 | 304 | REDACTED VERSION of 303 Jury Verdict. (fms) (Main Document 304 replaced on 4/18/2016) (fms). (Entered: 03/16/2016) |
| 3/16/2016 | 303 | [SEALED] JURY VERDICT. (fms) (Entered: 03/16/2016) |
| 3/16/2016 | 302 | MEMORANDUM ORDER granting 298 MOTION for Judgment as a Matter of Law filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Sue L. Robinson on 3/16/2016. (nmfn) (Entered: 03/16/2016) |
| 3/16/2016 | CORRECTING ENTRY: Per request of filer, the main attachment at D.I. 300 has been removed and replaced with a corrected version. (fms) (Entered: 03/16/2016) | |
| 3/15/2016 | 301 | NOTICE to Take Deposition of Mike Ryan on March 16, 2016 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 03/15/2016) |
| 3/15/2016 | 300 | [SEALED] MEMORANDUM in Opposition re 298 MOTION for Judgment as a Matter of Law of No Willful Infringement filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..Reply Brief due date per Local Rules is 3/28/2016. (Attachments: # 1 1, # 2 2, # 3 3, # 4 4, Part 1, # 5 4, Part 2, # 6 5)(Higgins, James) (Main Document 300 replaced on 3/16/2016) (fms). (Entered: 03/15/2016) |
| 3/15/2016 | Minute Entry for proceedings held before Judge Sue L. Robinson - Jury Trial held on 3/15/2016. Jury Deliberations. (DAY 6). (fms) (Entered: 03/15/2016) | |
| 3/15/2016 | CORRECTING ENTRY: Per request of filer, the.pdf at D.I. 298 has been removed and replaced. (fms) (Entered: 03/15/2016) | |
| 3/14/2016 | ORAL ORDER by Judge Sue L. Robinson in open court on 3/14/2016 granting in part and reserving judgment in part re: 282 MOTION for Judgment as a Matter of Law filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. See 3/14/2016 trial transcript for further details. (nmfn) (Entered: 03/16/2016) | |
| 3/14/2016 | Minute Entry for proceedings held before Judge Sue L. Robinson - Jury Trial held on 3/14/2016 (DAY 5). (Court Reporter V. Gunning.) (fms) (Entered: 03/14/2016) | |
| 3/14/2016 | 299 | Final Jury Instructions (Read in open court by Judge Robinson on 3/14/2016). (fms) (Entered: 03/14/2016) |
| 3/14/2016 | 298 | [SEALED] MOTION for Judgment as a Matter of Law - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Main Document 298 replaced on 3/15/2016) (fms). (Entered: 03/14/2016) |
| 3/14/2016 | 297 | Letter to The Honorable Sue L. Robinson from James L. Higgins, Esq. regarding Additional Proposed Jury Instructions - re 292 Letter, 284 Letter. (Attachments: # 1 Attachment - Redline)(Higgins, James) (Entered: 03/14/2016) |
| 3/14/2016 | 296 | [SEALED] STATEMENT re 286 Statement, [Response to Defendants' Request for Admission of Evidence Related to Amgen's Post-Priority Date Efforts] by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 1, # 2 2, # 3 3, # 4 4)(Higgins, James) (Entered: 03/14/2016) |
| 3/14/2016 | 295 | [SEALED] Proffer Concerning Post-Priority Crystal Structure Evidence from Dr. Anthony Rees, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 03/14/2016) |
| 3/14/2016 | 294 | [SEALED] Proffer Concerning Post-Priority Crystal Structure Evidence From Dr. Gregory Petsko, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 03/14/2016) |
| 3/13/2016 | 293 | Letter to The Honorable Sue L. Robinson from James L. Higgins, Esq. regarding Submission of the Parties' Joint Proposed Responses to Jurors' Questions. (Attachments: # 1 Joint Proposed Responses to Jurors' Questions)(Higgins, James) (Entered: 03/13/2016) |
| 3/13/2016 | 292 | Letter to The Honorable Sue L. Robinson from Steven J. Balick regarding Defendants' Response to Plaintiffs' March 13, 2016 Letter (D.I. 284) concerning the proposed Drinkware jury instructions and the antedating prior art instruction. (Attachments: # 1 Exhibit 1)(Balick, Steven) (Entered: 03/13/2016) |
| 3/13/2016 | 291 | STATEMENT [Defendants' Memorandum Regarding Disputed Jury Instructions] by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A)(Balick, Steven) (Entered: 03/13/2016) |
| 3/13/2016 | 290 | REDACTED VERSION of 253 Statement [Plaintiffs' One Page Memoranda Regarding Evidentiary Issuse 4 and 13] by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Entered: 03/13/2016) |
| 3/13/2016 | 289 | REDACTED VERSION of 252 Statement, [Plaintiffs' One Page Memoranda Regarding Evidentiary Issues 10 and 14] by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Entered: 03/13/2016) |
| 3/13/2016 | 288 | REDACTED VERSION of 234 Declaration,, of Shane G. Smith in Support of Plaintiffs' Opposition to Defendants' Motion for Reargument of the February 18 Memorandum Order Granting Amgen's Daubert Motion Regarding Post-Priority Date Evidence by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Entered: 03/13/2016) |
| 3/13/2016 | 287 | REDACTED VERSION of 233 Answering Brief in Opposition, to Defendants' Motion for Reargument of the February 18 Memorandum Order Granting Amgen's Daubert Motion Regarding Post-Priority Date Evidence by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Entered: 03/13/2016) |
| 3/13/2016 | 286 | [SEALED] STATEMENT [Defendants' Request for Admission of Evidence Related to Amgen's Post-Priority Date Efforts] by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Balick, Steven) (Entered: 03/13/2016) |
| 3/13/2016 | 285 | [SEALED] STATEMENT [Defendants' Response to Plaintiffs' Bench Memorandum (D.I. 283) and Proffer Regarding Prosecution of Unrelated Patents] by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Balick, Steven) (Entered: 03/13/2016) |
| 3/13/2016 | 284 | Letter to The Honorable Sue L. Robinson from Melanie K. Sharp, Esq. regarding Response to Two Prior Art Issues Raised at the Charging Conference. (Attachments: # 1 Proposed Prior Art Instruction)(Sharp, Melanie) (Entered: 03/13/2016) |
| 3/11/2016 | Minute Entry for proceedings held before Judge Sue L. Robinson - Jury Trial held on 3/11/2016 (DAY 4). (Court Reporter V. Gunning.) (fms) (Entered: 03/14/2016) | |
| 3/11/2016 | 283 | [SEALED] STATEMENT [Plaintiffs' Bench Memorandum on the Relevance of Defendants' Inconsistent Statements to the United States Patent Office] by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Higgins, James) (Entered: 03/11/2016) |
| 3/11/2016 | 282 | MOTION for Judgment as a Matter of Law - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Entered: 03/11/2016) |
| 3/11/2016 | 281 | Proposed Jury Instructions by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. [Plaintiffs' Amended Proposed Final Jury Instructions on Damages and Willfulness]. (Higgins, James) (Entered: 03/11/2016) |
| 3/10/2016 | Minute Entry for proceedings held before Judge Sue L. Robinson - Jury Trial held on 3/10/2016 (DAY 3). (Court Reporter V. Gunning.) (fms) (Entered: 03/10/2016) | |
| 3/10/2016 | 280 | MEMORANDUM ORDER that the relief requested vis a vis plaintiffs' evidentiary issues 10 and 14 is granted in part and denied in part. See Memorandum Order for further details. Signed by Judge Sue L. Robinson on 3/10/2016. (nmfn) (Entered: 03/10/2016) |
| 3/10/2016 | 279 | [SEALED] STATEMENT (Proffer of Michael J. Eck, M.D., Ph.D.) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 03/10/2016) |
| 3/10/2016 | 278 | [SEALED] STATEMENT (Proffer of Donald Siegel, M.D., Ph.D.) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 03/10/2016) |
| 3/10/2016 | 277 | [SEALED] STATEMENT (Defendants' bench memorandum on the relevance of post-priority date documents to show 2008 state of the art) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 1)(Mayo, Andrew) (Entered: 03/10/2016) |
| 3/9/2016 | Minute Entry for proceedings held before Judge Sue L. Robinson - Jury Trial held on 3/9/2016 (DAY 2). (Court Reporter V. Gunning.) (fms) (Entered: 03/09/2016) | |
| 3/9/2016 | SO ORDERED, re 275 MOTION for Pro Hac Vice Appearance of Attorney Stephanie L. Donahue filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC, 274 MOTION for Pro Hac Vice Appearance of Attorney Michael Flynn-O'Brien filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Sue L. Robinson on 3/9/2016. (fms) (Entered: 03/09/2016) | |
| 3/8/2016 | 276 | [SEALED] Letter to The Honorable Sue L. Robinson from Steven J. Balick regarding the impeachment of witnesses under FRE 609. (Balick, Steven) (Entered: 03/08/2016) |
| 3/8/2016 | 275 | MOTION for Pro Hac Vice Appearance of Attorney Stephanie L. Donahue - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Balick, Steven) (Entered: 03/08/2016) |
| 3/8/2016 | 274 | MOTION for Pro Hac Vice Appearance of Attorney Michael Flynn-O'Brien - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 03/08/2016) |
| 3/8/2016 | Minute Entry for proceedings held before Judge Sue L. Robinson - Jury Trial held on 3/8/2016. (Court Reporter V. Gunning.)(DAY 1) (nmfn) (Entered: 03/08/2016) | |
| 3/8/2016 | 273 | Preliminary Jury Instructions (Read in open court by Judge Robinson on 3/8/2016). (nmfn) (Entered: 03/08/2016) |
| 3/8/2016 | 272 | Voir Dire To Jury Panel (Read in open court by Judge Robinson on 3/8/2016). (fms) (Entered: 03/08/2016) |
| 3/8/2016 | SO ORDERED, re 258 MOTION for Pro Hac Vice Appearance of Attorney Steven D. Tang and Joshua Mack filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. Signed by Judge Sue L. Robinson on 3/8/2016. (fms) (Entered: 03/08/2016) | |
| 3/7/2016 | 271 | [SEALED] MOTION to Preclude [Amgen's Motion to Exclude Supplemental Expert Report, Exclude Non-Prior Art References from Evidence, and Exclude Evidence of Obviousness] - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Higgins, James) (Entered: 03/07/2016) |
| 3/7/2016 | 270 | Letter to The Honorable Sue L. Robinson from James L. Higgins, Esq. regarding request for permission to bring demonstrative exhibits, including molecule models and product samples to trial. (Higgins, James) (Entered: 03/07/2016) |
| 3/7/2016 | 269 | MEMORANDUM ORDER re: plaintiffs' evidentiary issues 4 and 13. Signed by Judge Sue L. Robinson on 3/7/2016. (nmfn) (Entered: 03/07/2016) |
| 3/7/2016 | 268 | [SEALED] STATEMENT (Defendants' Opposition to Plaintiffs' One Page Memoranda Regarding Plaintiffs' Evidentiary Issues 4 and 13) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Mayo, Andrew) (Entered: 03/07/2016) |
| 3/7/2016 | 267 | [SEALED] DECLARATION re 266 Statement, (Declaration of Jenna M. Pellecchia) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5)(Mayo, Andrew) (Entered: 03/07/2016) |
| 3/7/2016 | 266 | [SEALED] STATEMENT (Defendants' Opposition to Plaintiffs' One Page Memoranda Regarding Plaintiffs' Evidentiary Issues 10 and 14) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 03/07/2016) |
| 3/7/2016 | 265 | Letter to The Honorable Sue L. Robinson from James L. Higgins, Esq. regarding Submission of Amended Version of Preliminary Jury Instructions - re 223 Proposed Jury Instructions. (Attachments: # 1 Preliminary Jury Instructions)(Higgins, James) (Entered: 03/07/2016) |
| 3/7/2016 | 264 | MEMORANDUM ORDER re: evidentiary disputes. Signed by Judge Sue L. Robinson on 3/7/2016. (nmfn) (Entered: 03/07/2016) |
| 3/7/2016 | 263 | Letter to The Honorable Sue L. Robinson from James L. Higgins, Esq. regarding Submission of Amended form Voir Dire to Jury Panel - re 222 Proposed Voir Dire. (Attachments: # 1 Voir Dire to Jury Panel, # 2 Redline - Voir Dire to Jury Panel)(Higgins, James) (Entered: 03/07/2016) |
| 3/7/2016 | 262 | REDACTED VERSION of 241 Statement by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 03/07/2016) |
| 3/7/2016 | 261 | NOTICE OF SERVICE of Supplemental Expert Report of Jeffrey V. Ravetch, M.D., Ph.D. pursuant to D.I. 250 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 03/07/2016) |
| 3/7/2016 | CORRECTING ENTRY: Per request of filer, D.I. 241 has been placed under seal. (fms) (Entered: 03/07/2016) | |
| 3/7/2016 | 260 | [SEALED] Response to 254 Evidentiary Issue 12 & 13, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Higgins, James) Modified on 3/13/2018 (nms). (Entered: 03/07/2016) |
| 3/7/2016 | 259 | Response to 254 Evidentiary Issues 10 and 11, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 3/18/2019 (nms). (Entered: 03/07/2016) |
| 3/6/2016 | 258 | MOTION for Pro Hac Vice Appearance of Attorney Steven D. Tang and Joshua Mack - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certifications by Counsel)(Higgins, James) (Entered: 03/06/2016) |
| 3/6/2016 | 257 | NOTICE to Take Deposition of Dr. Jeffrey Ravetch on March 7, 2016 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 03/06/2016) |
| 3/4/2016 | 256 | REDACTED VERSION of 239 Statement, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 1 and 2)(Mayo, Andrew) (Entered: 03/04/2016) |
| 3/4/2016 | 255 | ORDER that, neither Mr. Bradway nor Dr. Schleifer may talk about the importance of patents in the context of their companies' business models, nor about the amount of money spent on research. See order for further details. Signed by Judge Sue L. Robinson on 3/4/2016. (Attachments: # 1 Statement to be read by the court to the jury after opening statements) (nmfn) (Entered: 03/04/2016) |
| 3/4/2016 | 254 | STATEMENT (Defendants' Opening Submission Regarding Evidentiary Issues 10-13) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4)(Lydon, Tiffany) (Entered: 03/04/2016) |
| 3/4/2016 | 253 | [SEALED] STATEMENT re 249 Memorandum and Order, [Plaintiffs' One Page Memoranda Regarding Evidentiary Issuse 4 and 13] by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 1)(Higgins, James) (Entered: 03/04/2016) |
| 3/4/2016 | 252 | [SEALED] STATEMENT re 250 Memorandum and Order [Plaintiffs' One Page Memoranda Regarding Evidentiary Issues 10 and 14] by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5)(Higgins, James) (Entered: 03/04/2016) |
| 3/4/2016 | Reset Hearings: The Jury Trial is rescheduled to begin 3/8/2016 at 09:00 AM in Courtroom 4B before Judge Sue L. Robinson. (nmfn) (Entered: 03/04/2016) | |
| 3/4/2016 | Minute Entry for proceedings held before Judge Sue L. Robinson - Conference held on 3/4/2016. (Court Reporter V. Gunning.) (nmfn) (Entered: 03/04/2016) | |
| 3/3/2016 | 251 | STATEMENT re 248 Statement (Defendants' Opposition to Plaintiffs' One Page Memorandum Regarding the Offer of Proof of Dr. Leonard Schleifer) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 03/03/2016) |
| 3/3/2016 | CORRECTING ENTRY: The pdf of D.I. 226 has been replaced with a corrected version to correct a typographical error on page 4. (nmfn) (Entered: 03/03/2016) | |
| 3/3/2016 | Set Hearings: A Conference is set for 3/4/2016 at 08:30 AM in Courtroom 4B before Judge Sue L. Robinson. (nmfn) (Entered: 03/03/2016) | |
| 3/2/2016 | 250 | MEMORANDUM ORDER re: evidentiary disputes. Signed by Judge Sue L. Robinson on 3/2/2016. (nmfn) (Entered: 03/02/2016) |
| 3/2/2016 | 249 | MEMORANDUM ORDER granting in part and denying in part 231 MOTION for Reargument of the February 18 Memorandum Order Granting Amgen's Daubert Motion Regarding Post-Priority Date Evidence. Signed by Judge Sue L. Robinson on 3/2/2016. (nmfn) (Entered: 03/02/2016) |
| 3/2/2016 | 248 | Memorandum Regarding Offer of Proof of Dr. Leonard Schleifer, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit)(Higgins, James) Modified on 3/13/2018 (nms). (Entered: 03/02/2016) |
| 3/2/2016 | 247 | Official Transcript of pretrial conference held on February 22, 2016 before Judge Robinson. Court Reporter/Transcriber Valerie Gunning,Telephone number 302-573-6194. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 3/23/2016. Redacted Transcript Deadline set for 4/4/2016. Release of Transcript Restriction set for 5/31/2016. (vjg) (Entered: 03/02/2016) |
| 3/1/2016 | SO ORDERED, re 246 MOTION for Pro Hac Vice Appearance of Attorney Michael N. Petegorsky filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Sue L. Robinson on 3/1/2016. (fms) (Entered: 03/01/2016) | |
| 3/1/2016 | 246 | MOTION for Pro Hac Vice Appearance of Attorney Michael N. Petegorsky - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 03/01/2016) |
| 2/29/2016 | 245 | NOTICE to Take Deposition of Dr. Frank Cottingham and Dr. Jay Edelberg on March 2, 2016 and March 4, 2016, respectively filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 02/29/2016) |
| 2/29/2016 | CORRECTING ENTRY: Per request of filer, D.I. 243 has been removed and replaced with the correct version. (fms) (Entered: 02/29/2016) | |
| 2/26/2016 | 244 | REDACTED VERSION of 232 Declaration, of Jonathan J. Underwood by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 02/26/2016) |
| 2/26/2016 | 243 | REDACTED VERSION of 231 MOTION for Reargument of the February 18 Memorandum Order Granting Amgen's Daubert Motion Regarding Post-Priority Date Evidence by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Main Document 243 replaced on 2/29/2016) (fms). (Entered: 02/26/2016) |
| 2/26/2016 | 242 | Letter to The Honorable Sue L. Robinson from James L. Higgins, Esq. regarding Submission of Amgen's responses to Defendants Arguments In Support of Their Evidentiary Issues 1 and 15, and 14 and Objections to Plaintiffs' Proffer of Testimony for Mr. Robert Bradway - re 239 Statement,. (Attachments: # 1 Amgen Response - Evidentiary Issues 1 and 15, # 2 Amgen Response - Evidentiary Issue 14, # 3 Amgen Response - R. Bradway Proffer)(Higgins, James) (Entered: 02/26/2016) |
| 2/26/2016 | 241 | STATEMENT re 240 Letter, (Defendants' Responses to Plaintiffs' Evidentiary Issues 1 and 2, and 5) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 02/26/2016) |
| 2/24/2016 | 240 | Letter to The Honorable Sue L. Robinson from James L. Higgins, Esq. regarding One-Page Memoranda on Evidentiary Issues Raised During Pretrial Conference. (Attachments: # 1 Amgen Evidentiary Issue 1 and 2, # 2 Amgen Evidentiary Issue 5)(Higgins, James) (Entered: 02/24/2016) |
| 2/24/2016 | 239 | [SEALED] STATEMENT (Defendants' Arguments in Support for Their Evidentiary Issues 1 and 15, and 14 and Objections to Plaintiffs' Proffer of Testimony for Mr. Robert Bradway) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Mayo, Andrew) (Entered: 02/24/2016) |
| 2/23/2016 | 238 | NOTICE to Take Deposition of Leonard S. Schleifer, M.D., Ph.D. on March 3, 2016 filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..(Higgins, James) (Entered: 02/23/2016) |
| 2/22/2016 | SO ORDERED, re 215 Proposed Pretrial Order. Signed by Judge Sue L. Robinson on 2/22/2016. (nmfn) (Entered: 02/23/2016) | |
| 2/22/2016 | Minute Entry for proceedings held before Judge Sue L. Robinson - Final Pretrial Conference held on 2/22/2016. (Court Reporter V. Gunning.) (nmfn) (Entered: 02/23/2016) | |
| 2/22/2016 | 237 | REDACTED VERSION of 215 Proposed Pretrial Order, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16)(Higgins, James) (Entered: 02/22/2016) |
| 2/22/2016 | SO ORDERED, re 235 Stipulation filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Sue L. Robinson on 2/22/2016. (fms) (Entered: 02/22/2016) | |
| 2/22/2016 | SO ORDERED, re 236 MOTION for Pro Hac Vice Appearance of Attorney Michael P. Kahn filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Sue L. Robinson on 2/22/2016. (fms) (Entered: 02/22/2016) | |
| 2/22/2016 | Reset Hearings: The Final Pretrial Conference is rescheduled for 2/22/2016 at 03:30 PM in Courtroom 4B before Judge Sue L. Robinson. (nmfn) (Entered: 02/22/2016) | |
| 2/22/2016 | 236 | MOTION for Pro Hac Vice Appearance of Attorney Michael P. Kahn - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 02/22/2016) |
| 2/22/2016 | 235 | STIPULATION of Infringement of Selected Claims by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 02/22/2016) |
| 2/22/2016 | 234 | [SEALED] DECLARATION of Shane G. Smith re 233 Answering Brief in Opposition, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 20, # 2 Exhibit 21, # 3 Exhibit 22, # 4 Exhibit 23, # 5 Exhibit 24, # 6 Exhibit 25, # 7 Exhibit 26)(Sharp, Melanie) Modified on 3/13/2018 (nms). (Entered: 02/22/2016) |
| 2/22/2016 | 233 | [SEALED] ANSWERING BRIEF in Opposition re 231 MOTION for Reargument of the February 18 Memorandum Order Granting Amgen's Daubert Motion Regarding Post-Priority Date Evidence filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Sharp, Melanie) (Entered: 02/22/2016) |
| 2/19/2016 | 232 | [SEALED] DECLARATION re 231 MOTION for Reargument of the February 18 Memorandum Order Granting Amgen's Daubert Motion Regarding Post-Priority Date Evidence (Declaration of Jonathan J. Underwood) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3)(Lydon, Tiffany) (Entered: 02/19/2016) |
| 2/19/2016 | 231 | [SEALED] MOTION for Reargument of the February 18 Memorandum Order Granting Amgen's Daubert Motion Regarding Post-Priority Date Evidence - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 02/19/2016) |
| 2/19/2016 | 230 | REDACTED VERSION of 211 Declaration, [Second Declaration of James L. Higgins in Support of Amgen's Motion to Exclude Expert Testimony of Ashley J. Stevens] by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Entered: 02/19/2016) |
| 2/19/2016 | 229 | REDACTED VERSION of 210 Reply Brief [Amgen's Daubert Motion to Exclude Expert Testimony and Opinion of Dr. Ashley J. Stevens] by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Entered: 02/19/2016) |
| 2/19/2016 | 228 | REDACTED VERSION of 213 Declaration, (of Jonathan J. Underwood) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 02/19/2016) |
| 2/19/2016 | 227 | REDACTED VERSION of 212 Reply Brief, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 02/19/2016) |
| 2/18/2016 | 226 | MEMORANDUM ORDER granting in part and denying in part 187 MOTION to Preclude [Amgen's Daubert Motion to Exclude Expert Testimony and Opinion of Dr. Ashley J. Stevens, granting in part and denying in part 185 MOTION to exclude certain expert testimony from plaintiffs on written description and reasonable royalties, granting 191 MOTION to Preclude [Amgen's Daubert Motion to Exclude Testimony on (1) Post-Priority Date Embodiments / Antibodies of the Selected Claims, and (2) Defendants' Expert Opinions as to the Patents' Disclosure of Representative Species]. Signed by Judge Sue L. Robinson on 2/18/2016. (nmfn) (Main Document 226 replaced on 3/3/2016) (nmfn, ). (Entered: 02/18/2016) |
| 2/17/2016 | 225 | VERDICT SHEET by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. [Proposed Verdict Sheets]. (Higgins, James) (Entered: 02/17/2016) |
| 2/17/2016 | 224 | Proposed Jury Instructions by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. [Final]. (Higgins, James) (Entered: 02/17/2016) |
| 2/17/2016 | 223 | Proposed Jury Instructions by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. [Preliminary]. (Higgins, James) (Entered: 02/17/2016) |
| 2/17/2016 | 222 | Proposed Voir Dire by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Entered: 02/17/2016) |
| 2/17/2016 | SO ORDERED, re 221 MOTION for Pro Hac Vice Appearance of Attorney Margaret P. Kammerud filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Sue L. Robinson on 2/17/2016. (fms) (Entered: 02/17/2016) | |
| 2/17/2016 | 221 | MOTION for Pro Hac Vice Appearance of Attorney Margaret P. Kammerud - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 02/17/2016) |
| 2/16/2016 | 220 | ANSWER to Amended Complaint, re: 184 Amended Complaint,,,, with Jury Demand by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Mayo, Andrew) (Entered: 02/16/2016) |
| 2/16/2016 | 219 | REDACTED VERSION of 207 Declaration of Matthew G. Hartman by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 02/16/2016) |
| 2/16/2016 | 218 | REDACTED VERSION of 206 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 02/16/2016) |
| 2/16/2016 | 217 | REDACTED VERSION of 205 Declaration, of Jenna M. Pellecchia by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 02/16/2016) |
| 2/16/2016 | 216 | REDACTED VERSION of 203 Answering Brief in Opposition, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 02/16/2016) |
| 2/15/2016 | 215 | [SEALED] Proposed Pretrial Order by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16)(Higgins, James) (Entered: 02/15/2016) |
| 2/15/2016 | 214 | REDACTED VERSION of 202 Answering Brief in Opposition, [Memorandum in Opposition to Defendants Daubert Motion to Exclude Certain Expert Testimony from Plaintiffs on Written Description and Reasonable Royalties] by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Entered: 02/15/2016) |
| 2/12/2016 | 213 | [SEALED] DECLARATION re 212 Reply Brief, (Supplemental Declaration of Jonathan J. Underwood) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 18, # 2 Exhibit 19, # 3 Exhibit 20, # 4 Exhibit 21, # 5 Exhibit 22)(Lydon, Tiffany) (Entered: 02/12/2016) |
| 2/12/2016 | 212 | [SEALED] REPLY BRIEF re 185 MOTION to exclude certain expert testimony from plaintiffs on written description and reasonable royalties filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 02/12/2016) |
| 2/12/2016 | 211 | [SEALED] Second DECLARATION re 210 Reply Brief [Declaration of James L. Higgins in Support of Amgen's Motion to Exclude Expert Testimony of Ashley J. Stevens] by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 5, # 2 Exhibit 6, # 3 Exhibit 7, # 4 Exhibit 8)(Higgins, James) (Entered: 02/12/2016) |
| 2/12/2016 | 210 | [SEALED] REPLY BRIEF re 187 MOTION to Preclude [Amgen's Daubert Motion to Exclude Expert Testimony and Opinion of Dr. Ashley J. Stevens filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Entered: 02/12/2016) |
| 2/12/2016 | 209 | DECLARATION re 208 Reply Brief, [Declaration of Shane G. Smith in Support of Plaintiffs' Reply Memorandum in Support of Amgen's Daubert Motion to Exclude Testimony on (1) Post-Priority Date Embodiments / Antibodies of the Selected Claims, and (2) Defendants' Expert Opinions as to the Patents' Disclosure of Representative Species] by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 17, # 2 Exhibit 18, # 3 Exhibit 19)(Higgins, James) (Entered: 02/12/2016) |
| 2/12/2016 | 208 | REPLY BRIEF re 191 MOTION to Preclude, filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 02/12/2016) |
| 2/11/2016 | CORRECTING ENTRY: Per request of filer, D.I. 203 has been placed under seal. (fms) (Entered: 02/11/2016) | |
| 2/10/2016 | SO ORDERED, re 201 MOTION for Pro Hac Vice Appearance of Attorney Esther E. Lin, Evan Boetticher and Mandy H. Kim filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc. Signed by Judge Sue L. Robinson on 2/10/2016. (fms) (Entered: 02/10/2016) | |
| 2/9/2016 | 207 | [SEALED] DECLARATION re 206 Answering Brief in Opposition, (Declaration of M. Hartman) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 1-7)(Lydon, Tiffany) (Entered: 02/09/2016) |
| 2/9/2016 | 206 | [SEALED] ANSWERING BRIEF in Opposition re 191 MOTION to Preclude [Amgen's Daubert Motion to Exclude Testimony on (1) Post-Priority Date Embodiments / Antibodies of the Selected Claims, and (2) Defendants' Expert Opinions as to the Patents' Disclosure of Representative Species] filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Reply Brief due date per Local Rules is 2/19/2016. (Lydon, Tiffany) (Entered: 02/09/2016) |
| 2/9/2016 | 205 | [SEALED] DECLARATION re 203 Answering Brief in Opposition, (Declaration of Jenna M. Pellecchia) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Lydon, Tiffany) (Entered: 02/09/2016) |
| 2/9/2016 | 204 | [SEALED] DECLARATION re 202 Answering Brief in Opposition, [Declaration of Shane G. Smith in Support of Plaintiffs' Memorandum in Opposition to Defendants' Daubert Motion to Exclude Certain Expert Testimony from Amgen on Written Description and Reasonable Royalties] by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 1 - 4, # 2 Exhibit 5, Part 1, # 3 Exhibit 5, Part 2, # 4 Exhibit 5, Part 3, # 5 Exhibit 5, Part 4, # 6 Exhibit 5, Part 5, # 7 Exhibit 6 - 10, # 8 Exhibit 11, Part 1, # 9 Exhibit 11, Part 2, # 10 Exhibit 11, Part 3, # 11 Exhibit 11, Part 4, # 12 Exhibit 12 - 20)(Higgins, James) (Entered: 02/09/2016) |
| 2/9/2016 | 203 | SEALED ANSWERING BRIEF in Opposition re 187 MOTION to Preclude [Amgen's Daubert Motion to Exclude Expert Testimony and Opinion of Dr. Ashley J. Stevens filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Reply Brief due date per Local Rules is 2/19/2016. (Lydon, Tiffany) Modified on 2/11/2016 (fms). (Entered: 02/09/2016) |
| 2/9/2016 | 202 | [SEALED] ANSWERING BRIEF in Opposition re 185 MOTION to exclude certain expert testimony from plaintiffs on written description and reasonable royalties filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..Reply Brief due date per Local Rules is 2/19/2016. (Higgins, James) (Entered: 02/09/2016) |
| 2/9/2016 | 201 | MOTION for Pro Hac Vice Appearance of Attorney Esther E. Lin, Evan Boetticher and Mandy H. Kim - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Certifcations by Counsel)(Higgins, James) (Entered: 02/09/2016) |
| 2/9/2016 | 200 | REDACTED VERSION of 188 Declaration of Jonathan J. Underwood, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibits 1-17)(Mayo, Andrew) Modified on 3/13/2018 (nms). (Entered: 02/09/2016) |
| 2/9/2016 | 199 | REDACTED VERSION of 186 Opening Brief in Support, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 02/09/2016) |
| 2/8/2016 | 198 | REDACTED VERSION of 190 Declaration, of James L. Higgins in Support of Amgen's Daubert Motion to Exclude Expert Testimony of Dr. Ashley J. Stevens by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Entered: 02/08/2016) |
| 2/8/2016 | 197 | REDACTED VERSION of 189 Opening Brief in Support, Amgen's Daubert Motion to Exclude Expert Testimony of Dr. Ashley J. Stevens by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Entered: 02/08/2016) |
| 2/8/2016 | 196 | REDACTED VERSION of 193 Declaration,, [of Shane G. Smith in Support of Amgen's Daubert Motion to Exclude Testimony on (1) Post-Priority Date Embodiments / Antibodies of the Selected Claims, and (2) Defendants' Expert Opinions as to the Patents' Disclosure of Representative Species] by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Entered: 02/08/2016) |
| 2/8/2016 | 195 | REDACTED VERSION of 192 Opening Brief in Support, [Amgen's Daubert Motion to Exclude Testimony on (1) Post-Priority Date Embodiments / Antibodies of the Selected Claims, and (2) Defendants' Expert Opinions as to the Pat ents' Disclosure of Representative Species] by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Higgins, James) (Entered: 02/08/2016) |
| 2/5/2016 | 194 | STATEMENT (Defendants' Notice Pursuant to 35 U.S.C. 282) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 02/05/2016) |
| 2/2/2016 | 193 | [SEALED] DECLARATION re 192 Opening Brief in Support, 191 MOTION to Preclude [Amgen's Daubert Motion to Exclude Testimony on (1) Post-Priority Date Embodiments / Antibodies of the Selected Claims, and (2) Defendants' Expert Opinions as to the Patents' Disclosure of Representative Species] by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16)(Higgins, James) (Entered: 02/02/2016) |
| 2/2/2016 | 192 | [SEALED] OPENING BRIEF in Support re 191 MOTION to Preclude [Amgen's Daubert Motion to Exclude Testimony on (1) Post-Priority Date Embodiments / Antibodies of the Selected Claims, and (2) Defendants' Expert Opinions as to the Patents' Disclosure of Representative Species] filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..Answering Brief/Response due date per Local Rules is 2/19/2016. (Higgins, James) (Entered: 02/02/2016) |
| 2/2/2016 | 191 | MOTION to Preclude [Amgen's Daubert Motion to Exclude Testimony on (1) Post-Priority Date Embodiments / Antibodies of the Selected Claims, and (2) Defendants' Expert Opinions as to the Patents' Disclosure of Representative Species] - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Proposed Order)(Higgins, James) (Entered: 02/02/2016) |
| 2/2/2016 | 190 | [SEALED] DECLARATION re 187 MOTION to Preclude [Amgen's Daubert Motion to Exclude Expert Testimony and Opinion of Dr. Ashley J. Stevens, 189 Opening Brief in Support, by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4)(Higgins, James) (Entered: 02/02/2016) |
| 2/2/2016 | 189 | [SEALED] OPENING BRIEF in Support re 187 MOTION to Preclude [Amgen's Daubert Motion to Exclude Expert Testimony and Opinion of Dr. Ashley J. Stevens filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc..Answering Brief/Response due date per Local Rules is 2/19/2016. (Higgins, James) (Entered: 02/02/2016) |
| 2/2/2016 | 188 | [SEALED] DECLARATION re 186 Opening Brief in Support, (Declaration of Jonathan J. Underwood) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 1-6, # 2 Exhibit 7, # 3 Exhibit 8, # 4 Exhibit 9-17)(Mayo, Andrew) (Entered: 02/02/2016) |
| 2/2/2016 | 187 | MOTION to Preclude [Amgen's Daubert Motion to Exclude Expert Testimony and Opinion of Dr. Ashley J. Stevens - filed by Amgen Inc., Amgen Manufacturing Limited, Amgen USA Inc.. (Attachments: # 1 Proposed Order)(Higgins, James) (Entered: 02/02/2016) |
| 2/2/2016 | 186 | [SEALED] OPENING BRIEF in Support re 185 MOTION to exclude certain expert testimony from plaintiffs on written description and reasonable royalties filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Answering Brief/Response due date per Local Rules is 2/19/2016. (Mayo, Andrew) (Entered: 02/02/2016) |
| 2/2/2016 | 185 | MOTION to exclude certain expert testimony from plaintiffs on written description and reasonable royalties - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 02/02/2016) |
| 2/1/2016 | Patent report notice docketed on 2/1/16 has been removed from the docket. The patent reports for the patents are filed in this civil action as well as the member cases: 14-1393 SLR, 14-1414 SLR, and 14-1349 SLR. (fms) (Entered: 02/01/2016) | |
| 1/29/2016 | 184 | AMENDED COMPLAINT [Supplemental and Second Amended Complaint for Patent Infringement and Declaratory Judgment of Patent Infringement] against Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC- filed by Amgen Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, Part 1, # 3 Exhibit 2, Part 2, # 4 Exhibit 2, Part 3, # 5 Exhibit 2, Part 4, # 6 Exhibit 2, Part 5, # 7 Exhibit 2, Part 6, # 8 Exhibit 3, Part 1, # 9 Exhibit 3, Part 2, # 10 Exhibit 3, Part 3, # 11 Exhibit 3, Part 4, # 12 Exhibit 4, Part 1, # 13 Exhibit 4, Part 2, # 14 Exhibit 4, Part 3, # 15 Exhibit 4, Part 4, # 16 Exhibit 5, Part 1, # 17 Exhibit 5, Part 2, # 18 Exhibit 5, Part 3, # 19 Exhibit 5, Part 4, # 20 Exhibit 5, Part 5, # 21 Exhibit 6, Part 1, # 22 Exhibit 6, Part 2, # 23 Exhibit 6, Part 3, # 24 Exhibit 6, Part 4, # 25 Exhibit 6, Part 5, # 26 Exhibit 7, Part 1, # 27 Exhibit 7, Part 2, # 28 Exhibit 7, Part 3, # 29 Exhibit 7, Part 4, # 30 Exhibit 7, Part 5, # 31 Exhibit 8)(Higgins, James) (Entered: 01/29/2016) |
| 1/29/2016 | 183 | MEMORANDUM ORDER granting 119 MOTION to Amend/Correct 10 Amended Complaint Plaintiff's Motion for Leave to File a Supplemental and Second Amended Complaint for Patent Infringement and Declaratory Judgment of Patent Infringement filed by Amgen Inc. Signed by Judge Sue L. Robinson on 1/29/2016. (nmfn) (Entered: 01/29/2016) |
| 1/28/2016 | 182 | Letter to The Honorable Sue L. Robinson from Steven J. Balick regarding submission of a copy of the Kwon reference. (Attachments: # 1 Kwon reference)(Balick, Steven) (Entered: 01/28/2016) |
| 1/27/2016 | Minute Entry for proceedings held before Judge Sue L. Robinson - In-Person Status Conference re: Expert Discovery held on 1/27/2016. (Court Reporter V. Gunning.) (nmfn) (Entered: 01/28/2016) | |
| 1/13/2016 | 181 | NOTICE to Take Deposition of Kathryn Doyle, Ashley J. Stevens, Sharon M. Oster, Dr. Robert H. Eckel, Federico Mingozzi, Dr. Jeffrey V. Ravetch, Dr. Donald Siegel, Carla S. Mulhern and Dr. Michael Eck on [See Notice] filed by Amgen Inc..(Higgins, James) (Entered: 01/13/2016) |
| 12/30/2015 | 180 | NOTICE OF SERVICE of Supplemental Expert Report of Jeffrey V. Ravetch, M.D., Ph.D., Supplemental Report of Donald Siegel, M.D., Ph.D. and Supplemental Report of Michael J. Eck, M.D., Ph.D. filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 12/30/2015) |
| 12/30/2015 | 179 | NOTICE OF SERVICE of (1) the Supplemental Expert Report of Gregory A. Petsko, D.Phil., Regarding Infringement of the Selected Claims of the Patents-at-Issue; (2) the Supplemental Expert Report of Paul K. Meyer; (3) the Supplemental Expert Report of Evan A. Stein, M.D., Ph.D. in Response to Report of Robert H. Eckel, M.D.; and (4) the Supplemental Expert Report of Ernst R. Berndt filed by Amgen Inc..(Higgins, James) (Entered: 12/30/2015) |
| 12/23/2015 | 178 | NOTICE OF SERVICE of Defendants' Disclosure of Rebuttal Fact Witnesses filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 12/23/2015) |
| 12/23/2015 | 177 | NOTICE OF SERVICE of Plaintiff's Third Supplemental Rule 26(a) Initial Disclosures filed by Amgen Inc..(Higgins, James) (Entered: 12/23/2015) |
| 12/22/2015 | Pro Hac Vice Attorney Robert Greenfeld for Sanofi added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (dmp, ) (Entered: 12/22/2015) | |
| 12/21/2015 | 176 | NOTICE OF SERVICE of Amgen Inc.'s List of Rebuttal Fact Witnesses it Intends to Call at Trial filed by Amgen Inc..(Higgins, James) (Entered: 12/21/2015) |
| 12/16/2015 | 175 | NOTICE OF SERVICE of Amgen Inc.'s Amended List of Fact Witnesses It Intends to Call at Trial filed by Amgen Inc..(Higgins, James) (Entered: 12/16/2015) |
| 12/15/2015 | 174 | NOTICE OF SERVICE of Defendants' Disclosure of Fact Witnesses filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 12/15/2015) |
| 12/14/2015 | 173 | NOTICE OF SERVICE of Plaintiff Amgen Inc.'s List of Fact Witnesses it Intends to Call at Trial filed by Amgen Inc..(Higgins, James) (Entered: 12/14/2015) |
| 12/8/2015 | 172 | NOTICE OF SERVICE of (1) the Rebuttal Expert Report of Gregory A. Petsko, D.Phil., Regarding Alleged Invalidity of the Selected Claims of the Patents-at-Issue; (2) the Rebuttal Expert Report of Anthony Robert Rees, D.Phil., Regarding Validity of the Selected Claims of the Patents-at-Issue; (3) the Rebuttal Expert Report of Stephen G. Kunin; and (4) the Rebuttal Expert Report of Edward A. Fisher, M.D., M.P.H., Ph.D. Regarding Non-Obviousness of the Selected Claims of the Patents-at-Issue filed by Amgen Inc..(Higgins, James) (Entered: 12/08/2015) |
| 12/7/2015 | 171 | NOTICE OF SERVICE of (1) Expert Report of Ashley J. Stevens; (2) Expert Report of Sharon M. Oster; (3) Report of Robert H. Eckel, M.D.; and (4) Rebuttal Expert Report of Carla S. Mulhern filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 12/07/2015) |
| 12/2/2015 | Minute Entry for proceedings held before Judge Sue L. Robinson - Telephone Conference held on 12/2/2015. (Court Reporter V. Gunning.) (nmfn) (Entered: 12/02/2015) | |
| 12/1/2015 | 170 | REDACTED VERSION of 168 Letter to The Honorable Sue L. Robinson from James L. Higgins on behalf of Plaintiff regarding Defendants' Request for Emergency Relief by Amgen Inc.. (Attachments: # 1 Exhibit A and B)(Higgins, James) (Entered: 12/01/2015) |
| 12/1/2015 | 169 | Letter to The Honorable Sue L. Robinson from Tiffany Geyer Lydon regarding Dr. Fisher issue for December 2 teleconference. (Attachments: # 1 Exhibit 1)(Lydon, Tiffany) (Entered: 12/01/2015) |
| 12/1/2015 | 168 | [SEALED] Letter to The Honorable Sue L. Robinson from James L. Higgins on behalf of Plaintiff regarding Defendants' Request for Emergency Relief. (Attachments: # 1 Exhibit A and B)(Higgins, James) (Entered: 12/01/2015) |
| 11/30/2015 | Set Hearings: A Telephone Conference is set for 12/2/2015 at 10:00 AM before Judge Sue L. Robinson. (nmfn) (Entered: 11/30/2015) | |
| 11/25/2015 | 167 | REDACTED VERSION of 164 Letter, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 11/25/2015) |
| 11/24/2015 | REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # 164. (fms) (Entered: 11/24/2015) | |
| 11/23/2015 | 166 | ORDER that plaintiff's request to compel the production of notebook pages and a presentation is granted. Signed by Judge Sue L. Robinson on 11/23/2015. (nmfn) (Entered: 11/23/2015) |
| 11/16/2015 | 165 | REDACTED VERSION of 159 Letter, to The Honorable Sue L. Robinson from Melanie K. Sharp, Esq. regarding Request for Order Compelling Production of Documents by Dr. Engel by Amgen Inc.. (Higgins, James) (Entered: 11/16/2015) |
| 11/16/2015 | REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # 159. (fms) (Entered: 11/16/2015) | |
| 11/9/2015 | 164 | [SEALED] Letter to The Honorable Sue L. Robinson from Andrew C. Mayo regarding Defendants' Response to Plaintiff's October 30, 2015 Request for an Order Compelling Production of Documents by Dr. Engel - re 159 Letter,. (Mayo, Andrew) (Entered: 11/09/2015) |
| 11/6/2015 | 163 | NOTICE OF SERVICE of (1) the Expert Report of Ernst R. Berndt; (2) the Expert Report of Paul K. Meyer; (3) the First Expert Report of Gregory A. Petsko, D.Phil., Regarding Infringement of SElected Claims of the Patents-at-Issue; (4) the Opening Expert Report of Anthony Robert Rees Regarding Infringement of Claim 24 of U.S. Patent No. 8,871,941; and (5) the Expert Report of Evan S. Stein, M.D., Ph.D. filed by Amgen Inc..(Sharp, Melanie) (Entered: 11/06/2015) |
| 11/6/2015 | 162 | NOTICE OF SERVICE of (1) Report of Michael J. Eck, M.D., Ph.D.; (2) Report of Federico Mingozzi, Ph.D.; (3) Report of Kathryn Doyle, Ph.D., Esq.; (4) Expert Report of Jeffrey V. Ravetch, M.D., Ph.D.; and (3) Opening Report of Donald Siegel, M.D., Ph.D. filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 11/06/2015) |
| 11/3/2015 | 161 | NOTICE OF SERVICE of Plaintiff Amgen Inc.'s Further Disclosure of Narrowed Selected Claims filed by Amgen Inc..(Higgins, James) (Entered: 11/03/2015) |
| 11/2/2015 | 160 | NOTICE OF SERVICE of Defendants' Final Invalidity Contentions filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 11/02/2015) |
| 10/30/2015 | 159 | [SEALED] Letter to The Honorable Sue L. Robinson from Melanie K. Sharp, Esq. regarding Request for Order Compelling Production of Documents by Dr. Engel. (Attachments: # 1 Exhibit A-E, # 2 Ex. F, Part 1, # 3 Ex. F, Part 2, # 4 Ex. F, Part 3, # 5 Ex. F, Part 4, # 6 Ex. F, Part 5, # 7 Ex. F, Part 6, # 8 Ex. F, Part 7, # 9 Ex. F, Part 8, # 10 Ex. F, Part 9, # 11 Ex. F, Part 10)(Sharp, Melanie) (Entered: 10/30/2015) |
| 10/30/2015 | Pro Hac Vice Attorney Christopher Mead for Amgen Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (klc) (Entered: 10/30/2015) | |
| 10/29/2015 | 158 | REDACTED VERSION of 145 Declaration of William G. Gaede, III, by Amgen Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 10/29/2015) |
| 10/29/2015 | 157 | REDACTED VERSION of 146 Reply Brief, by Amgen Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 10/29/2015) |
| 10/28/2015 | REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI Nos. 145 and 146. (fms) (Entered: 10/28/2015) | |
| 10/27/2015 | 156 | NOTICE OF SERVICE of Amgen Inc.'s Final Infringement Contentions with Claim Charts Relating Each Accused Product to the Selected Claims filed by Amgen Inc..(Higgins, James) (Entered: 10/27/2015) |
| 10/26/2015 | Minute Entry for proceedings held before Judge Sue L. Robinson - In-Person Status Conference held on 10/26/2015. (Court Reporter V. Gunning.) (nmfn) (Entered: 10/26/2015) | |
| 10/26/2015 | SO ORDERED, re 155 MOTION for Pro Hac Vice Appearance of Attorney Christopher B. Mead filed by Amgen Inc. Signed by Judge Sue L. Robinson on 10/26/2015. (fms) (Entered: 10/26/2015) | |
| 10/26/2015 | 155 | MOTION for Pro Hac Vice Appearance of Attorney Christopher B. Mead - filed by Amgen Inc.. (Attachments: # 1 Certification by Counsel)(Sharp, Melanie) (Entered: 10/26/2015) |
| 10/23/2015 | 154 | NOTICE OF SERVICE of Plaintiff Amgen Inc.'s Disclosure of Narrowed Selected Claims filed by Amgen Inc..(Higgins, James) (Entered: 10/23/2015) |
| 10/22/2015 | SO ORDERED, re 153 Stipulation Regarding Documents Produced by Merck, Sharp & Dohme, Corp.filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Sue L. Robinson on 10/22/2015. (nmfn) (Entered: 10/22/2015) | |
| 10/21/2015 | 153 | STIPULATION regarding Merck documents by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 10/21/2015) |
| 10/21/2015 | SO ORDERED, re 152 Stipulation and Proposed Order Amending Scheduling Order filed by Amgen Inc. Signed by Judge Sue L. Robinson on 10/21/2015. (fms) (Entered: 10/21/2015) | |
| 10/20/2015 | 152 | Joint PROPOSED ORDER Amending Scheduling Order re 49 Scheduling Order,,,, by Amgen Inc.. (Higgins, James) (Entered: 10/20/2015) |
| 10/20/2015 | 151 | MEMORANDUM ORDER re: claim construction. Signed by Judge Sue L. Robinson on 10/20/2015. (nmfn) (Entered: 10/20/2015) |
| 10/16/2015 | 150 | REDACTED VERSION of 136 Letter, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A-L)(Lydon, Tiffany) (Entered: 10/16/2015) |
| 10/16/2015 | Pro Hac Vice Attorney Jenna M. Pellecchia for Regeneron Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (dmp, ) (Entered: 10/16/2015) | |
| 10/16/2015 | 149 | ORDER, Rescheduling Hearings( The In-Person Status Conference is rescheduled for 10/26/2015 at 02:00 PM in Courtroom 4B before Judge Sue L. Robinson.) Signed by Judge Sue L. Robinson on 10/16/2015. (nmfn) (Entered: 10/16/2015) |
| 10/15/2015 | SO ORDERED, re 147 MOTION for Pro Hac Vice Appearance of Attorney David L. Larson, Michael V. O'Shaughnessy and Rebecca Harker Duttry filed by Amgen Inc. Signed by Judge Sue L. Robinson on 10/15/2015. (fms) (Entered: 10/15/2015) | |
| 10/14/2015 | 148 | REDACTED VERSION of 125 Letter, to The Honorable Sue L. Robinson from Melanie K. Sharp, Esq. regarding Response to September 14, 2015 E-mail Response to Emergency Request for Relief by Amgen Inc.. (Higgins, James) (Entered: 10/14/2015) |
| 10/14/2015 | 147 | MOTION for Pro Hac Vice Appearance of Attorney David L. Larson, Michael V. O'Shaughnessy and Rebecca Harker Duttry - filed by Amgen Inc.. (Attachments: # 1 Certification - D. Larson, # 2 Certification - M. O'Shaughnessy, # 3 Certification - R. Harker Duttry)(Higgins, James) (Entered: 10/14/2015) |
| 10/13/2015 | 146 | [SEALED] REPLY BRIEF re 119 MOTION to Amend/Correct 10 Amended Complaint Plaintiff's Motion for Leave to File a Supplemental and Second Amended Complaint for Patent Infringement and Declaratory Judgment of Patent Infringement filed by Amgen Inc.. (Attachments: # 1 Certificate of Service)(Higgins, James) (Entered: 10/13/2015) |
| 10/13/2015 | 145 | [SEALED] DECLARATION re 119 MOTION to Amend/Correct 10 Amended Complaint Plaintiff's Motion for Leave to File a Supplemental and Second Amended Complaint for Patent Infringement and Declaratory Judgment of Patent Infringement [Declaration of William G. Gaede, III, in Support of Plaintiff's Reply] by Amgen Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, Part 1, # 4 Exhibit 3, Part 2, # 5 Exhibit 3, Part 3, # 6 Exhibit 3, Part 4, # 7 Exhibit 3, Part 5, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Certificate of Service)(Higgins, James) (Entered: 10/13/2015) |
| 10/13/2015 | 144 | ORDER re 136 Letter, 125 Letter. ORDER that the deposition of Dr. Engel shall go forward without the benefit of the disputed documents. SEE ORDER FOR FURTHER DETAILS. Signed by Judge Sue L. Robinson on 10/13/2015. (nmfn) (Entered: 10/13/2015) |
| 10/13/2015 | SO ORDERED, re 143 MOTION for Pro Hac Vice Appearance of Attorney Larry Coury and Lynda Q. Nguyen filed by Regeneron Pharmaceuticals Inc. Signed by Judge Sue L. Robinson on 10/13/2015. (fms) (Entered: 10/13/2015) | |
| 10/12/2015 | 143 | MOTION for Pro Hac Vice Appearance of Attorney Larry Coury and Lynda Q. Nguyen - filed by Regeneron Pharmaceuticals Inc.. (Lydon, Tiffany) (Entered: 10/12/2015) |
| 10/12/2015 | 142 | NOTICE OF SERVICE of Sanofi's First Amended Rule 26(a)(1) Initial Disclosures filed by Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 10/12/2015) |
| 10/9/2015 | 141 | NOTICE OF SERVICE of (i) Defendants Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC, f/d/b/a Aventis Pharmaceuticals Inc., and Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Plaintiff Amgen Inc.'s First Set of Requests for Admission (Nos. 1-50); (ii) Defendants Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC, f/d/b/a Aventis Pharmaceuticals Inc. and Regeneron Pharmaceuticals, Inc.'s Second Supplemental Objections and Responses to Plaintiff Amgen Inc.'s First Set of Joint Interrogatories (Nos. 4-7); (iii) Defendant Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Plaintiff Amgen Inc.'s First Set of Interrogatories (Nos. 1-15); (iv) Sanofi's Objections and Responses to Plaintiffs First Set of Interrogatories to Sanofi, Sanofi-Aventis U.S. LLC, and Aventisub LLC f/d/b/a Aventis Pharmaceuticals Inc. (Nos. 1-15); (v) Defendants Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC, f/d/b/a Aventis Pharmaceuticals Inc. and Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Plaintiff Amgen Inc.'s Second Set of Joint Interrogatories (Nos. 8-25) filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 10/09/2015) |
| 10/9/2015 | 140 | NOTICE OF SERVICE of (1) Plaintiff Amgen Inc.'s Supplemental Responses and Objections to Defendants' Second Set of Interrogatories (Nos. 11, 17, 18); (2) Plaintiff Amgen Inc.'s Supplemental Responses and Objections to Regeneron's First Set of Interrogatories (Nos. 7, 9, & 10-13); (3) Plaintiff Amgen Inc.'s Supplemental Responses and Objections to Sanofi's First Set of Interrogatories (Nos. 1, 3, 6 & 10) and (4) Plaintiff Amgen Inc.'s Second Supplemental Responses and Objections to Defendants' First Set of Interrogatories (Nos. 1-10) filed by Amgen Inc..(Higgins, James) (Entered: 10/09/2015) |
| 10/8/2015 | 139 | NOTICE to Take Deposition of Christian Engel on October 16, 2015 [Second Amended] filed by Amgen Inc..(Higgins, James) (Entered: 10/08/2015) |
| 10/8/2015 | REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI No. 125. (fms) (Entered: 10/08/2015) | |
| 10/6/2015 | 138 | NOTICE OF SERVICE of Regeneron's Second Supplemental Rule 26(a)(1) Initial Disclosures filed by Regeneron Pharmaceuticals Inc..(Lydon, Tiffany) (Entered: 10/06/2015) |
| 10/5/2015 | 137 | NOTICE OF SERVICE of Notice of Deposition of Shaun Kelleher filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 10/05/2015) |
| 10/5/2015 | 136 | [SEALED] Letter to The Honorable Sue L. Robinson from Steven J. Balick regarding Defendants' response to Amgen's September 23, 2015 Letter (D.I. 125) Concerning Privilege Dispute. (Attachments: # 1 Index of Exhibits, # 2 Exhibit A-L)(Balick, Steven) (Entered: 10/05/2015) |
| 10/5/2015 | 135 | NOTICE OF SERVICE of (i) Notice of Deposition of Gwen Cummings; (ii) Notice of Deposition of Bethany Mancilla; and (iii) Notice of Deposition of Mary Lehmann filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 10/05/2015) |
| 10/5/2015 | 134 | Letter to The Honorable Sue L. Robinson from Steven J. Balick regarding Defendants' Response to Amgen's Post-Hearing Submission on Claim Construction (D.I. 128). (Balick, Steven) (Entered: 10/05/2015) |
| 10/2/2015 | 133 | NOTICE OF SERVICE of (1) Plaintiff Amgen Inc.'s Responses and Objections to Defendant's Third Set of Requests for the Production of Documents and Things (Nos. 50-71); (2) Plaintiff Amgen Inc.'s Objections and Responses to Defendants' First Set of Requests for Admission (Nos. 1-50); (3) Plaintiff Amgen Inc.'s Responses and Objections to Defendants' Third Set of Interrogatories (Nos. 20-24); (4) Plaintiff Amgen Inc.'s Responses and Objections to Sanofi's First Set of Interrogatories (Nos. 1-15) and (5) Plaintiff Amgen Inc.'s Responses and Objections to Regeneron's First Set of Interrogatories (Nos. 1-13) filed by Amgen Inc..(Higgins, James) (Entered: 10/02/2015) |
| 10/2/2015 | 132 | DECLARATION re 131 Answering Brief in Opposition, (Declaration of Jonathan J. Underwood) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 10/02/2015) |
| 10/2/2015 | 131 | ANSWERING BRIEF in Opposition re 119 MOTION to Amend/Correct 10 Amended Complaint Plaintiff's Motion for Leave to File a Supplemental and Second Amended Complaint for Patent Infringement and Declaratory Judgment of Patent Infringement filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.Reply Brief due date per Local Rules is 10/13/2015. (Lydon, Tiffany) (Entered: 10/02/2015) |
| 9/30/2015 | 130 | NOTICE to Take Deposition of Stuart Watt on October 9, 2015 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Mayo, Andrew) (Entered: 09/30/2015) |
| 9/29/2015 | 129 | NOTICE to Take Deposition of Robert Terifay on October 9, 2015 [Amended] filed by Amgen Inc..(Higgins, James) (Entered: 09/29/2015) |
| 9/29/2015 | 128 | Letter to The Honorable Sue L. Robinson from Melanie K. Sharp on behalf of Plaintiff Amgen Inc. regarding possible compromise claim constructions. (Sharp, Melanie) (Entered: 09/29/2015) |
| 9/29/2015 | 127 | NOTICE OF SERVICE of Plaintiff's Second Supplemental Rule 26(a) Initial Disclosures filed by Amgen Inc..(Higgins, James) (Entered: 09/29/2015) |
| 9/28/2015 | 126 | NOTICE to Take Deposition of Dan Van Plew on October 5, 2015 filed by Amgen Inc..(Higgins, James) (Entered: 09/28/2015) |
| 9/23/2015 | 125 | [SEALED] Letter to The Honorable Sue L. Robinson from Melanie K. Sharp, Esq. regarding Response to September 14, 2015 E-mail Response to Emergency Request for Relief. (Attachments: # 1 Index to Exhibits, # 2 Exhibit 1, Part 1, # 3 Exhibit 1, Part 2, # 4 Exhibit 2-10, # 5 Exhibit 11-16)(Sharp, Melanie) (Entered: 09/23/2015) |
| 9/22/2015 | 124 | REDACTED VERSION of 119 MOTION to Amend/Correct 10 Amended Complaint Plaintiff's Motion for Leave to File a Supplemental and Second Amended Complaint for Patent Infringement and Declaratory Judgment of Patent Infringement by Amgen Inc.. (Higgins, James) (Entered: 09/22/2015) |
| 9/22/2015 | 123 | NOTICE OF SERVICE of Plaintiff Amgen Inc.'s Objections and Responses to Defendants' Second Set of Interrogatories (Nos. 11-19) filed by Amgen Inc..(Higgins, James) (Entered: 09/22/2015) |
| 9/21/2015 | 122 | NOTICE to Take Deposition of Merck Sharp & Dohme Corp., f/d/b/a Schering Corporation and of Subpoena on September 29, 2015 filed by Amgen Inc..(Higgins, James) (Entered: 09/21/2015) |
| 9/18/2015 | 121 | NOTICE OF SERVICE of Plaintiff Amgen Inc.'s Responses and Objections to Defendants' Second Set of Requests for the Production of Documents and Things (No. 49) and this Notice filed by Amgen Inc..(Higgins, James) (Entered: 09/18/2015) |
| 9/17/2015 | Minute Entry for proceedings held before Judge Sue L. Robinson - Markman Hearing held on 9/17/2015. (Court Reporter V. Gunning.) (nmfn) (Entered: 09/17/2015) | |
| 9/16/2015 | SO ORDERED, re 118 MOTION for Pro Hac Vice Appearance of Attorney Richard Praseuth filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Sue L. Robinson on 9/16/2015. (fms) (Entered: 09/16/2015) | |
| 9/15/2015 | 120 | EXHIBITS re 119 Motion for Leave to File a Supplemental and Second Amended Complaint for Patent Infringement and Declaratory Judgment of Patent Infringement, by Amgen Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit A1, # 3 Exhibit A2 Part 1, # 4 Exhibit A2 Part 2, # 5 Exhibit A2 Part 3, # 6 Exhibit A2 Part 4, # 7 Exhibit A3 Part 1, # 8 Exhibit A3 Part 2, # 9 Exhibit A3 Part 3, # 10 Exhibit A3 Part 4, # 11 Exhibit A4 Part 1, # 12 Exhibit A4 Part 2, # 13 Exhibit A4 Part 3, # 14 Exhibit A4 Part 4, # 15 Exhibit A5 Part 1, # 16 Exhibit A5 Part 2, # 17 Exhibit A5 Part 3, # 18 Exhibit A5 Part 4, # 19 Exhibit A6 Part 1, # 20 Exhibit A6 Part 2, # 21 Exhibit A 6 Part 3, # 22 Exhibit A6 Part 4, # 23 Exhibit A7 Part 1, # 24 Exhibit A7 Part 2, # 25 Exhibit A7 Part 3, # 26 Exhibit A7 Part 4, # 27 Exhibit A8 Part 1, # 28 Exhibit A8 Part 2, # 29 Exhibit A8 Part 3 (part 1), # 30 Exhibit A8 Part 3 (part 2), # 31 Exhibit A8 Part 4, # 32 Exhibit B)(Higgins, James) Modified on 3/13/2018 (nms). (Entered: 09/15/2015) |
| 9/15/2015 | 119 | [SEALED] Motion for Leave to File a Supplemental and Second Amended Complaint for Patent Infringement and Declaratory Judgment of Patent Infringement - filed by Amgen Inc.. (Attachments: # 1 7.1.1 Certification, # 2 Proposed Order)(Higgins, James) Modified on 3/13/2018 (nms). (Entered: 09/15/2015) |
| 9/15/2015 | 118 | MOTION for Pro Hac Vice Appearance of Attorney Richard Praseuth - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 09/15/2015) |
| 9/15/2015 | 117 | NOTICE OF SERVICE of Notice of Subpoena and Deposition filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 09/15/2015) |
| 9/11/2015 | 116 | NOTICE to Take Deposition of Christian Engel, Bruce LaCombe, Jana Bodorova, Yannick Traversino, Ophra Rebiere, William J. Sasiela, Ph.D., Victoria Carey, Kerry Reinertsen, Joel H. Martin, Jay Edelberg and Neil Stahl on [multiple date listed in Notice] filed by Amgen Inc..(Higgins, James) (Entered: 09/11/2015) |
| 9/10/2015 | SO ORDERED, re 114 MOTION for Pro Hac Vice Appearance of Attorney Jenna M. Pellecchia filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC, 113 MOTION for Pro Hac Vice Appearance of Attorney Robert Greenfeld filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Sue L. Robinson on 9/10/2015. (fms) (Entered: 09/10/2015) | |
| 9/9/2015 | 115 | NOTICE OF SERVICE of (1) Plaintiff's First Set of Requests for Admission to Defendants Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC f/d/b/a Aventis Pharmaceuticals Inc. and Regeneron Pharmaceuticals, Inc. (Nos. 1-50); (2) Plaintiff's Second Set of Joint Interrogatories to Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC f/d/b/a Aventis Pharmaceuticals Inc. and Regeneron Pharmaceuticals, Inc. (Nos. 8-25); (3) Plaintiff's First Set of Interrogatories to Defendant Regeneron Pharmaceuticals, Inc. (Nos. 1-15); (4) Plaintiff's First Set of Interrogatories to Sanofi, Sanofi-Aventis U.S. LLC, and Aventisub LLC f/d/b/a Aventis Pharmaceuticals Inc. (Nos. 1-15) filed by Amgen Inc..(Higgins, James) (Entered: 09/09/2015) |
| 9/9/2015 | 114 | MOTION for Pro Hac Vice Appearance of Attorney Jenna M. Pellecchia - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 09/09/2015) |
| 9/9/2015 | 113 | MOTION for Pro Hac Vice Appearance of Attorney Robert Greenfeld - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 09/09/2015) |
| 9/8/2015 | 112 | NOTICE OF SERVICE of Defendant Sanofi's Objections and Responses to Plaintiff Amgen Inc.'s Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 09/08/2015) |
| 9/2/2015 | 111 | NOTICE OF SERVICE of (i) Defendants' First Set of Requests for Admission (Nos. 1-50); (ii) Defendants' Third Set of Requests for the Production of Documents and Things to Plaintiff Amgen Inc. (Nos. 50-71); (iii) Defendants' Third Set of Interrogatories (Nos. 20-24); (iv) Regeneron's First Set of Interrogatories (Nos. 1-13); and (v) Sanofi's First Set of Interrogatories (Nos. 1-15) filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 09/02/2015) |
| 9/2/2015 | 110 | NOTICE to Take Deposition of Ned Braunstein on September 18, 2015 filed by Amgen Inc..(Higgins, James) (Entered: 09/02/2015) |
| 9/2/2015 | SO ORDERED, re 108 MOTION for Pro Hac Vice Appearance of Attorney Dennis Smith filed by Amgen Inc. Signed by Judge Sue L. Robinson on 9/2/2015. (fms) (Entered: 09/02/2015) | |
| 8/31/2015 | 109 | NOTICE OF SERVICE of Defendant Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Plaintiff Amgen Inc.'s Notice of Deposition of Defendant Regeneron Pharmaceuticals, Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Regeneron Pharmaceuticals Inc..(Lydon, Tiffany) (Entered: 08/31/2015) |
| 8/28/2015 | 108 | MOTION for Pro Hac Vice Appearance of Attorney Dennis Smith - filed by Amgen Inc.. (Attachments: # 1 Certification by Counsel)(Higgins, James) (Entered: 08/28/2015) |
| 8/28/2015 | 107 | DECLARATION re 106 Claim Construction Surreply Brief (Second Declaration of Jonathan J. Underwood) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 13-17)(Lydon, Tiffany) (Entered: 08/28/2015) |
| 8/28/2015 | 106 | CLAIM CONSTRUCTION SURREPLY BRIEF filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 08/28/2015) |
| 8/28/2015 | 105 | NOTICE to Take Deposition of Nicholas Papadopoulos on September 10, 2015 [Amended] filed by Amgen Inc..(Higgins, James) (Entered: 08/28/2015) |
| 8/28/2015 | 104 | NOTICE to Take Deposition of Andrew Murphy on September 16, 2015 [Amended] filed by Amgen Inc..(Higgins, James) (Entered: 08/28/2015) |
| 8/28/2015 | 103 | NOTICE to Take Deposition of Douglas MacDonald on September 3, 2015 [Amended] filed by Amgen Inc..(Higgins, James) (Entered: 08/28/2015) |
| 8/28/2015 | 102 | NOTICE to Take Deposition of Jeanette Fairhurst on September 1, 2015 [Amended] filed by Amgen Inc..(Higgins, James) (Entered: 08/28/2015) |
| 8/27/2015 | 101 | NOTICE OF SERVICE of (1) Notice of Deposition of Jane Xia; (2) Notice of Deposition of Mark Neumann; and (3) Notice of Deposition of Charles Tilton filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 08/27/2015) |
| 8/21/2015 | 100 | NOTICE OF SERVICE of Defendants' Second Set of Interrogatories (Nos. 11-19) filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 08/21/2015) |
| 8/21/2015 | 99 | NOTICE OF SERVICE of Non-Party Wenyan Shen's Responses and Objections to Defendants' Notice and Subpoena for Testimony and Documents filed by Amgen Inc..(Higgins, James) (Entered: 08/21/2015) |
| 8/20/2015 | 98 | NOTICE OF SERVICE of Plaintiff Amgen Inc.'s Supplemental Responses and Objections to Defendants' Interrogatories (Nos. 1 & 2) filed by Amgen Inc..(Higgins, James) (Entered: 08/20/2015) |
| 8/20/2015 | 97 | NOTICE OF SERVICE of Defendants Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC, f/d/b/a Aventis Pharmaceuticals Inc. and Regeneron Pharmaceuticals, Inc.'s First Supplemental Objections and Responses to Plaintiff Amgen Inc.'s First Set of Joint Interrogatories (Nos. 1- 3) filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 08/20/2015) |
| 8/19/2015 | 96 | NOTICE to Take Deposition of Joel H. Martin on September 14, 2015 filed by Amgen Inc..(Higgins, James) (Entered: 08/19/2015) |
| 8/19/2015 | 95 | NOTICE OF SERVICE of Defendants' Second Set of Requests for the Production of Documents and Things to Plaintiff Amgen Inc. (No. 49) filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 08/19/2015) |
| 8/14/2015 | 94 | DECLARATION re 93 Claim Construction Reply Brief [Supplemental Declaration of William G. Gaede, III in Support of Plaintiff's Reply Claim Construction Brief] by Amgen Inc.. (Attachments: # 1 Exhibit 12)(Higgins, James) (Entered: 08/14/2015) |
| 8/14/2015 | 93 | CLAIM CONSTRUCTION REPLY BRIEF re 65 Claim Construction Opening Brief filed by Amgen Inc.. (Higgins, James) (Entered: 08/14/2015) |
| 8/14/2015 | SO ORDERED, re 90 Stipulated Second Amended Protective Order filed by Amgen Inc. Signed by Judge Sue L. Robinson on 8/14/2015. (fms) (Entered: 08/14/2015) | |
| 8/12/2015 | 92 | NOTICE OF SERVICE of Mark Sleeman's Objections and Responses to Amgen Inc.'s Testimony and Production Subpoena Served August 4, 2015 filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Mayo, Andrew) (Entered: 08/12/2015) |
| 8/12/2015 | 91 | NOTICE OF SERVICE of Notice of Subpoenas filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Mayo, Andrew) (Entered: 08/12/2015) |
| 8/12/2015 | 90 | Joint PROPOSED ORDER Stipulated Second Amended Protective Order re 44 Proposed Order, 32 Proposed Order by Amgen Inc.. (Higgins, James) (Entered: 08/12/2015) |
| 8/7/2015 | 89 | NOTICE OF SERVICE of (1) Non-Party Nigel Pelham Clinton Walker's Responses and Objections to Defendants' Notice and Subpoena for Testimony and Documents; (2) Non-Party Christopher Mehlin's Responses and Objections to Defendants' Notice and Subpoena for Testimony and Documents; and (3) Non-Party Randal Robert Ketchem's Responses and Objections to Defendants' Notice and Subpoena for Testimony and Documents filed by Amgen Inc..(Higgins, James) (Entered: 08/07/2015) |
| 8/6/2015 | 88 | ORDER, having reviewed the parties' letters submitted in connection with the discovery dispute raised in a July 13, 2015 email (D.I. 72 , 73 ); and assuming said dispute is still an active one; IT IS ORDERED that: 1. On or before September 3, 2015, Amgen shall produce all post-August 22, 2008 technical documents that address the 40+ disclosed antibody examples in the Amgen specification. 2. Amgen need not comply with the second disputed request for production, that is, Amgen's testing of non-prior art PCSK9 antibodies other than the examples expressly disclosed in its patents. Signed by Judge Sue L. Robinson on 8/6/2015. (nmfn) (Entered: 08/06/2015) |
| 8/6/2015 | 87 | NOTICE to Take Deposition of Nick Papadopoulos on September 9, 2015 filed by Amgen Inc..(Higgins, James) (Entered: 08/06/2015) |
| 8/6/2015 | 86 | NOTICE to Take Deposition of Andrew Murphy on September 2, 2015 filed by Amgen Inc..(Higgins, James) (Entered: 08/06/2015) |
| 8/6/2015 | 85 | NOTICE to Take Deposition of Douglas MacDonald on September 11, 2015 filed by Amgen Inc..(Higgins, James) (Entered: 08/06/2015) |
| 8/6/2015 | 84 | NOTICE to Take Deposition of Jeanette Fairhurst on September 4, 2015 filed by Amgen Inc..(Higgins, James) (Entered: 08/06/2015) |
| 8/6/2015 | 83 | NOTICE to Take Deposition of Christian Engel on September 10, 2015 filed by Amgen Inc..(Higgins, James) (Entered: 08/06/2015) |
| 8/4/2015 | 82 | NOTICE OF SERVICE of Notice of Deposition of Gregory A. Petsko filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 08/04/2015) |
| 8/4/2015 | 81 | NOTICE of Subpoena Directed to Mark W. Sleeman by Amgen Inc. (Higgins, James) (Entered: 08/04/2015) |
| 7/31/2015 | 80 | NOTICE OF SERVICE of Plaintiff Amgen Inc.'s Corrected Notice of Deposition of Defendants Sanofi, Sanofi-Aventis U.S. LLC, and Aventisub LLC f/d/b/a Aventis Pharmaceuticals Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Amgen Inc..(Higgins, James) (Entered: 07/31/2015) |
| 7/31/2015 | 79 | DECLARATION re 78 Claim Construction Answering Brief (Declaration of Jonathan J. Underwood) by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12)(Lydon, Tiffany) (Entered: 07/31/2015) |
| 7/31/2015 | 78 | CLAIM CONSTRUCTION ANSWERING BRIEF filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 07/31/2015) |
| 7/30/2015 | 77 | NOTICE OF SERVICE of 1) Non-Party Knobbe, Martens, Olson & Bear LLP' Responses and Objections to Defendants' Notice and Subpoena for Documents; and (2) Non-Party Dr. Eli Loots' Responses and Objections to Defendants' Notice and Subpoena for Testimony and Documents filed by Amgen Inc..(Higgins, James) (Entered: 07/30/2015) |
| 7/29/2015 | 76 | NOTICE OF SERVICE of Plaintiff Amgen Inc.'s Notice of Deposition of Defendant Regeneron Pharmaceuticals, Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) and Plaintiff Amgen Inc.'s Notice of Deposition of Defendants Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC f/d/b/a Aventis Pharmaceuticals Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Amgen Inc..(Higgins, James) (Entered: 07/29/2015) |
| 7/24/2015 | 75 | NOTICE OF SERVICE of (1) Notice of Deposition of Rayne Waller; (2) Notice of Deposition of Simon Mark Jackson; (3) Notice of Deposition of Chadwick Terence King; (4) Notice of Deposition of Mike Ryan; (5) Notice of Deposition of Rob Scott; (6) Notice of Deposition of Vanessa Broadhurst; and (7) Notice of Deposition of Derek Evan Piper filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 07/24/2015) |
| 7/24/2015 | 74 | NOTICE OF SERVICE of Notice of Subpoenas filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 07/24/2015) |
| 7/23/2015 | 73 | Letter to The Honorable Sue L. Robinson from Steven J. Balick regarding defendants' discovery dispute letter-memorandum, as requested in the Court's July 20 response to defendants' e-mail request for emergency relief. (Balick, Steven) (Entered: 07/23/2015) |
| 7/23/2015 | 72 | Letter to The Honorable Sue L. Robinson from Melanie K. Sharp, Esq. regarding Defendants' Request for Emergency Relief. (Sharp, Melanie) (Entered: 07/23/2015) |
| 7/23/2015 | 71 | NOTICE OF SERVICE of Plaintiff Amgen Inc.'s Responses and Objections to Defendants' Notice of Deposition filed by Amgen Inc..(Higgins, James) (Entered: 07/23/2015) |
| 7/22/2015 | 70 | REDACTED VERSION of 68 Notice (Other) of Subpoena Directed to Merck Sharp & Dohme Corp. f/d/b/a Schering Corporation by Amgen Inc.. (Higgins, James) (Entered: 07/22/2015) |
| 7/22/2015 | 69 | NOTICE OF SERVICE of Regeneron's Supplemental Rule 26(a)(1) Initial Disclosures filed by Regeneron Pharmaceuticals Inc..(Lydon, Tiffany) (Entered: 07/22/2015) |
| 7/15/2015 | 68 | [SEALED] NOTICE of Subpoena by Amgen Inc. (Attachments: # 1 Subpoena Directed to Merck Sharp & Dohme Corp. f.d.b.a. Schering Corporation, # 2 Certificate of Service)(Higgins, James) (Entered: 07/15/2015) |
| 7/10/2015 | 67 | DECLARATION re 65 Claim Construction Opening Brief [Expert Declaration of Gregory A. Petsko, D. Phil. Regarding the Proper Construction of the Disputed Claim Elements from the Patents-At-Issue] by Amgen Inc.. (Attachments: # 1 Attachment 1, # 2 Attachment 2)(Higgins, James) (Entered: 07/10/2015) |
| 7/10/2015 | 66 | DECLARATION of William G. Gaede, III re 65 Claim Construction Opening Brief, by Amgen Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, Part 1, # 5 Exhibit 4, Part 2, # 6 Exhibit 5, Part 1, # 7 Exhibit 5, Part 2, # 8 Exhibit 6, # 9 Exhibit 7, # 10 Exhibit 8, # 11 Exhibit 9, # 12 Exhibit 10, # 13 Exhibit 11)(Higgins, James) Modified on 3/13/2018 (nms). (Entered: 07/10/2015) |
| 7/10/2015 | 65 | CLAIM CONSTRUCTION OPENING BRIEF filed by Amgen Inc.. (Attachments: # 1 Attachment 1)(Higgins, James) (Entered: 07/10/2015) |
| 7/10/2015 | 64 | NOTICE OF SERVICE of Notice of Deposition and Subpoena and Notice of Subpoena filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 07/10/2015) |
| 7/8/2015 | 63 | NOTICE OF SERVICE of Defendants' Notice of Deposition Pursuant to Federal Rule of Civil Procedure 30(b)(6) filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 07/08/2015) |
| 6/26/2015 | 62 | NOTICE OF SERVICE of Defendants Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC f/d/b/a Aventis Pharmaceuticals Inc. and Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Plaintiff's Second Set of Requests for Production (Nos. 25-74) filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 06/26/2015) |
| 6/24/2015 | 61 | Joint Claim Construction Statement, by Amgen Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 06/24/2015) |
| 6/22/2015 | 60 | NOTICE OF SERVICE of Defendants' First Amended Preliminary Invalidity Contentions filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 06/22/2015) |
| 6/20/2015 | 59 | NOTICE OF SERVICE of Plaintiff's Supplemental Rule 26(a) Initial Disclosures filed by Amgen Inc..(Higgins, James) (Entered: 06/20/2015) |
| 6/8/2015 | 58 | NOTICE OF SERVICE of Defendants' List of Claim Terms and Proposed Constructions filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 06/08/2015) |
| 6/5/2015 | 57 | NOTICE OF SERVICE of Plaintiff Amgen Inc.'s List of Claim Terms to be Construed and Proposed Constructions filed by Amgen Inc..(Higgins, James) (Entered: 06/05/2015) |
| 6/5/2015 | ORAL ORDER- IT IS HEREBY ORDERED that: the court shall conduct a status teleconference on 11/2/2015 at 11:00 AM before Judge Sherry R. Fallon. Signed by Judge Sherry R. Fallon on 6/5/2015. (lih) (Entered: 06/05/2015) | |
| 5/27/2015 | 56 | NOTICE OF SERVICE of Plaintiff's Second Set of Requests for Production of Documents and Things to Defendants Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC f.d.b.a Aventis Pharmaceuticals Inc. and Regeneron Pharmaceuticals, Inc. (Nos. 25-74) filed by Amgen Inc..(Higgins, James) (Entered: 05/27/2015) |
| 5/27/2015 | 55 | NOTICE OF SERVICE of Notice of Subpoenas filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 05/27/2015) |
| 5/8/2015 | 54 | NOTICE OF SERVICE of Defendants' Preliminary Invalidity Contentions filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 05/08/2015) |
| 5/4/2015 | 53 | NOTICE OF SERVICE of Defendants Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC, f/d/b/a Aventis Pharmaceuticals Inc. and Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Plaintiff Amgen Inc.'s First Set of Joint Interrogatories (Nos. 1-7) filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 05/04/2015) |
| 4/22/2015 | 52 | ORDER Setting Teleconference: plaintiffs counsel shall initiate the call. A Telephone Conference is set for 6/4/2015 at 12:00 PM before Judge Sherry R. Fallon to discuss ADR. Signed by Judge Sherry R. Fallon on 4/22/2015. (lih) (Entered: 04/22/2015) |
| 4/22/2015 | CASE REFERRED to Judge Fallon for Mediation. (lih) (Entered: 04/22/2015) | |
| 4/21/2015 | 51 | NOTICE OF SERVICE of Amgen's Disclosures Pursuant to Paragraph H of the Document Production Protocol re SO ORDERED, 41 Proposed Order filed by Amgen Inc..(Higgins, James) (Entered: 04/21/2015) |
| 4/21/2015 | 50 | NOTICE OF SERVICE of Sanofi's Initial Disclosures Pursuant to Paragraph H of the Parties' Stipulated Document Production Protocol and Regeneron's Initial Disclosures Pursuant to Stipulated Document Production Protocol, Paragraph H filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 04/21/2015) |
| 4/21/2015 | 49 | SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Joinder of Parties due by 9/15/2015. Amended Pleadings due by 9/15/2015. Discovery due by 1/22/2016. Claim Construction Opening Brief due by 7/10/2015. Claim Construction Answering Brief due by 7/31/2015. Claim Construction Reply Brief due by 8/14/2015. Claim Construction Surreply Brief due by 8/28/2015. A Markman Hearing is set for 9/17/2015 at 01:00 PM in Courtroom 4B before Judge Sue L. Robinson. A Status Conference is set for 10/20/2015 at 04:30 PM in Courtroom 4B before Judge Sue L. Robinson. A Status Conference re expert discovery is set for 1/27/2016 at 04:30 PM in Courtroom 4B before Judge Sue L. Robinson. A Final Pretrial Conference is set for 2/22/2016 at 04:30 PM in Courtroom 4B before Judge Sue L. Robinson. A Jury Trial is set for 3/7/2016 at 09:00 AM in Courtroom 4B before Judge Sue L. Robinson.. A Permanent Injunction Hearing is set for 3/23/2016 and 3/24/2016 at 09:00 AM in Courtroom 4B before Judge Sue L. Robinson. Signed by Judge Sue L. Robinson on 4/21/2015. (fms) (Entered: 04/21/2015) |
| 4/17/2015 | 48 | Joint PROPOSED ORDER Scheduling Order re Scheduling Conference by Amgen Inc.. (Attachments: # 1 Agreed Trial Schedule (Table), # 2 Letter to The Honorable Sue L. Robinson)(Higgins, James) (Entered: 04/17/2015) |
| 4/14/2015 | 47 | NOTICE OF SERVICE of (1) Plaintiff Amgen Inc.'s Responses and Objections to Defendants' First Set of Interrogatories (Nos. 1-10) and (2) Plaintiff Amgen Inc.'s Responses and Objections to Defendants' First Set of Requests for the Production of Documents and Things (Nos. 1-48) filed by Amgen Inc..(Higgins, James) (Entered: 04/14/2015) |
| 4/13/2015 | SO ORDERED, re 46 MOTION for Pro Hac Vice Appearance of Attorney Jonathan J. Underwood filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Sue L. Robinson on 4/13/2015. (fms) (Entered: 04/13/2015) | |
| 4/13/2015 | 46 | MOTION for Pro Hac Vice Appearance of Attorney Jonathan J. Underwood - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 04/13/2015) |
| 4/9/2015 | 45 | NOTICE OF SERVICE of Plaintiff Amgen Inc.'s Initial Claim Charts Relating Each Accused Product to the Selected Claims filed by Amgen Inc..(Higgins, James) (Entered: 04/09/2015) |
| 4/9/2015 | Minute Entry for proceedings held before Judge Sue L. Robinson - In-Person Scheduling Conference held on 4/9/2015. Counsel to submit the final proposed scheduling order to the court. (Court Reporter V. Gunning.) (fms) (Entered: 04/09/2015) | |
| 4/9/2015 | SO ORDERED, re 44 Proposed Order filed by Amgen Inc.. Signed by Judge Sue L. Robinson on 4/9/2015. (fms) (Entered: 04/09/2015) | |
| 4/8/2015 | 44 | Joint PROPOSED ORDER Amended Protective Order re 32 Proposed Order by Amgen Inc.. (Higgins, James) (Entered: 04/08/2015) |
| 4/8/2015 | SO ORDERED, re 41 Stipulated and Proposed Order Regarding Document Production Protocol filed by Amgen Inc. Signed by Judge Sue L. Robinson on 4/8/2015. (fms) (Entered: 04/08/2015) | |
| 4/8/2015 | 43 | Letter to The Honorable Sue L. Robinson from James L. Higgins regarding submission of table outlining the parties' respective proposed case schedules - re Set/Reset Hearings. (Attachments: # 1 Proposed Trial Schedule)(Higgins, James) (Entered: 04/08/2015) |
| 4/7/2015 | 42 | NOTICE OF SERVICE of Defendants' Disclosure of Defenses filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Mayo, Andrew) (Entered: 04/07/2015) |
| 4/7/2015 | 41 | Joint PROPOSED ORDER Regarding Document Production Protocol by Amgen Inc.. (Higgins, James) (Entered: 04/07/2015) |
| 4/2/2015 | 40 | NOTICE OF SERVICE of Plaintiff's First Set of Joint Interrogatories to Sanofi, Sanofi-Aventis U.S., LLC, Aventisub LLC f/d/b/a Aventis Pharmaceuticals Inc., and Regeneron Pharmaceuticals, Inc. (Nos. 1-7) filed by Amgen Inc..(Higgins, James) (Entered: 04/02/2015) |
| 3/31/2015 | Reset Hearings: The in-person status and scheduling conference set for 4/16/2015 is cancelled. In-person status and scheduling conference is reset for 4/9/2015 at 03:00 PM in Courtroom 4B before Judge Sue L. Robinson. (fms) (Entered: 03/31/2015) | |
| 3/30/2015 | 39 | ORDER - the in-person status and scheduling conference originally scheduled for 4/9/2015 is rescheduled to 4/16/2015 at 03:00 PM in Courtroom 4B before Judge Sue L. Robinson.. Signed by Judge Sue L. Robinson on 3/27/2015. (fms) (Entered: 03/30/2015) |
| 3/27/2015 | 38 | NOTICE OF SERVICE of Plaintiff Amgen Inc.'s Disclosure of Selected Claims re 30 Order,,, Order Setting Scheduling Conference,, filed by Amgen Inc..(Higgins, James) (Entered: 03/27/2015) |
| 3/26/2015 | 37 | NOTICE OF SERVICE of Plaintiff's Rule 26(a) Initial Disclosures filed by Amgen Inc..(Higgins, James) (Entered: 03/26/2015) |
| 3/26/2015 | 36 | NOTICE OF SERVICE of Regeneron's Rule 26(a)(1) Initial Disclosures and Sanofi's Rule 26(a)(1) Initial Disclosures filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 03/26/2015) |
| 3/17/2015 | SO ORDERED, re 33 MOTION for Pro Hac Vice Appearance of Attorney John Josef Molenda, Vishal Chandra Gupta, Jeffrey C. Lee, and Siew Yen Chong filed by Regeneron Pharmaceuticals Inc. Signed by Judge Sue L. Robinson on 3/17/2015. (fms) (Entered: 03/17/2015) | |
| 3/16/2015 | SO ORDERED, re 35 MOTION for Pro Hac Vice Appearance of Attorney Cassandra Adams filed by Regeneron Pharmaceuticals Inc., Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Sue L. Robinson on 3/16/2015. (fms) (Entered: 03/16/2015) | |
| 3/16/2015 | 35 | MOTION for Pro Hac Vice Appearance of Attorney Cassandra Adams - filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 03/16/2015) |
| 3/13/2015 | 34 | NOTICE OF SERVICE of Defendants' First Set of Interrogatories (Nos. 1-10) and (2) Defendants' First Set of Requests for the Production of Documents and Things to Plaintiff Amgen Inc. (Nos. 1-48) filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 03/13/2015) |
| 3/13/2015 | 33 | MOTION for Pro Hac Vice Appearance of Attorney John Josef Molenda, Vishal Chandra Gupta, Jeffrey C. Lee, and Siew Yen Chong - filed by Regeneron Pharmaceuticals Inc.. (Mayo, Andrew) (Entered: 03/13/2015) |
| 3/9/2015 | SO ORDERED, re 32 Proposed Stipulated Protective Order filed by Amgen Inc. Signed by Judge Sue L. Robinson on 3/9/2015. (fms) (Entered: 03/09/2015) | |
| 3/4/2015 | Pro Hac Vice Attorney Angela Verrecchio for Regeneron Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (els) (Entered: 03/04/2015) | |
| 3/3/2015 | 32 | PROPOSED Stipulated Protective Orde, by Amgen Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 03/03/2015) |
| 2/26/2015 | 31 | NOTICE OF SERVICE of (1) Defendant Regeneron Pharmaceutical, Inc.'s Objections and Responses to Plaintiff Amgen Inc.'s First Set of Requests for Production (Nos. 1-24) and (2) Sanofi's Response to Plaintiff's First Set of Requests for Production of Documents and Things to Defendant Sanofi-Aventis U.S. LLC (Nos. 1-24) filed by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Lydon, Tiffany) (Entered: 02/26/2015) |
| 2/25/2015 | 30 | ORDER that the parties will exchange the agreed upon documents on or before March 17, 2015. On or before March 27, 2015, plaintiff shall narrow the number of asserted claims. On or before April 7, 2015, defendants shall identify their asserted defenses, commensurate in scope to the limited number of claims. Order Setting In-Person Scheduling and Status Conference:( A Scheduling and Status Conference is set for 4/9/2015 at 03:00 PM in Courtroom 4B before Judge Sue L. Robinson). Signed by Judge Sue L. Robinson on 2/25/2015. (nmfn) (Entered: 02/25/2015) |
| 2/24/2015 | Minute Entry for proceedings held before Judge Sue L. Robinson - In-Person Status Conference held on 2/24/2015. (Court Reporter V. Gunning.) (nmfn) (Entered: 02/24/2015) | |
| 2/18/2015 | Reset Hearings: The In-Person Scheduling Conference is rescheduled for 2/24/2015 at 02:00 PM in Courtroom 4B before Judge Sue L. Robinson. (nmfn) (Entered: 02/18/2015) | |
| 2/16/2015 | 29 | NOTICE OF SERVICE of Plaintiff's Initial Disclosure of Accused Products, Asserted Patents, Patent File Histories, and Damages Model filed by Amgen Inc..(Higgins, James) (Entered: 02/16/2015) |
| 2/13/2015 | 28 | Joint PROPOSED ORDER Scheduling Order re 21 Order Setting Scheduling Conference by Amgen Inc.. (Attachments: # 1 Letter to The Honorable Sue L. Robinson from James L. Higgins, Esquire)(Higgins, James) (Entered: 02/13/2015) |
| 2/13/2015 | SO ORDERED, re 26 MOTION for Pro Hac Vice Appearance of Attorney Angela Verrecchio filed by Regeneron Pharmaceuticals Inc., 25 MOTION for Pro Hac Vice Appearance of Attorney Dianne B. Elderkin, Steven D. Maslowski, Matthew G. Hartman, and Angela Verrecchio filed by Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Sue L. Robinson on 2/13/2015. (fms) (Entered: 02/13/2015) | |
| 2/13/2015 | 27 | NOTICE of Appearance by Matthew Alan Pearson on behalf of Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC (Pearson, Matthew) (Entered: 02/13/2015) |
| 2/13/2015 | 26 | MOTION for Pro Hac Vice Appearance of Attorney Angela Verrecchio - filed by Regeneron Pharmaceuticals Inc.. (Mayo, Andrew) (Entered: 02/13/2015) |
| 2/13/2015 | 25 | MOTION for Pro Hac Vice Appearance of Attorney Dianne B. Elderkin, Steven D. Maslowski, Matthew G. Hartman, and Angela Verrecchio - filed by Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 02/13/2015) |
| 1/30/2015 | 24 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Regeneron Pharmaceuticals Inc.. (Lydon, Tiffany) (Entered: 01/30/2015) |
| 1/30/2015 | 23 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Sanofi for Aventisub LLC, Sanofi-Aventis U.S. LLC; Corporate Parent No Corporate Parent for Sanofi filed by Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. (Lydon, Tiffany) (Entered: 01/30/2015) |
| 1/27/2015 | 22 | NOTICE OF SERVICE of Plaintiff's First Set of Requests for Production of Documents and Things to Defendant Sanofi-Aventis U.S., LLC (Nos. 1-24) and Plaintiffs First Set of Requests for Production of Documents and Things to Defendant Regeneron Pharmaceuticals, Inc. (Nos. 1-24) filed by Amgen Inc..(Higgins, James) (Entered: 01/27/2015) |
| 1/5/2015 | 21 | Order Setting In-Person Patent Scheduling Conference: A Scheduling Conference is set for 2/17/2015 at 03:00 PM in Courtroom 4B before Judge Sue L. Robinson. Signed by Judge Sue L. Robinson on 1/2/2015. (nmfn) (Entered: 01/05/2015) |
| 12/15/2014 | 20 | ANSWER to Complaint with Jury Demand, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Balick, Steven) Modified on 3/13/2018 (nms). (Entered: 12/15/2014) |
| 12/15/2014 | 19 | ANSWER to Complaint with Jury Demand, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Balick, Steven) Modified on 3/13/2018 (nms). (Entered: 12/15/2014) |
| 12/15/2014 | 18 | ANSWER to Amended Complaint with Jury Demand, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Balick, Steven) Modified on 3/13/2018 (nms). (Entered: 12/15/2014) |
| 12/15/2014 | 17 | ANSWER to Amended Complaint with Jury Demand, by Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC.(Balick, Steven) Modified on 3/13/2018 (nms). (Entered: 12/15/2014) |
| 12/15/2014 | SO ORDERED, re (14 in 1:14-cv-01349-SLR, 16 in 1:14-cv-01317-SLR, 10 in 1:14-cv-01414-SLR, 13 in 1:14-cv-01393-SLR) Proposed Order Consolidating Cases filed by Amgen Inc. All future filings shall be made only in C.A. No. 14-1317-SLR. Signed by Judge Sue L. Robinson on 12/15/2014. Associated Cases: 1:14-cv-01317-SLR, 1:14-cv-01349-SLR, 1:14-cv-01393-SLR, 1:14-cv-01414-SLR(fms) (Entered: 12/15/2014) | |
| 12/12/2014 | 16 | Joint PROPOSED ORDER Consolidating Cases by Amgen Inc.. (Sharp, Melanie) (Entered: 12/12/2014) |
| 12/3/2014 | SO ORDERED, re 15 Proposed Order, filed by Amgen Inc., Set/Reset Answer Deadlines: Aventisub LLC answer due 12/15/2014; Regeneron Pharmaceuticals Inc. answer due 12/15/2014; Sanofi answer due 12/15/2014; Sanofi-Aventis U.S. LLC answer due 12/15/2014. Signed by Judge Sue L. Robinson on 12/3/2014. (fms) (Entered: 12/03/2014) | |
| 12/2/2014 | 15 | Joint Proposed Order Setting Deadline to Respond to Complaints, by Amgen Inc.. (Higgins, James) Modified on 3/13/2018 (nms). (Entered: 12/02/2014) |
| 12/1/2014 | Pro Hac Vice Attorney Steven D. Maslowski,Matthew G Hartman for Regeneron Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mas, ) (Entered: 12/01/2014) | |
| 12/1/2014 | Pro Hac Vice Attorney Dianne B. Elderkin for Regeneron Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mas, ) (Entered: 12/01/2014) | |
| 11/25/2014 | Pro Hac Vice Attorney Siew Yen Chong,Vishal C. Gupta,Jeffrey C. Lee,John J. Molenda for Sanofi added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (dmp, ) (Entered: 11/25/2014) | |
| 11/21/2014 | 14 | AFFIDAVIT of Service for Summons and Amended Complaint for Patent Infringement and Declaratory Judgment of Patent Infringement served on Sanofi-Aventis U.S. LLC on November 19, 2014, filed by Amgen Inc.. (Higgins, James) (Entered: 11/21/2014) |
| 11/20/2014 | SO ORDERED, re 13 MOTION for Pro Hac Vice Appearance of Attorney John Josef Molenda, Vishal Chandra Gupta, Jeffrey C. Lee, and Siew Yen Chong filed by Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. Signed by Judge Sue L. Robinson on 11/20/2014. (fms) (Entered: 11/20/2014) | |
| 11/20/2014 | 13 | MOTION for Pro Hac Vice Appearance of Attorney John Josef Molenda, Vishal Chandra Gupta, Jeffrey C. Lee, and Siew Yen Chong - filed by Aventisub LLC, Sanofi, Sanofi-Aventis U.S. LLC. (Mayo, Andrew) (Entered: 11/20/2014) |
| 11/19/2014 | SO ORDERED, re 12 MOTION for Pro Hac Vice Appearance of Attorney Dianne B. Elderkin, Steven D. Maslowski, and Matthew G. Hartman filed by Regeneron Pharmaceuticals Inc. Signed by Judge Sue L. Robinson on 11/19/2014. (fms) (Entered: 11/19/2014) | |
| 11/19/2014 | CORRECTING ENTRY: The Notice of Appearance docket code should have been used to docket D.I. 11 . The use of the proper code would have allowed the filer to add the attorney to the docket. Matthew A. Pearson has been added to the docket per D.I. 11 . (fms) (Entered: 11/19/2014) | |
| 11/18/2014 | 12 | MOTION for Pro Hac Vice Appearance of Attorney Dianne B. Elderkin, Steven D. Maslowski, and Matthew G. Hartman - filed by Regeneron Pharmaceuticals Inc.. (Mayo, Andrew) (Entered: 11/18/2014) |
| 11/18/2014 | 11 | NOTICE of Appearance of Matthew A. Pearson on behalf of Regeneron Pharmaceuticals, Inc. by Regeneron Pharmaceuticals Inc. (Mayo, Andrew) (Entered: 11/18/2014) |
| 11/17/2014 | 10 | AMENDED COMPLAINT against Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC- filed by Amgen Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4)(Sharp, Melanie) (Entered: 11/17/2014) |
| 11/7/2014 | 9 | SUMMONS Returned Executed by Amgen Inc.. Sanofi served on 11/3/2014, answer due 11/24/2014. (Higgins, James) (Entered: 11/07/2014) |
| 10/30/2014 | 8 | SUMMONS Returned Executed by Amgen Inc.. Regeneron Pharmaceuticals Inc. served on 10/28/2014, answer due 11/18/2014. (Higgins, James) (Entered: 10/30/2014) |
| 10/30/2014 | 7 | SUMMONS Returned Executed by Amgen Inc.. Aventisub LLC served on 10/28/2014, answer due 11/18/2014. (Higgins, James) (Entered: 10/30/2014) |
| 10/30/2014 | Pro Hac Vice Attorney William G. Gaede, III for Amgen Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (dmp, ) (Entered: 10/30/2014) | |
| 10/28/2014 | Summons Issued with Magistrate Consent Notice attached as to Aventisub LLC, and Aventisub LLC f/d/b/a Aventis Pharmaceuticals, Inc, on 10/28/2014; Regeneron Pharmaceuticals Inc. on 10/28/2014; Sanofi on 10/28/2014. (rbe) (Entered: 10/28/2014) | |
| 10/27/2014 | SO ORDERED, re 6 MOTION for Pro Hac Vice Appearance of Attorney Wendy A. Whiteford and Erica S. Olson filed by Amgen Inc. Signed by Judge Sue L. Robinson on 10/27/2014. (fms) (Entered: 10/27/2014) | |
| 10/27/2014 | 6 | MOTION for Pro Hac Vice Appearance of Attorney Wendy A. Whiteford and Erica S. Olson - filed by Amgen Inc.. (Attachments: # 1 Certifications by Counsel)(Higgins, James) (Entered: 10/27/2014) |
| 10/24/2014 | SO ORDERED, re 5 MOTION for Pro Hac Vice Appearance of Attorney William G. Gaede, III, Eric W. Hagen, Terry W. Ahearn, Bhanu K.Sadasivan, Shane G. Smith, Sarah C. Columbia, Katherine Nicole Clouse and Lauren Martin filed by Amgen Inc. Signed by Judge Sue L. Robinson on 10/24/2014. (nmfn) (Entered: 10/24/2014) | |
| 10/22/2014 | Case Assigned to Judge Sue L. Robinson. Please include the initials of the Judge (SLR) after the case number on all documents filed. (rjb) (Entered: 10/22/2014) | |
| 10/21/2014 | 5 | MOTION for Pro Hac Vice Appearance of Attorney William G. Gaede, III, Eric W. Hagen, Terry W. Ahearn, Bhanu K.Sadasivan, Shane G. Smith, Sarah C. Columbia, Katherine Nicole Clouse and Lauren Martin - filed by Amgen Inc.. (Attachments: # 1 Certifications by Counsel)(Higgins, James) (Entered: 10/21/2014) |
| 10/17/2014 | No Summons Issued. (mas) (Entered: 10/17/2014) | |
| 10/17/2014 | 4 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Amgen Inc.. (mas) (Entered: 10/17/2014) |
| 10/17/2014 | 3 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,563,698; 8,829,165; 8,859,741;. (mas) (Entered: 10/17/2014) |
| 10/17/2014 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mas) (Entered: 10/17/2014) |
| 10/17/2014 | 1 | COMPLAINT FOR PATENT INFRINGEMENT AND DECLARATORY JUDGMENT OF PATENT INFRINGEMENT filed with jury demand against Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1609166.) - filed by Amgen Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Civil Cover Sheet)(mas) (Entered: 10/17/2014) |
